3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha-keto acid dehydrogenase kinase inhibitors for treating diabetes, kidney disease, NASH and heart failure
3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives enhance BCKDH activity by inhibiting BCKDK, addressing impaired BCAA catabolism in diabetes, NASH, and heart failure, offering therapeutic benefits for these conditions.
Patent Information
- Application Number
- JP2024532157
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-14
- Filing Date
- 2022-11-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-11-28
AI Technical Summary
Current treatments for diseases associated with impaired branched-chain amino acid (BCAA) catabolism, such as diabetes, non-alcoholic steatohepatitis (NASH), and heart failure, lack effective BCKDK inhibitors or degraders that can enhance BCKDH activity and increase BCAA catabolism.
Development of 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives that act as BCKDK inhibitors or degraders, increasing BCKDH activity and promoting BCAA catabolism, thereby treating conditions like diabetes, NASH, and heart failure.
The compounds effectively increase BCAA catabolism, providing therapeutic benefits for diabetes, NASH, heart failure, and other metabolic disorders by inhibiting or degrading BCKDK, thus alleviating symptoms and preventing disease progression.
Smart Images

Figure 2024543938000001_ABST
Abstract
Description
[Technical field]
[0001] The present application provides compounds that are branched chain alpha keto acid dehydrogenase kinase inhibitors and / or degraders, pharmaceutical compositions containing such compounds and their uses for treating, for example, diabetes, NASH, kidney disease and heart failure. [Background technology]
[0002] Branched-chain amino acids (BCAAs) account for approximately 40% of the essential amino acids in healthy subjects and must be obtained through a balanced diet. Although branched-chain amino acids are toxic in excess, they are required for protein synthesis and cell signaling processes. BCAAs undergo transamination by branched-chain aminotransferase (BCAT) to their alpha-keto acid forms: alpha-ketoisocaproate (KIC / ketroucine), 2-keto-3-methylvalerate (KMV / ketoisoleucine) and alpha-ketoisovalerate (KIV / ketovaline). Branched-chain keto acids (BCKAs) are then oxidatively decarboxylated by the branched-chain ketoacid dehydrogenase (BCKDH) enzyme complex, which consists of multiple copies of the BCKDH E1α / β tetramer, BCKDH E2, and BCKDH E3 subunits. This complex is regulated by inhibitory phosphorylation mediated by BCKDH kinase (BCKDK), and this same phosphorylation site is dephosphorylated by the phosphatase PPM1K. Inhibition of complex phosphorylation promotes BCKDH activity and thus the irreversible catabolism of BCKA (Lynch CJ, Adams SH: Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014, 10:723-36). Deletion of Bckdk in mice confirms this regulation, as Bckdk-deficient mice showed elevated BCKDH activity in multiple tissues (Joshi MA, Jeoung NH, Obayashi M, Hatab EM, Brocken EG, Liechty EA, Kubek MJ, Vattem KM, Wek RC, Harris RA: Impaired growth and neurological abnormalities in branched-chain alpha-keto acid dehydrogenase kinase-deficient mice. Biochem J 2006, 400:153-62).
[0003] No. 9,078,865 describes, for example, a method for reducing plasma levels of one or more branched chain amino acids or branched chain alpha-keto acids, for example, to treat an inborn error of metabolism in newborns known as maple syrup urine disease (MSUD), by administering to an individual in need thereof a therapeutically effective amount of a compound of the formula: phenyl-CH2-(CH2) n -COOH, where n is 0, 2, 4, 6, or 8. MSUD, also known as branched chain ketoaciduria, is an autosomal recessive disorder.
[0004] A strong correlation exists between BCAA catabolism and cardiometabolic health. Elevated BCAA / BCKA levels have been observed in plasma of patients with type 2 diabetes in multiple studies (Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE: Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-53; Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Jr., Eisenson ... H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311~26).
[0005] Decreased levels of PPM1K and increased levels of BCKDK were observed in human NASH (Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ:Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015, 47:603-15).
[0006] Decreased mRNA levels for enzymes in catabolic pathways have also been observed in skeletal muscle of human diabetic patients (Lerin C, Goldfine AB, Boes T, Liu M, Kasif S, Dreyfuss JM, De Sousa-Coelho AL, Daher G, Manoli I, Sysol JR, Isganaitis E, Jessen N, Goodyear LJ, Beebe K, Gall W, Venditti CP, Patti ME:Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Mol Metab 2016, 5:926-36).
[0007] Similarly, metabolomic and RNA profiling data from mouse hearts also suggest that genes in the BCAA / BCKA catabolic pathway are downregulated in heart failure (Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J, Kapoor K, Koves TR, Stevens R, Ilkayeva OR, Vega RB, Attie AD, Muoio DM, Kelly DP:Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 2014, 7:1022-31; Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S, Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y: Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 2016, 133:2038~49).
[0008] Collectively, these data suggest that BCAA catabolism is impaired in multiple human disease states. One mechanism for increasing BCAA catabolism is BCKDK inhibitors and / or degraders. Inhibiting and / or degrading BCKDK increases BCKDH activity and increases BCAA catabolism. Summary of the Invention [Problem to be solved by the invention]
[0009] Recently, inhibitors of BCKDK have been reported in the literature and patent applications, including commonly assigned PCT applications PCT / IB2020 / 056066 and PCT / IB2020 / 055974, both published as WO2020 / 261205 and WO2020 / 261144, respectively, on December 30, 2020. Although there has been some initial research on BCKDK, there remains a need for pharmaceutical agents that have BCKDK inhibitory / degrading activity and are useful in treating, preventing or reducing the symptoms of the diseases described herein. [Means for solving the problem]
[0010] The present application relates to a compound of formula I
[0011] [ka] [In the formula, Z is O or S; A is,
[0012] [ka] and X1 is a CR 11 or N, X2 and X3 are independent of each other, CR 11 or O, and if X2 is O, then X3 is CR 11 and X4 and X5 are both C, or one of X4 and X5 is C and the other is O. If X4 is O, then R 6 does not exist, and X5 is O, then R 8 does not exist, R 1 , R 3 and R 4 are each independently selected from H and fluoro; R 2 is H, fluoro or chloro, R 5 , R 6 , R7 , R 8 , R 9 and R 11 are each independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)fluoroalkyl, (C3-C6)fluorocycloalkyl, (C1-C4)fluoroalkoxy, or (C1-C4)alkyl-(C1-C4)alkoxy; R 10 is H, hydroxy, fluoro, chloro, cyano, or (C1-C4) alkyl; A is
[0013] [ka] and X1 is CR 11 If i) R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 At least one of is halo, and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 at least one other of Z is other than H, or ii) Z is S and R 2 is a halo] or a pharma- ceutically acceptable salt of said compound.
[0014] The present application relates to a compound of formula I
[0015] [ka] [In the formula, Z is O or S; A is,
[0016] [ka] and X1 is a CR 11 or N, X2 and X3 are independent of each other, CR 11 or O, and if X2 is O, then X3 is CR 11 and R 1 , R 3 and R 4 are each independently selected from H and fluoro; R 2 is H, fluoro or chloro, R 5 , R 6 , R 7 , R 8 , R 9 and R 11 are each independently selected from H, halo, hydroxyl, amino, cyano, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)fluoroalkyl, (C3-C6)fluorocycloalkyl, (C1-C4)fluoroalkoxy, or (C1-C4)alkyl-(C1-C4)alkoxy; R 10 is H, fluoro, chloro, cyano, or (C1-C4) alkyl; A,
[0017] [ka] and X1 is CR 11 If R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 At least one of is halo, and R 1 , R 2 , R3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 and at least one of the other is other than H. or a pharma- ceutically acceptable salt of said compound.
[0018] The present application relates to the treatment of fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with liver cirrhosis, nonalcoholic steatohepatitis with liver cirrhosis, hepatocellular carcinoma, kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, gastric adenocarcinoma, adrenocortical carcinoma, papillary renal cell carcinoma, cervical and endocervical carcinoma, and the like, by administering to a human in need of such treatment a therapeutically effective amount of a compound of formula I or a pharma- ceutical acceptable salt of said compound. carcinoma, urothelial carcinoma of the bladder, lung adenocarcinoma, diabetes mellitus type I, diabetes mellitus type II, idiopathic diabetes mellitus type I (type Ib), latent autoimmune diabetes in adults (LADA), early-onset type 2 diabetes (EOD), atypical diabetes mellitus of the young (YOAD), maturity-onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT), impaired fasting plasma glucose (IFG), Also covered are methods for treating hyperglycemia, hypertension, hypercalcaemia, chronic kidney disease, diabetes, and other conditions, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, glucose metabolism disorders, skin and connective tissue disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and vascular compliance disorders, hyperapo B lipoproteinemia, renal disease, end stage renal disease, chronic renal disease at risk for progression, and maple syrup urine disease.
[0019] The application is also directed to methods of treating or reducing the risk of hospitalization due to heart failure, cardiovascular death, congestive heart failure, heart failure with New York Heart Association Class I-IV symptoms, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), heart failure with mid-range ejection fraction (HF-mrEF), cardiovascular death, heart failure in patients with diabetes mellitus type II, coronary heart disease, unstable angina, peripheral arterial disease, peripheral vascular disease, renal vascular disease, pulmonary hypertension, vasculitis, acute coronary syndromes, and modifying cardiovascular risk by administering a therapeutically effective amount of a compound of Formula I or a pharma- ceutically acceptable salt of said compound to a human in need of such treatment.
[0020] The present application is also directed to pharmaceutical compositions having a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt of said compound, and a pharma- ceutically acceptable carrier, vehicle, or excipient.
[0021] This application is a first compound which is a compound of formula I or a pharma- ceutically acceptable salt of said compound; a second compound which is an antidiabetic agent; an agent for treating non-alcoholic steatohepatitis, an agent for treating non-alcoholic fatty liver disease, or an anti-heart failure agent; and Pharmaceutical Carriers, Vehicles or Excipients Also of interest is a pharmaceutical combination composition comprising a therapeutically effective amount of a composition having the formula:
[0022] This application is also directed to crystalline forms of the compound of formula I.
[0023] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. [Brief description of the drawings]
[0024] [Figure 1]FIG. 1 is a characteristic X-ray powder diffraction pattern of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (Example 9), anhydrous Form 1 (vertical axis: intensity (CPS); horizontal axis: 2 theta (degrees)). [Diagram 2] FIG. 1 is a characteristic X-ray powder diffraction pattern of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (Example 9), anhydrous Form 2 (vertical axis: intensity (CPS); horizontal axis: 2 theta (degrees)). [Diagram 3] FIG. 1 is a characteristic X-ray powder diffraction pattern for 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (Example 9), amorphous form 3 (vertical axis: intensity (CPS); horizontal axis: 2 theta (degrees)). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] The present application may be understood more readily by reference to the following detailed description of exemplary embodiments of the invention and the examples included therein.
[0026] It is to be understood that the present invention is not limited to specific synthetic methods for preparation, which may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:
[0027] As used herein, "a" or "an" can mean one or more. When used in the claims, when used in conjunction with the word "comprising," the words "a" or "an" can mean one or more than one. As used herein, "another" can mean at least a second or more.
[0028] The term "about" refers to a relative term indicating an approximation of plus or minus 10% of the nominal value, in one embodiment plus or minus 5%, and in another embodiment plus or minus 2%. In the field of this disclosure, this level of approximation is appropriate unless the value is specifically stated to require a narrower range.
[0029] The term "and / or" means one or more. For example, "X and / or Y" is to be understood to mean either "X and Y" or "X or Y" and is to be interpreted as providing clear support for both meanings or for either meaning. Similarly, when more than two indications are listed, such as in "X, Y and / or Z", this is to be understood to mean either i) "X and Y", "X, Y and Z", "X and Z", or "Y and Z", or ii) "X or Y or Z" and is to be interpreted as providing clear support for all meanings.
[0030] The term "alkyl", alone or in combination, refers to an acyclic saturated hydrocarbon group of formula CnH2n+1, which may be linear or branched. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, isobutyl, and t-butyl. The carbon atom content of alkyl and various other hydrocarbon-containing moieties is indicated by prefixes that specify the lower and upper numbers of carbon atoms in the moiety, i.e., the prefixes Ci-Cj indicate a moiety from integer "i" to integer "j" carbon atoms, inclusive. Thus, for example, C1-C3 alkyl refers to an alkyl of 1 to 3 carbon atoms, inclusive.
[0031] "Fluoroalkyl" means alkyl, as defined herein, substituted with one, two or three fluoro atoms. Exemplary (C1) fluoroalkyl compounds include fluoromethyl, difluoromethyl and trifluoromethyl; exemplary (C2) fluoroalkyl compounds include 1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1-trifluoroethyl, 1,1,2-trifluoroethyl, and the like.
[0032] "Cycloalkyl" refers to a non-aromatic ring that is a fully hydrogenated group of formula CnH2n-1. Examples of such carbocyclic rings include cyclopropyl and cyclobutyl.
[0033] "Fluorocycloalkyl" means a non-aromatic cycloalkyl ring, as defined herein, substituted with one, two or three fluoro atoms. Exemplary (C3) fluorocycloalkyl compounds include fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl; exemplary (C4) fluorocycloalkyl compounds include 1-fluorocyclobutyl, 2-fluorocyclobutyl, 1,1-difluorocyclobutyl, 1,2-difluorocyclobutyl, 1,1,1-trifluorocyclobutyl, 1,1,2-trifluorocyclobutyl, and the like.
[0034] By "alkoxy" is meant a straight chain saturated alkyl or branched chain saturated alkyl bonded through an oxy. Illustrative of such alkoxy groups (assuming the specified length encompasses the particular example) are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexoxy, isohexoxy, heptoxy, and octoxy.
[0035] By "fluoroalkoxy" is meant alkoxy as defined herein substituted with one, two or three fluoro atoms. Exemplary (C1) fluoroalkoxy compounds include fluoromethoxy, difluoromethoxy and trifluoromethoxy; exemplary (C2) fluoroalkyl compounds include 1-fluoroethoxy, 2-fluoroethoxy, 1,1-difluoroethoxy, 1,2-difluoroethoxy, 1,1,1-trifluoroethoxy, 1,1,2-trifluoroethoxy, and the like.
[0036] "Halo" refers to bromo, chloro, fluoro or iodo.
[0037] "Compound" as used herein includes conformational isomers (e.g., cis and trans isomers), atropisomers (i.e., stereoisomers resulting from hindered rotation), and all optical isomers (e.g., enantiomers and diastereomers), racemic, diastereomeric and other mixtures of such isomers, as well as any pharma- ceutically acceptable derivatives or variations, including solvates, hydrates, isomorphs, polymorphs, tautomers, esters, salt forms and prodrugs. The expression "prodrug" refers to a compound that is a drug precursor that releases a drug in vivo through some chemical or physiological process after administration (e.g., the prodrug is converted to the desired drug form when brought to physiological pH or through enzymatic action). Upon cleavage, exemplary prodrugs release the corresponding free acid, and such hydrolyzable ester-forming residues of compounds of formula I include those in which the free hydrogen is (C1-C4) alkyl, (C2-C7) alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having 5 to 8 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having 3 to 9 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having 5 to 8 ... These include, but are not limited to, N-(alkoxycarbonyl)aminomethyl having 4 to 10 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolactone-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl, and those having a carboxyl portion replaced by piperidino-, pyrrolidino-, or morpholino(C2-C3)alkyl.
[0038] As used herein, an arrow,
[0039] [ka] " or a wavy line, "
[0040] [ka] " indicates the point of attachment of a substituent to another group.
[0041] The term "mammal" refers to a human, a domestic animal, or a companion animal.
[0042] The term "companion animal" or "companion animals" refers to animals that are kept as pets or household animals. Examples of companion animals include dogs, cats, and rodents, including hamsters, guinea pigs, gerbils, etc., rabbits, and ferrets.
[0043] The term "livestock" refers to animals that are kept or raised in an agricultural environment to produce products, such as food or fiber, or for their labor. In some embodiments, livestock are suitable for consumption by mammals, e.g., humans. Examples of livestock animals include cows, goats, horses, pigs, sheep, including lambs, and rabbits.
[0044] "Patient" refers to warm-blooded animals such as, for example, guinea pigs, mice, rats, gerbils, cats, rabbits, dogs, cows, goats, sheep, horses, monkeys, chimpanzees, and humans.
[0045] The term "treating" or "treatment" refers to the alleviation of symptoms associated with a disease, disorder or condition, or the cessation of further progression or worsening of those symptoms. Depending on the disease and condition of the patient, the term "treatment" as used herein may include one or more of curative, palliative, and preventive treatment. Treatment may also include administering pharmaceutical preparations in combination with other treatments.
[0046] "Therapeutically effective amount" means an amount of a compound of the invention that (i) treats or prevents a particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.
[0047] The term "pharmaceutical acceptable" means a substance (eg, a compound of the invention) and any salts thereof, or a composition containing a substance or salt of the invention, that is suitable for administration to a patient.
[0048] In one embodiment of the compound, Z is S and A is
[0049] [ka] and R 2 is fluoro or chloro, and X1 is CR 11 or a pharma- ceutically acceptable salt thereof.
[0050] In another embodiment of the compound, R 1 , R 3 and R 4 are H and R, respectively. 2 is fluoro, or a pharma- ceutically acceptable salt thereof.
[0051] In another embodiment of the compound, R 5 is fluoro, chloro, cyano or (C1-C4) alkyl; R 10 is H, fluoro or chloro, or a pharma- ceutically acceptable salt thereof.
[0052] In another embodiment of the compound, R 6 and R 7 are each independently selected from H, fluoro, chloro, cyano, (C1-C4)alkyl, and (C1-C4)alkoxy; or a pharma- ceutically acceptable salt thereof.
[0053] In another embodiment of the compound, R 11 is H, fluoro, chloro, cyano, (C1-C4)alkyl, or (C1-C4)alkoxy, or a pharma- ceutically acceptable salt thereof.
[0054] In one embodiment of the method of treatment, a method is provided for treating fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic steatohepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma comprising administering to a human in need of such treatment a therapeutically effective amount of a compound described herein or a pharma- ceutically acceptable salt of said compound.
[0055] In another embodiment of the method of treatment, non-alcoholic steatohepatitis is treated.
[0056] In another embodiment of the method of treatment, a method is provided for treating or reducing the risk of hospitalization due to heart failure, cardiovascular death, congestive heart failure, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), cardiovascular death, heart failure in patients with type II diabetes mellitus, coronary heart disease, peripheral vascular disease, renovascular disease, pulmonary hypertension, vasculitis, acute coronary syndromes, and modifying cardiovascular risk comprising administering to a human in need of such treatment a therapeutically effective amount of a compound described herein or a pharma- ceutically acceptable salt of said compound.
[0057] In another embodiment of the method of treatment, heart failure is treated.
[0058] In another embodiment of the method of treatment, the method comprises administering to a human in need of such treatment a therapeutically effective amount of a compound described herein or a pharma- ceutically acceptable salt of said compound, for use in treating type I diabetes, type II diabetes mellitus, idiopathic type I diabetes (type Ib), latent autoimmune diabetes in adults (LADA), early onset type 2 diabetes (EOD), atypical diabetes of the young (YOAD), maturity-onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, postprandial lipemia, The present invention provides for treating conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, glucose metabolic disorders, skin and connective tissue disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and vascular compliance abnormalities, hyperapo B lipoproteinemia, renal disease, end stage renal disease, chronic renal disease at risk of progression, and maple syrup urine disease.
[0059] In another embodiment of the method of treatment, renal disease is treated.
[0060] In another embodiment of the method of treatment, a method is provided for treating hepatocellular carcinoma, kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, gastric adenocarcinoma, adrenocortical carcinoma, papillary renal cell carcinoma, cervical and endocervical carcinoma, bladder urothelial carcinoma, lung adenocarcinoma comprising administering to a human in need of such treatment a therapeutically effective amount of a compound described herein or a pharma- ceutical acceptable salt thereof.
[0061] In another embodiment of the method of treatment, hepatocellular carcinoma is treated.
[0062] In one embodiment of the pharmaceutical composition, the composition comprises a therapeutically effective amount of a compound as described herein or a pharma- ceutically acceptable salt of said compound and a pharma- ceutically acceptable carrier, vehicle or excipient.
[0063] In another embodiment of the pharmaceutical composition, the composition comprises: a first compound which is a compound as described herein or a pharma- ceutically acceptable salt of said compound; a second compound which is an anti-diabetic agent; an agent for treating non-alcoholic steatohepatitis, a non-alcoholic fatty liver disease, a renal disease, or an anti-heart failure treatment; and a pharmaceutical carrier, vehicle, or excipient. The pharmaceutical combination includes a therapeutically effective amount of a composition comprising:
[0064] In another embodiment of the pharmaceutical composition, the combination composition contains as the second compound 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid; [(1R,5S,6R)-3-{2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid; 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-o (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide; or 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharma- ceutically acceptable salt thereof.
[0065] In another embodiment of the pharmaceutical composition, in the combination composition, the non-alcoholic steatohepatitis treating agent or non-alcoholic fatty liver disease treating agent is an ACC inhibitor, a GLP1 receptor agonist, a DGAT-2 inhibitor, an FXR agonist, metformin, an incretin analog, or an incretin receptor modulator.
[0066] In another embodiment of the pharmaceutical composition, in the combination composition, the antidiabetic agent is an SGLT-2 inhibitor, metformin, an incretin analog, an incretin receptor modulator, a DPP-4 inhibitor, or a PPAR agonist.
[0067] In another embodiment of the pharmaceutical composition, in a combination composition, the antidiabetic agent is metformin, sitagliptin or ertuglifozin.
[0068] In another embodiment of the pharmaceutical composition, the anti-heart failure agent is an ACE inhibitor, an SGLT-2 inhibitor, an angiotensin receptor blocker, an angiotensin receptor neprilysin inhibitor, a beta adrenergic receptor blocker, a calcium channel blocker, or a vasodilator.
[0069] In another embodiment of the pharmaceutical composition, the anti-heart failure agent is valsartan, sacubitril, dapagliflozin, empagliflozin, canagliflozin or ertugliflozin.
[0070] In one embodiment of the crystalline form, the powder X-ray diffraction pattern has 2-theta values (CuKα radiation, wavelength 1.54056 Å) of 7.6±0.2, 14.6±0.2, and 27.9±0.2.
[0071] In another embodiment of the crystalline form, the powder X-ray diffraction pattern has 2-theta values (CuKα radiation, wavelength of 1.54056 Å) of 10.2±0.2, 13.9±0.2, and 24.7±0.2.
[0072] One embodiment includes the use of a compound of formula I or a pharma- ceutically acceptable salt of said compound for the manufacture of a medicament in treating fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic steatohepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma, comprising administering a therapeutically effective amount to a mammal, such as a human, in need of such treatment.
[0073] Another embodiment includes the use of a compound of formula I or a pharma- ceutically acceptable salt of said compound for the manufacture of a medicament in treating or reducing the risk of hospitalization due to heart failure, cardiovascular death, congestive heart failure, heart failure with New York Heart Association Class I-IV symptoms, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), heart failure with mid-range ejection fraction (HF-mrEF), cardiovascular death, heart failure in patients with diabetes mellitus type II, coronary heart disease, unstable angina, peripheral arterial disease, peripheral vascular disease, renal vascular disease, pulmonary hypertension, vasculitis, acute coronary syndromes, and modifying cardiovascular risk, comprising administering a therapeutically effective amount to a mammal, such as a human, in need of such treatment.
[0074] Another embodiment is a method for treating type I diabetes, type II diabetes mellitus, idiopathic type I diabetes (Type Ib), latent autoimmune diabetes in adults (LADA), early onset type 2 diabetes (EOD), atypical diabetes of the young (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT), fasting plasma glucose abnormalities, and the like, comprising administering to a mammal, such as a human, in need of such treatment a therapeutically effective amount of a compound of formula I or a pharmacologic acceptable salt of said compound. The present invention also includes the use of a compound of formula I or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament in the treatment of normal conditions, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, glucose metabolism disorders, skin and connective tissue disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and vascular compliance disorders, hyperapo B lipoproteinemia, renal disease, end stage renal disease, chronic renal disease at risk of progression and maple syrup urine disease.
[0075] Another embodiment includes the use of a composition comprising a compound of Formula I, or a pharma- ceutically acceptable salt of said compound, for the manufacture of a medicament in treating hepatocellular carcinoma, kidney clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, gastric adenocarcinoma, adrenocortical carcinoma, papillary renal cell carcinoma, cervical and endocervical carcinoma, bladder urothelial carcinoma, lung adenocarcinoma, comprising administering a therapeutically effective amount of a compound of Formula I, or a pharma- ceutically acceptable salt of said compound, to a mammal, such as a human, in need of such treatment.
[0076] Another embodiment includes a compound selected from any of the examples described herein, or a pharma- ceutically acceptable salt thereof.
[0077] Another embodiment includes a prodrug of any of the examples described herein, or a pharma- ceutically acceptable salt thereof.
[0078] Another embodiment includes a phosphate ester prodrug of any of the examples described herein, or a pharma- ceutically acceptable salt thereof.
[0079] Another embodiment includes any novel genus of intermediates described in the general schemes or examples.
[0080] Further embodiments include any of the novel specific intermediates described in the preparations and examples described herein.
[0081] Alternative embodiments include any of the novel processes described herein.
[0082] All pharma- ceutically acceptable isotopically labeled compounds of Formula I, in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, are within the scope of this application.
[0083] Examples of isotopes suitable for inclusion in the compounds of the present invention are: 2 H and 3 Hydrogen such as H 11 C. 13 C and 14 Carbon such as C, 36 Chlorine such as Cl, 18 Fluorine such as F, 13 N and 15 Nitrogen such as N 15 O. 17 O and 18 Oxygen such as O, 35 Includes isotopes of sulfur such as S.
[0084] Certain isotopically labeled compounds of formula I, for example those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e. 3 H, and carbon-14, i.e. 14C are particularly useful for this purpose given their ease of incorporation and ready means of detection.
[0085] Deuterium, i.e. 2 Substitution with heavier isotopes, such as H, may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferable in some circumstances.
[0086] 11 C. 18 F, 15 O and 13 Substitution with positron emitting isotopes, such as N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
[0087] Isotopically labeled compounds of formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations, substituting an appropriate isotopically labeled reagent for the non-labeled reagent previously used.
[0088] Certain compounds of formula I and intermediates described herein may generally exist in multiple crystal forms (generally referred to as "polymorphs").Polymorphs may be prepared under various conditions, such as by crystallization using different solvents or different solvent mixtures for recrystallization; crystallization at different temperatures; and / or by various cooling modes ranging from very fast to very slow cooling during crystallization.Polymorphs may be obtained by heating or melting the compound, followed by slow or fast cooling.The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or other such techniques.
[0089] Salts encompassed by the term "pharmaceutically acceptable salts" generally refer to compounds of the present invention prepared by reacting a free base or free acid with a suitable organic or inorganic acid, or a suitable organic or inorganic base, respectively, to provide a salt of the compound of the present invention that is suitable for administration to a patient. Base salts are preferred, however, some compounds may also form acid salts. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples are acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, hydrogen sulfate / sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate. , malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate.
[0090] Suitable base salts are formed from bases that form non-toxic salts. Examples include aluminum, arginine, calcium, choline, diethylamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, trimethamine and zinc salts. Hemisalts of acids and bases can also be formed, such as hemisulfate and hemicalcium salts. For a general overview of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).
[0091] Hemisalts of acids and bases can also be formed, such as hemisulfates and hemicalcium salts. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).
[0092] Pharmaceutically acceptable salts of compounds of formula I can be prepared by one or more of three methods: (i) by reacting a compound of formula I with a desired acid or base; (ii) by removing an acid- or base-labile protecting group from a suitable precursor of a compound of the invention, or by ring-opening a suitable cyclic precursor, such as a lactone or lactam, using a desired acid or base; or (iii) by converting one salt of a compound of the invention into another salt by reaction with an appropriate acid or base, or by using a suitable ion exchange column.
[0093] All three reactions are typically carried out in solution. The resulting salt can be precipitated and filtered off or can be recovered by evaporating the solvent. The degree of ionization in the resulting salt can vary from completely ionized to nearly non-ionized.
[0094] The compound of formula I and its pharmaceutically acceptable salts can exist in both non-solvated and solvated form.The term "solvate" is used herein to describe the molecular complex that comprises the compound of formula I or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable solvent molecules, such as ethanol.The term "hydrate" is used when said solvent is water.
[0095] The currently accepted classification system for organic hydrates defines isolated site, channel or metal ion coordinated hydrates. See Polymorphism in Pharmaceutical Solids, by KR Morris (ed. HG Brittain, Marcel Dekker, 1995). Isolated site hydrates are those in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are adjacent to other water molecules. In metal ion coordinated hydrates, the water molecules are associated with the metal ion.
[0096] If the solvent or water is tightly bound, the complex may have a well-defined stoichiometry that is independent of humidity. However, if the solvent or water is weakly bound, such as in channel solvates and hygroscopic compounds, the water / solvent content may depend on humidity and drying conditions. In such cases, non-stoichiometry becomes the norm.
[0097] Also included within the scope of the present invention are multicomponent complexes (other than salts and solvates) in which the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. This type of complex includes clathrates (drug-host inclusion complexes) and cocrystals. The latter are typically defined as crystalline complexes of neutral molecular components bound together through non-covalent interactions, but may also be complexes of neutral molecules and salts. Cocrystals can be prepared by melt crystallization, by recrystallization from a solvent, or by physically grinding the components together. See Chem Commun, 17, 1889-1896, by O. Almarsson and MJ Zaworotko (2004). For a general review of multicomponent complexes, see J Pharm Sci, 64(8), 1269-1288, by Haleblian (August 1975).
[0098] Also included within the scope of the invention are active metabolites of compounds of formula I (including prodrugs), i.e., compounds that are formed in vivo upon administration of the drug, often by oxidation or dealkylation. Some examples of metabolites according to the invention are: (i) When the compound of formula I contains a methyl group, its hydroxymethyl derivative (-CH3 → -CH2OH) and (ii) When the compound of formula I contains an alkoxy group, its hydroxy derivative (-OR→-OH) Includes.
[0099] The compounds of the present invention may exist in a continuum of solid states ranging from completely amorphous to completely crystalline. The term "amorphous" refers to a state in which the material lacks long-range order at the molecular level and may exhibit the physical properties of a solid or liquid depending on temperature. Typically, such materials do not exhibit a distinctive X-ray diffraction pattern, and while they exhibit the properties of a solid, they are more formally described as liquids. Upon heating, a change from solid to liquid properties occurs, which is typically characterized by a second-order state change ("glass transition"). The term "crystalline" refers to a solid phase in which the material has an internal structure that is regularly ordered at the molecular level and exhibits a distinctive X-ray diffraction pattern with defined peaks. When such materials are heated sufficiently, they also exhibit the properties of a liquid, but the change from solid to liquid is typically characterized by a first-order phase change ("melting point").
[0100] Compounds of formula I may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between the true crystalline state and the true liquid state (melt or solution). Liquid crystallinity resulting from a change in temperature is described as "thermotropic" and liquid crystallinity resulting from the addition of a second component such as water or another solvent is described as "lyotropic". Compounds that may form lyotropic mesophases are described as "amphiphilic" and may be ionic (-COO - Na + , -COO - K + , or -SO3 - Na +) or non-ionic (-N - N + It consists of molecules with a polar head group (such as (CH3)3). For more information, see Crystals and the Polarizing Microscope, 4th Edition, by N.H. Hartshorne and A. Stuart (Edward Arnold, 1970).
[0101] Compounds of formula I may exhibit polymorphism and / or one or more types of isomerism (e.g., optical, geometric, or tautomerism). Compounds of formula I may be isotopically labeled. Such variations are implicit in the compounds of formula I defined as such by reference to their structural features, and are therefore within the scope of the present invention.
[0102] The term "room temperature or ambient temperature" means a temperature between 18° C. and 25° C., "HPLC" refers to high pressure liquid chromatography, "MPLC" refers to medium pressure liquid chromatography, "TLC" refers to thin layer chromatography, "MS" refers to mass spectrometry or mass analysis or mass spectrometry, "NMR" refers to nuclear magnetic resonance spectroscopy, "DCM" refers to dichloromethane, "DMSO" refers to dimethylsulfoxide, "DME" refers to 1,2-dimethoxyethane, "EtOAc" refers to ethyl acetate, "MeOH" refers to methanol, "Ph" refers to a phenyl group, "Pr" refers to propyl, "trityl" refers to a triphenylmethyl group, "ACN" refers to acetonitrile, "DEAD" refers to diethyl azodicarboxylate, and "DIAD" refers to diisopropyl azodicarboxylate.
[0103] Generally, the compounds of the present invention can be prepared by processes including those similar to those known in the chemical art, especially in light of the description contained herein.Certain processes for the preparation of the compounds of the present invention are provided as further features of the present invention and are illustrated by the following reaction schemes.Other processes can be described in the experimental section.Specific synthetic schemes for preparing the compounds of formula I are outlined below.
[0104] As used herein, the expressions "reaction inert solvent" and "inert solvent" refer to a solvent or mixture thereof that does not interact with the starting materials, reagents, intermediates, or products in a manner that adversely affects the yield of the desired product.
[0105] As an initial note on the preparation of the compounds of formula I, it should be noted that some of the preparation methods useful for preparing the compounds described herein may require protection of remote functional groups (e.g., primary amines, secondary amines, carboxyls in the precursors of formula I). The need for such protection will vary depending on the nature of the remote functional group and the conditions of the preparation method. The need for such protection is easily determined by those skilled in the art. The use of such protection / deprotection methods is also within the skill of those skilled in the art. For a general overview of protecting groups and their use, see TW Greene, Protective Groups in Organic Synthesis, John Wiley&Sons, New York, 1991.
[0106] For example, certain compounds contain primary amine or carboxylic acid functional groups that, if left unprotected, may interfere with reactions at other sites of the molecule. Therefore, such functional groups may be protected by suitable protecting groups that can be removed in a subsequent step. Suitable protecting groups for amine and carboxylic acid protection include those commonly used in peptide synthesis (such as N-tert-butoxycarbonyl, benzyloxycarbonyl and 9-fluorenylmethyleneoxycarbonyl for amines, and lower alkyl or benzyl esters for carboxylic acids), which are generally not chemically reactive under the reaction conditions described, and can typically be removed without chemically altering other functional groups in the compound of formula I.
[0107] The compounds and intermediates of formula I may contain asymmetric or chiral centers, and therefore may exist in various stereoisomeric forms.Unless otherwise specified, all stereoisomeric forms of the compounds, as well as mixtures thereof, including racemic mixtures, are intended to be included herein.In addition, all geometric and positional isomers are included within the scope of the compounds.For example, if a compound introduces a double bond or a condensed ring, both cis and trans forms, as well as mixtures, are included within the scope of the present invention.
[0108] In addition, the compounds and intermediates of formula I include all atropisomers and stereoisomeric mixtures thereof, including racemic mixtures. Atropisomers include those that can be isolated as separate stereoisomers and maintain their stereoisomeric purity over various periods of time, including medium and long term. Atropisomers also include isomers that cannot be readily separated as separate stereoisomers by interconversion over some period of time, including short to medium term.
[0109] The chiral compounds of the invention (and their chiral precursors) can be obtained in enantiomerically enriched form on the resin using chromatography, typically high pressure liquid chromatography (HPLC) or supercritical fluid chromatography (SFC), with a chiral stationary phase and a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing 0 to 50% isopropanol, typically 2 to 20%, and 0 to 5% alkylamine, typically diethylamine (DEA) or 0.1% isopropylamine. The eluent is concentrated to give the enriched mixture.
[0110] Diastereoisomeric mixtures can be separated into their individual diastereoisomers on the basis of their physicochemical differences by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereoisomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers, and converting the individual diastereoisomers into the corresponding pure enantiomers (e.g., by hydrolysis). Enantiomers can also be separated by the use of chiral HPLC columns. Alternatively, specific stereoisomers can be synthesized by using optically active starting materials, by asymmetric synthesis using optically active reagents, substrates, catalysts, or solvents, or by asymmetric transformation to convert one stereoisomer into another.
[0111] Where a compound has two or more asymmetric centers and the absolute or relative stereochemistry is indicated in the name, the symbols R and S each refer to each asymmetric center in ascending numerical order (1, 2, 3, etc.) according to the conventional IUPAC numbering scheme for each molecule. Where a compound has one or more asymmetric centers and the stereochemistry is not indicated in the name or structural formula, it is understood that the name or structure is intended to encompass all forms of the compound, including racemates.
[0112] The compounds of the present invention may contain olefin-like double bonds. When such bonds exist, the compounds of the present invention exist as cis and trans configurations, as well as mixtures thereof. The term "cis" refers to the orientation of two substituents relative to each other and to the plane of the ring (either both "up" or both "down"). Similarly, the term "trans" refers to the orientation of two substituents relative to each other and to the plane of the ring (they are on opposite sides of the ring).
[0113] The intermediates and compounds of formula I may also exist in different tautomeric forms, and all such forms are included within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via the migration of a proton, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is the tetrazole moiety, where a proton can migrate between the four ring nitrogens as follows:
[0114] [ka]
[0115] Valence tautomers include interconversions by reorganization of some of the bonding electrons.
[0116] All stereoisomers, geometric isomers, and tautomeric forms of the compounds of formula I, including compounds exhibiting more than one type of isomerism and mixtures thereof, are included within the scope of the claimed compounds of the present invention. Also included are acid addition or base salts in which the counterion is optically active, such as D-lactate or L-lysine, or racemic, such as DL-tartrate or DL-arginine.
[0117] Compounds of formula I can be prepared according to the general schemes and examples provided herein.
[0118] General Scheme Compounds of formula I can be prepared according to Schemes I-X, in which the variables A, X1, X2, X3, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and Z are given the previously described meanings unless otherwise noted. Further, in Schemes I-X, the variable group R 14 is H or C1-C6 (alkyl), R 15 is C1-C6 (alkyl), R * is H or C1-C6 (alkyl), R ** is H or C1-C6 (alkyl), or R * and R ** together with the O atom and the B group form a heterocyclic compound which may be substituted with 1, 2, 3, 4, 5 or 6 C1-C6 (alkyl).
[0119] [ka]
[0120] Compounds of formula I can be prepared by hydrolysis of compounds of formula H, as shown in Scheme I. One skilled in the art will recognize that there are various methods for ester hydrolysis. Benzothiopheneic or benzofuranic compounds of formula I can be prepared from formula H esters by hydrolysis reaction with a suitable hydroxide source. Conditions for this conversion include, but are not limited to, reaction of the ester with an inorganic hydroxide, including the following exemplary procedures. The formula H ester is hydrolyzed to the corresponding formula I, for example, by reaction with sodium hydroxide or with lithium hydroxide. Suitable solvents include methanol, ethanol, water, 2-methyltetrahydrofuran, and tetrahydrofuran. The reaction is heated at a temperature of about 25° C. to about 90° C., typically at about 25° C., for about 1 hour to about 16 hours, typically about 16 hours.
[0121] [ka]
[0122] The benzothiophene or benzofuran acid compound of formula I is
[0123] [ka] Alternatively, compounds of formula I' having A as shown in Scheme II can be prepared using later aryl ring modification of formula IA or IB acids as shown in Scheme II. For example, formula IA acids having a methoxy group can be dealkylated with various reagents including boron tribromide in a suitable solvent such as dichloromethane at about 0°C to about 25°C, usually for about 16 hours. Formula IB acids having an acidic hydrogen on the same aryl ring can be deprotonated by various methods known to those skilled in the art. For example, deprotonation of compounds of formula IB can be achieved with n-butyllithium or lithium diisopropylamide, preferably lithium diisopropylamide, in a suitable solvent such as tetrahydrofuran at a temperature of approximately -60°C for about 1 hour. The anion can then be trapped with a number of electrophiles such as N-chlorosuccinimide at about -60°C for about 1 hour.
[0124] [ka]
[0125] Formula H esters can be prepared from the corresponding compounds of formula E or formula F by a variety of methods known to those skilled in the art, as shown in Scheme III. As an example, Suzuki reaction with coupling partners such as compounds of formula D and formula G could provide compounds of formula H. This derivatization can be accomplished using a variety of reagents including potassium fluoride, tripotassium phosphate, potassium carbonate, potassium bicarbonate and cesium carbonate, preferably potassium fluoride, in a wide range of solvents including tetrahydrofuran, 1,4-dioxane, toluene and water. The reaction can proceed using a number of suitable catalysts and catalyst-ligand combinations. Exemplary catalysts and catalyst-ligand combinations include chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2), tris(dibenzylideneacetone)dipalladium(0), tetrakis(triphenylphosphine)palladium(0), methanesulfonyl[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) [P(t-Bu)3Pd G3], allylpalladium(II) chloride dimer, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) [Pd(amphos)2Cl2] and / or chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) [P(t-Bu)3Pd G2]. Exemplary ligands include tri-tert-butylphosphine, tri-tert-butylphosphonium tetrafluoroborate and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl. Heating may be required to drive the reaction at a temperature of about 60°C to about 120°C, usually about 80°C, for a period of about 1 to 24 hours, usually about 16 hours. Where atropisomerism is observed, separation using chiral techniques known to those skilled in the art may result in single atropisomers.
[0126] [ka]
[0127] Alternatively, as shown in Scheme IV, esters of formula H can be synthesized by additional methods available to one of skill in the art. For example, compounds of formula K can be obtained by brominating compounds of formula J using a suitable reagent such as N-bromosuccinimide in various suitable polar solvents such as N,N-dimethylformamide, acetonitrile, or preferably acetic acid. A suitable temperature for the reaction is about 80° C. for 16 hours. Compounds of formula H can be prepared from the corresponding compounds of formula K by various methods known to those of skill in the art. As shown in Scheme IV, Suzuki coupling reaction with a corresponding coupling partner such as a compound of formula D can provide compounds of formula H. This derivatization can be achieved in a suitable solvent system such as 1,4-dioxane and water with various reagents including, but not limited to, cesium carbonate and tetrakis(triphenylphosphine)palladium(0). The reaction can proceed at a temperature of 80° C. for 16 hours. Further exemplary Suzuki coupling reaction conditions are described in Scheme III.
[0128] Aryl bromides such as the compound of formula M can be prepared by various methods available to one skilled in the art. For example, the compound of formula L can be brominated in various suitable organic solvents, preferably dichloromethane, using a suitable reagent such as N-bromosuccinimide. The suitable temperature for the reaction is about 25°C to about 35°C for 20 hours. The aryl bromides of formula M can be derivatized to the compound of formula H by catalytic esterification under carbon monoxide atmosphere. A list of suitable catalyst-ligand combinations includes, but is not limited to, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane complex. Various bases, preferably N,N-diisopropylethylamine, can be used for this transformation. The reaction can proceed with heating at about 70°C for 16 hours. Various protic solvents can be used for this esterification, but methanol is preferred.
[0129] Compounds of formula H can also be prepared from compounds of formula N by reaction of Weinreb amide compounds such as those described by compounds of formula N after metal-halogen exchange of aryl halides of formula G to give compounds of formula O. This metal-halogen exchange can be carried out under various conditions known to those skilled in the art. For example, reagents such as isopropyl magnesium chloride and tert-butyl lithium can be used, but preferably n-butyl lithium is used. Various aprotic solvents such as diethyl ether, 2-methyltetrahydrofuran, and tetrahydrofuran can be used for this reaction. The reaction can proceed at a temperature of about -78°C for about 3 hours. Condensation of compounds of formula O with acetate as shown in scheme IV can provide compounds of formula H. An example of this transformation can involve the use of ethyl sulfanylacetate and other reagents such as potassium carbonate and N,N-dimethylformamide. The reaction can be heated to 100°C for about 16 hours to give compounds of formula H.
[0130] [ka]
[0131] Amino-benzothiophene and amino-benzofuran compounds of formula E2 can be prepared from formula P1 or formula P2 nitriles by alkylation followed by internal condensation with the nitrile group as shown in Scheme V. Conditions for this transformation include, but are not limited to, reacting the formula P1 compound with an alkyl sulfanylacetate and treating with a base to obtain the desired amino-benzothiophene. A list of suitable bases for this reaction includes sodium hydroxide, potassium carbonate, and triethylamine. Dimethylsulfoxide and N,N-dimethylformamide can be used as solvents, and the use of 18-crown-6 could facilitate this condensation. The reaction can be carried out at a temperature of about 0° C. to about 130° C. in certain cases, typically at about 0° C., for about 3 hours to about 16 hours, typically about 3 hours. Alkylation of the formula P2 compound with an alkyl bromoacetate can provide the compound of formula E1. As an example, this transformation can proceed with acetonitrile as a suitable solvent and potassium carbonate as a suitable base. The reaction can be carried out at a temperature of 15° C. for about 16 hours. The desired amino-benzofuran can be obtained from cyclization of the formula E1 compound with tetrahydrofuran as a suitable solvent and potassium tert-butoxide as a suitable base. The reaction can proceed at a temperature of about 0° C. for about 2 hours.
[0132] Esters of formula E can be prepared, for example, by Sandmeyer reaction of amines of formula E2. This can be accomplished using a variety of reagents depending on the desired aryl halide of formula E. These include copper(II) bromide, copper(I) iodide, copper(II) chloride, diiodomethane, tert-butyl nitrite and 3-methylbutyl nitrite in a suitable solvent such as acetonitrile. The reaction can proceed at 0° C. or the reaction can be heated to the reflux temperature of the appropriate solvent. Suitable reaction times are typically between about 1 hour and 16 hours. Aryl boronic esters of formula F can then be prepared from aryl halides of formula E by Miyaura reaction with a boronic ester source such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane. The reaction can occur in a variety of suitable solvents including 1,4-dioxane and a suitable base such as potassium acetate can be used. The conversion may require the use of a catalyst-ligand combination such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). The reaction can be heated to the reflux temperature of the appropriate solvent. The suitable reaction time is typically about 16 hours.
[0133] [ka]
[0134] The required boronic acids or esters of formula D above can be prepared by various methods known to those skilled in the art, as shown in Scheme VI. For example, compounds of formula D can be obtained by Miyaura boration of aryl halides of formula G1, typically aryl bromides or aryl iodides. Various catalysts and catalyst-ligand combinations can be used, including but not limited to [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II). A variety of ligands and reagents such as 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, tetrahydroxydiborane, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane, potassium acetate, sodium tert-butoxide, and ethane-1,2-diol can be used to affect the Miyaura transformation. Suitable solvents for this reaction can be N,N-dimethylformamide, 1,4-dioxane, and methanol. The reaction can proceed at a temperature of about 50° C. to about 100° C. for about 16 hours.
[0135] Alternatively, boronic acids or esters of formula D can be prepared by metal-halogen exchange or deprotonation of compounds of formula G1. Reagents such as n-butyl lithium and isopropyl magnesium chloride can be used to carry out the exchange. Various reagents such as 4,4,5,5-tetramethyl-2-(propan-2-yloxy)-1,3,2-dioxaborolane and trimethyl borate can be used as boronate sources. The reaction can be carried out at a temperature of about -78°C to about 25°C, preferably at -78°C, for about 1 hour. Aprotic solvents such as diethyl ether, 2-methyltetrahydrofuran, methyl tert-butyl ether, but preferably tetrahydrofuran, can be used.
[0136] An alternative method to obtain boronic acids or esters of formula D can be boronation by CH activation of arenes such as compounds of formula G1. An example of this transformation can use (1,5-cyclooctadiene)(methoxy)iridium(I) dimer as catalyst and 4,4'-di-tert-butyl-2,2'-bipyridine as ligand. A suitable boronate source for this reaction can be 4,4,5,5-tetramethyl-1,3,2-dioxaborolane, and tetrahydrofuran can be used as a suitable solvent for this derivatization. A temperature of about 80°C for about 16 hours can be required to obtain the desired boronic acid or ester.
[0137] [ka]
[0138] Arenes of formula Q1, Q2, Q3 and Q4 can be prepared from various conventional modifications known to those skilled in the art as shown in Scheme VII. Examples of these modifications can include, but are not limited to, the reaction of an aldehyde of formula T with a suitable reagent such as methylmagnesium bromide in tetrahydrofuran at a temperature of about -78°C to 0°C for about 2 hours. A secondary alcohol of formula U can be reacted with an activating group such as methanesulfonyl chloride to obtain a compound of formula V where LG is a leaving group such as mesylate, tosylate, or triflate. A suitable base to use for this reaction can be triethylamine, and a suitable solvent for this transformation can be dichloromethane at a temperature of about 0°C for about 30 minutes. Reduction of the compound of formula V can be achieved with lithium triethylborohydride. A variety of aprotic solvents can be used for this reaction, but tetrahydrofuran may be preferred. A suitable reaction temperature can be about 0°C for about 30 minutes to obtain a compound such as formula Q1 arene.
[0139] Compounds of formula Q2 can be prepared from compounds of formula W by iodination followed by halogen dance reaction known to those skilled in the art. Iodination of compounds of formula W can be carried out with electrophiles such as n-butyllithium and iodine at temperatures of about -78°C to about 20°C for about 3 hours. Many aprotic solvents can be used for this process, but tetrahydrofuran may be preferred. Compounds of formula X can be treated with a base such as lithium diisopropylamide in a suitable solvent such as tetrahydrofuran to transfer the halogen. Typical temperatures for this reaction can be from -65°C to about 20°C for 2 hours.
[0140] Benzoic acids of formula Y can be iodized by a palladium catalyzed process to give compounds of formula Z. Various catalysts such as palladium (II) acetate can be used to carry out this reaction with reagents such as iodine and (diacetoxyiodo)benzene. An aprotic solvent such as N,N-dimethylformamide at a temperature of about 120° C. for about 16 hours may be required for the conversion to occur. Compounds of formula AA can be prepared from compounds of formula Z by conditions known to those skilled in the art. As an example, compounds of formula Z can be treated with 1H-benzotriazol-1-ol, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 4-methylmorpholine and aqueous ammonium hydroxide. Many aprotic solvents can be used for this reaction, but tetrahydrofuran may be preferred. The reaction temperature can be about 15° C. for about 16 hours. Aryl nitriles of formula Q3 can be synthesized from compounds of formula AA under dehydrating conditions. Various reagents such as trifluoroacetic anhydride and pyridine may be suitable for this conversion. Dichloromethane may be a suitable solvent for this reaction at a temperature of about 15° C. for about 16 hours.
[0141] Modification of iodoarenes of formula AB can be accomplished with a suitable base, such as lithium diisopropylamide, at temperatures of about −78° C. to 25° C. A number of electrophiles, such as iodomethane, can then be used for about 1 hour to give compounds of formula Q4. About 16 hours may be required for derivatization to occur.
[0142] [ka]
[0143] In addition, R ’ Compounds of formula Q5, where is (C1-C4) alkyl or (C1-C4) fluoroalkyl, can be prepared by an alternative route, as shown in Scheme VIII. Nucleophilic displacement of a leaving group on an arene, such as a compound of formula AC, can provide a compound of formula AD. For example, a compound of formula AD can be prepared using a suitable nucleophile, such as sodium methoxide, in methanol, when an aryl ether is shown. A suitable temperature for the reaction can typically be about 25° C. for about 16 hours. Compounds of formula AD can be mono-debrominated to provide compounds of formula Q5 using a variety of conditions known to those skilled in the art. As an example, a base such as n-butyl lithium can be used with a suitable solvent such as diethyl ether. A typical reaction temperature for this reaction can be −78° C. for about 5 hours.
[0144] Alternatively, arenes of formula Q5 can be prepared from aryl bromides of formula AE. For example, boronation of a compound of formula AE with a base such as lithium diisopropylamide can provide the desired aryl boronic acid of formula AF. This transformation can be carried out in a number of suitable solvents such as tetrahydrofuran and diethyl ether, preferably in methyl tert-butyl ether. The lithium-aryl complex can be quenched with an electrophile such as trimethyl borate, which will provide an arene of formula AF when treated with an aqueous acid such as hydrogen chloride. Typical temperatures for this reaction can be from about -70°C to about 0°C for about 4 hours. Phenols of formula AG can be prepared by hydroxylation of boronic acids of formula AE using a variety of reagents, preferably hydrogen peroxide. When a solvent is used, suitable solvents include ethanol, methanol, N,N-dimethylformamide, or preferably dichloromethane. Suitable temperatures for the above reaction are typically between 30°C and 40°C. Suitable reaction times are typically about 16 hours. Aryl ethers of formula Q5 can be conveniently prepared from the corresponding phenols of formula AG by reaction under a variety of conditions including alkylation with iodomethane in a suitable polar aprotic solvent such as acetone for about 16 hours at a temperature between about −10° C. and 30° C., preferably at ambient temperature, with the addition of an inorganic base such as potassium carbonate. It will be apparent to one of skill in the art that there are other methods of accomplishing this transformation in addition to those described.
[0145] [ka]
[0146] There are a wide variety of approaches that one skilled in the art can follow to prepare compounds of formula R as shown in Scheme IX, where X represents halo. For example, a compound of formula AH can be reacted with ethyl (triphenyl-λ) ether in a suitable solvent, such as dichloromethane. 5-phosphanylidene) acetate can give arylethyl prop-2-enoates. A typical temperature for this transformation can be about 25° C. for 16 hours. The resulting alkene can be reduced with a catalyst such as nickel(II) hexahydrate in combination with sodium borohydride to give compounds of formula AI. A variety of solvents or combinations of solvents can be used, but preferably a mixture of tetrahydrofuran and methanol can be used. The reaction can be carried out at a temperature of about 0° C. for about 1 hour. Acid catalyzed condensation of phenols of formula AI with an acid such as p-toluenesulfonic acid can give compounds of formula AJ. A typical reaction time can be 16 hours at a suitable temperature of about 130° C. Compounds of formula AK can be prepared from compounds of formula AJ with a reducing agent such as diisobutylaluminum hydride. A suitable solvent for this transformation can be dichloromethane for about 3 hours. A suitable temperature for the reaction is between about −78° C. and 0° C., preferably about −78° C.
[0147] For compounds of formula AK, further derivatization can be carried out by the addition of an alkylating agent, including but not limited to methylmagnesium bromide, in a suitable aprotic solvent such as diethyl ether to give diols of formula AL. The suitable temperature for the reaction is between about 0° C. and 25° C., preferably about 0° C. The reaction time is about 3 to about 16 hours, typically about 3 hours. Acid-mediated dehydration of compounds of formula AL can finally give compounds of formula R. An example of a reagent combination that can be used for this reaction is a mixture of sulfuric acid and acetic acid. Typically, the reaction can be carried out at a suitable temperature of about 100° C. for about 3 hours.
[0148] Additional methods for obtaining compounds of formula R can be derived from compounds of formula AM. As an example, alkylation of phenols of formula AM with electrophiles such as 1,3-dibromopropane in a suitable solvent such as acetonitrile can be carried out in the presence of an inorganic base such as potassium carbonate. A suitable temperature for this derivatization can be about 80° C. for 16 hours. Compounds of formula R can be prepared from compounds of formula AN. This transformation can be carried out using a base such as n-butyl lithium. The reaction can proceed in a variety of aprotic solvents such as methyl tert-butyl ether, diethyl ether, 2-methyltetrahydrofuran, or preferably tetrahydrofuran. The reaction can provide compounds of formula R at temperatures from about −78° C. to about room temperature for 2 to about 16 hours. Alternatively, compounds of formula AP can be used to synthesize compounds of formula R. Compounds of formula AQ can be prepared by treating compounds of formula AP with a reagent such as (2E)-but-2-enoic acid in the presence of an acid such as methanesulfonic acid. The reaction may proceed at a temperature of about 100° C. for about 16 hours. Reduction of the compound of formula AQ may be carried out with an organo-silane such as triethylsilane under acidic conditions. Typically, trifluoroacetic acid may be used. A suitable temperature for carrying out the reaction is about 25° C. for about 3 days.
[0149] Base-promoted condensation of a compound of formula AR with an appropriate aldehyde can provide a compound of formula AQ. Typically, pyrrolidine can be used for this transformation in a suitable protic solvent such as ethanol. The temperature of the reaction can range from about 20° C. to about 70° C. for about 3 hours. A compound of formula R can be obtained after reduction of a compound of formula AQ under similar reaction conditions as described above using an organo-silane reagent such as triethylsilane and an acid such as trifluoroacetic acid. In addition, a compound of formula AQ can be derivatized by treatment with an alkylating agent such as methylmagnesium bromide in a suitable solvent such as tetrahydrofuran to give a compound of formula AO. Cerium(III) chloride can be used to facilitate this transformation, which can be achieved at a temperature of about −50° C. to about 25° C. for about 16 hours. Reductive dehydration of a compound of formula AO can finally provide a compound of formula R by treatment with a reagent such as triethylsilane in combination with boron trifluoride diethyl etherate. A typical reaction temperature can be about 0° C. for 30 minutes.
[0150] [ka]
[0151] The compound of formula AR can be further refined by various methods known to those skilled in the art prior to Suzuki coupling. Such transformations include, but are not limited to, the example shown in Scheme X. For example, the compound of formula AR can be derivatized at the alpha position of the ketone by various methods. By way of example, alkylation at the alpha position to the ketone can be initiated by enolate formation with a combination of reagents such as lithium diisopropylamide and N,N,N',N',N",N"-hexamethylphosphoric triamide. A variety of suitable polar aprotic solvents can be used, such as diethyl ether or preferably tetrahydrofuran. A suitable temperature for the reaction is between about -78°C and 0°C. Addition of the electrophile can result in a compound of formula AQ after a typical reaction time of about 4 hours in total. Reduction of the carbonyl in the compound of formula AQ to give the compound of formula S can be carried out using an organosilane such as triethylsilane under acidic conditions. Typically, trifluoroacetic acid can be used. A suitable temperature for carrying out the reaction is about 50°C for about 16 hours. It will be apparent to those skilled in the art that many of these derivatives may themselves be suitable for further manipulation to access additional compounds of formula S.
[0152] In a similar manner, derivatization of a compound of formula AS can also provide a compound of formula S. For example, metal-halogen exchange of a compound of formula AS with a suitable reagent such as (propan-2-yl)magnesium chloride in a suitable aprotic solvent such as tetrahydrofuran can be followed by reaction with an electrophile in the presence of copper(I) iodide to obtain a compound of formula AT. A variety of electrophiles can be used for similar transformations known to those skilled in the art, for example, the use of 3-bromo-2-methylprop-1-ene can provide a compound of formula AT at a typical temperature of about -20°C to about 25°C. The reaction can require about 16 hours. Hydroboration-oxidation of a compound of formula AT can provide a compound of formula AU. Many reagents can be used to achieve the above transformation; for example, the use of borane in tetrahydrofuran can provide a compound of formula AU with the use of sodium hydroxide and hydrogen peroxide. Typical reaction temperatures can be from about 0°C to about 60°C over about 4 hours in a stepwise approach. Intramolecular nucleophilic aromatic substitution of a compound of formula AU can provide a compound of formula S. As an example, the use of a compound of formula AU with sodium hydride in a variety of solvents known to those skilled in the art, but preferably a mixture of toluene and N,N-dimethylformamide, can provide a compound of formula S. Suitable temperatures for carrying out the reaction are between about 0° C. and room temperature. Suitable reaction times are about 16 hours. It will be apparent to those skilled in the art that many of these derivatives may themselves be suitable for further manipulation to access additional compounds of formula S.
[0153] The starting materials and reagents for the above-mentioned formula I compounds are also easily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis.For example, many of the compounds used herein are related to or derived from compounds that have great scientific interest and practical demand, and therefore many of these compounds are commercially available or have been reported in the literature, or can be easily prepared from other commercially available materials by methods that have been reported in the literature.
[0154] The present application is also directed to pharmaceutical compositions having a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt of said compound, and a pharma- ceutically acceptable carrier, vehicle, or excipient.
[0155] The compounds of the present invention may also be used in conjunction with other medicinal agents (e.g., anti-atherosclerotic and anti-thrombotic agents) to treat the diseases / conditions described herein. a first compound which is any compound of formula I or a pharma- ceutically acceptable salt of said compound; a second compound which is a treatment for kidney disease, an antidiabetic agent; a treatment for nonalcoholic steatohepatitis, a treatment for nonalcoholic fatty liver disease, or an anti-heart failure treatment, and Pharmaceutical Carriers, Vehicles or Excipients Also of interest is a pharmaceutical combination composition comprising a therapeutically effective amount of a composition having the formula:
[0156] In one embodiment, the treatment for renal disease is useful for treating acute and / or chronic renal disease.
[0157] In one embodiment, the agent treating non-alcoholic steatohepatitis or non-alcoholic fatty liver disease is an ACC inhibitor, a KHK inhibitor, a DGAT-2 inhibitor, an FXR agonist, a GLP-1R agonist, metformin, an incretin analog, or an incretin receptor modulator.
[0158] In another embodiment, the antidiabetic agent is an SGLT-2 inhibitor, metformin, an incretin analog, an incretin receptor modulator, a DPP-4 inhibitor, or a PPAR agonist.
[0159] In another embodiment, the antidiabetic agent is metformin, sitagliptin, or ertuglifozin.
[0160] In another embodiment, the anti-heart failure agent is an ACE inhibitor, angiotensin receptor blocker, angiotensin-receptor neprilysin inhibitor, beta adrenergic receptor blocker, calcium channel blocker, or a vasodilator.
[0161] Combination drugs The compound may be administered alone or in combination with one or more additional therapeutic agents. By "administered in combination" or "combination therapy" is meant that the compound and one or more additional therapeutic agents are administered simultaneously to the mammal being treated. When administered in combination, each component may be administered simultaneously or sequentially in any order at different times. Thus, each component may be administered separately but sufficiently close in time to provide the desired therapeutic effect. The phrases "concurrent administration", "co-administration", "simultaneous administration" and "administered at the same time" mean that the compound is administered in combination. Thus, the methods of prevention and treatment described herein include the use of combinations.
[0162] The combination is administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" is meant an amount of a compound of formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to treat the desired disease / condition (e.g., NASH, heart failure, kidney disease, or diabetes).
[0163] Given the NASH / NAFLD activity of the compounds of the present invention, they are useful in treating non-alcoholic steatohepatitis (NASH) and / or non-alcoholic fatty liver disease (NAFLD) and related diseases / conditions, as well as in treating chronic inflammatory bowel disease (CIHD) and / or chronic obstructive pulmonary disease (COPD) and related conditions, including, but not limited to, orlistat, TZDs and other insulin sensitizers, FGF21 analogs, metformin, omega-3-acid ethyl esters (e.g., Lovaza), fibrates, HMG-CoA reductase inhibitors (e.g., pravastatin), and other inflammatory bowel disease inhibitors (e.g., cerebrovascular disease, pulmonary arterial disease, and pulmonary arterial disease). , lovastatin, atorvastatin, simvastatin, fluvastatin, NK-104 (also known as itavastatin, nisvastatin, or nisbastatin) and ZD-4522 (also known as rosuvastatin, atavastatin, or visastatin), ezetimibe, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors (e.g., evolocumab, alirocumab), probucol, ursodeoxycholic acid, TGR5 agonists , FXR agonists, vitamin E, betaine, pentoxifylline, CB1 antagonists, carnitine, N-acetylcysteine, reduced glutathione, lorcaserin, combinations of naltrexone and bupropion, SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, ertugliflozin, ASP-1941, THR1474, TS-071, ISIS388626 and LX4211 and WO2010023594 in ), phentermine, topiramate, GLP-1 receptor agonists, GIP receptor agonists, dual GLP-1 receptor / glucagon receptor agonists (i.e., OPK88003, MEDI0382, JNJ-64565111, NN9277, BI456906), dual GLP-1 receptor / GIP receptor agonists (i.e., tirzepatide (LY3298176), NN9423), angiotensin receptor blockers acetyl-CoA carboxylates The compound may be co-administered with an ACC inhibitor, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, such as those described in WO09016462 or WO2010086820, AZD7687 or LCQ908, a diacylglycerol O-acyltransferase 2 (DGAT-2) inhibitor, a PNPLA3 inhibitor, an FGF21 analogue, an FGF19 analogue, a PPAR agonist, an FXR agonist, an AMPK activator, an SCD1 inhibitor or an MPO inhibitor.
[0164] Exemplary GLP-1 receptor agonists include liraglutide, albiglutide, exenatide, albiglutide, lixisenatide, dulaglutide, semaglutide, HM15211, LY3298176, Medi-0382, NN-9924, TTP-054, TTP-273, epheglenatide, those described in WO2018109607, and those described in PCT / IB2019 / 054867, filed June 11, 2019, including: 2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-3-(1,3-oxazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-4-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(pyridin-3-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-5-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-1,2,3-triazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, DIAST-X2; and 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharma- ceutically acceptable salt thereof.
[0165] Exemplary ACC inhibitors include 4-(4-[(1-isopropyl-7-oxo-1,4,6,7-tetrahydro-1'H-spiro[indazole-5,4'-piperidine]-1'-yl)carbonyl]-6-methoxypyridin-2-yl)benzoic acid; and Filsocostat (GS-0976), and pharma-ceutically acceptable salts thereof.
[0166] Exemplary FXR agonists include tropifexor (2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid); cilofexor (GS-9674); obeticholic acid, LY2562175; Met409; TERN-101; and EDP-305, and pharma-ceutical acceptable salts thereof.
[0167] An exemplary DGAT2 inhibitor is (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxy-5-fluoropyridin-2-yl)oxy)pyridin-3-yl)-N-((3R,4S)-4-fluoropiperidin-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxy-5-fluoropyridin-2-yl)oxy)pyridin-3-yl)-N-((3S,5S)-5-fluoropiperidin-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3R,4S)-4-fluoropiperidin-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3R,4R)-4-fluoropiperidin-3-yl)pyrimidine-5-carboxamide; 2-(5-((3-ethoxy-5-fluoropyridin-2-yl)oxy)pyridin-3-yl)-N-((3R,4R)-4-fluoropiperidin-3-yl)pyrimidine-5-carboxamide; and 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3S,5S)-5-fluoropiperidin-3-yl)pyrimidine-5-carboxamide, or a pharma- ceutically acceptable salt thereof.
[0168] Exemplary KHK inhibitors include [(1R,5S,6R)-3-{2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid and pharma- ceutically acceptable salts thereof.
[0169] Considering the antidiabetic activity of the compounds of the present invention, they may be co-administered with other antidiabetic agents. Suitable antidiabetic agents include insulin, metformin, GLP-1 receptor agonists (as described herein above), acetyl-CoA carboxylase (ACC) inhibitors (as described herein above), SGLT2 inhibitors (as described herein above), monoacylglycerol O-acyltransferase inhibitors, phosphodiesterase (PDE)-10 inhibitors, AMPK activators, sulfonylureas (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), meglitinides, α-amylase inhibitors (e.g., tendamistat, trestatin, and AL-3688), α-glucosides hydrochloride, cyclosporine ... dolorase inhibitors (e.g., acarbose), α-glucosidase inhibitors (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), PPARγ agonists (e.g., balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, and rosiglitazone), tazone), PPARα / γ agonists (e.g., CLX-0940, GW-1536, GW-1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767, and SB-219994), protein tyrosine phosphatase-1B (PTP-1B) inhibitors (e.g., trodusquemine, hyrtiosal extract, and Zhang, S.Drug Discovery Today, 12(9 / 10), 373-381 (2007)), SIRT-1 activators (e.g., resveratrol, GSK2245840 or GSK184072), dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., those in WO2005116014, sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin and saxagliptin), insulin secretagogues, fatty acid oxidation inhibitors, A2 antagonists, c-jun amino-terminal kinase (JNK) inhibitors, glutamate antagonists, glycerol ... Cokinase activators (GKa), such as those described in WO2010103437, WO201010343f8, WO2010013161, WO2007122482, TTP-399, TTP-355, TTP-547, AZD1656, ARRY403, MK-0599, TAK-329, AZD5658 or GKM-001, insulin, insulin mimetics, glycogen phosphorylase inhibitors (e.g., GSK1362885), VPAC2 receptor agonists, glucagon receptor modulators, such as those described in Demong, DE et al., Annual Reports in Medicinal Chemistry 2008, 43, 119-137, GPR119 modulators, particularly agonists, for example those described in WO2010140092, WO2010128425, WO2010128414, WO2010106457, Jones, RM et al., Medicinal Chemistry 2009, 44, 149-170 (e.g. MBX-2982, GSK1292263, APD597 and PSN821), FGF21 derivatives or analogues, for example those described in Kharitonenkov, A. et al., Current Opinion in Investigational Drugs 2009, 44, 149-170 (e.g. MBX-2982, GSK1292263, APD597 and PSN821), 2009, 10(4) 359-364, TGR5 (also called GPBAR1) receptor modulators, particularly agonists, e.g., those described in Zhong, M., Current Topics in Medicinal Chemistry, 2010, 10(4), 386-396 and INT777, GPR40 agonists, including but not limited to TAK-875, Medina, JC, Annual Reports in Medicinal Chemistry, 2008, 43, 75-85, GPR120 modulators, particularly agonists, high affinity nicotinic acid receptor (HM74A) activators, and SGLT1 inhibitors, including GSK1614235. A further representative list of antidiabetic agents that can be combined with the compounds of the present application can be found, for example, in WO2011005611, page 28, line 35 to page 30, line 19.
[0170] Other antidiabetic agents may include inhibitors or modulators of the enzyme carnitine palmitoyltransferase, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 and / or CCR5, inhibitors of PKC isoforms (e.g., PKCα, PKCβ, PKCγ), inhibitors of fatty acid synthase, inhibitors of serine palmitoyltransferase, modulators of GPR81, GPR39, GPR43, GPR41, GPR105, Kv1.3, retinol binding protein 4, glucocorticoid receptors, somatostain receptors (e.g., SSTR1, SSTR2, SSTR3 and SSTR5), inhibitors or modulators of PDHK2 or PDHK4, inhibitors of MAP4K4, modulators of the IL1 family including IL1 beta, modulators of RXR alpha. In addition, suitable antidiabetic agents include those mechanisms listed by Carpino, PA, Goodwin, B. Expert Opin. Ther. Pat, 2010, 20(12), 1627-51.
[0171] Considering the anti-heart failure activity of the compounds of the present application, they are ACE inhibitors (e.g., captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril), angiotensin II receptor blockers (e.g., candesartan, losartan, valsartan), angiotensin-receptor neprilysin inhibitors (sacubitril / valsartan), I f It may be co-administered with other anti-heart failure agents such as the channel blockers ivabradine, beta-adrenergic blockers (e.g., bisoprolol, metoprolol succinate, carvedilol), SGLT2 inhibitors, aldosterone antagonists (e.g., spironolactone, eplerenone), cardiac myosin activators (e.g., omecamtiv mecarbil), guanylate cyclase stimulators (e.g., vericiguat), cardiac myosin inhibitors (e.g., mavacamten), SERCA2a activators (e.g., istaloxime), hydralazine and isosorbide diacid, diuretics (e.g., furosemide, bumetanide, torsemide, chlorothiazide, amiloride, hydrochlorothiazide, indapamide, metolazone, triamterene), or digoxin.
[0172] The compounds of formula I may be used in combination with antihypertensive agents, and such antihypertensive activity is readily determined by those skilled in the art according to standard assays (eg, blood pressure measurements). Examples of suitable antihypertensive agents include alpha adrenergic blockers; beta adrenergic blockers; calcium channel blockers (e.g., diltiazem, verapamil, nifedipine, and amlodipine); vasodilators (e.g., hydralazine), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid, tricrynafen, chlorthalidone, torsemide, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone); renin inhibitors; ACE inhibitors (e.g., captopril, ril, zofenopril, fosinopril, enalapril, ceranopril, cilazapril, delapril, pentopril, quinapril, ramipril, lisinopril; AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan); ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265); dual ET / AII antagonists (e.g., compounds disclosed in WO00 / 01389); neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., gemopatrilat and nitrates). An exemplary antianginal agent is ivabradine.
[0173] Examples of suitable calcium channel blockers (L-type or T-type) include diltiazem, verapamil, nifedipine and amlodipine, as well as mybefradil.
[0174] Examples of suitable cardiac glycosides include digitalis and ouabain.
[0175] In one embodiment, the compound of formula I may be co-administered with one or more diuretics. Examples of suitable diuretics include (a) loop diuretics, such as furosemide (such as LASIX™), torsemide (such as DEMADEX™), bumetanide (such as BUMEX™), and ethacrynic acid (such as EDECRIN™); (b) thiazide diuretics, such as chlorothiazide (such as DIURIL™, ESIDRIX™, or HYDRODIURIL™), hydrochlorothiazide (such as MICROZIDE™ or ORETIC™), benzthiazide, hydroflumethiazide (such as SALURON™), benthiazide, benzo ... (c) phthalimidine diuretics, such as chlorthalidone (such as HYGROTON™) and metolazone (such as ZAROXOLYN™); (d) quinazoline diuretics, such as quinethazone; and (e) potassium-sparing diuretics, such as triamterene (such as DYRENIUM™) and amiloride (such as MIDAMOR™ or MODURETIC™).
[0176] In another embodiment, the compound of formula I may be co-administered with a loop diuretic. In yet another embodiment, the loop diuretic is selected from furosemide and torsemide. In yet another embodiment, one or more compounds of formula I may be co-administered with furosemide. In yet another embodiment, one or more compounds of formula I may be co-administered with torsemide, which may be a controlled or modified release form of torsemide.
[0177] In another embodiment, the compound of formula I may be co-administered with a thiazide diuretic. In yet another embodiment, the thiazide diuretic is selected from the group consisting of chlorothiazide and hydrochlorothiazide. In yet another embodiment, one or more compounds of formula I may be co-administered with chlorothiazide. In yet another embodiment, one or more compounds of formula I may be co-administered with hydrochlorothiazide.
[0178] In another embodiment, one or more compounds of formula I may be co-administered with a phthalimidine diuretic, hi yet another embodiment, the phthalimidine diuretic is chlorthalidone.
[0179] Examples of suitable mineralocorticoid receptor antagonists include spironolactone and eplerenone.
[0180] Examples of suitable phosphodiesterase inhibitors include PDE III inhibitors (such as cilostazol) and PDE V inhibitors (such as sildenafil).
[0181] Those of skill in the art will recognize that the compounds of the present invention may be used in conjunction with other cardiovascular or cerebrovascular procedures, including PCI, stenting, drug-eluting stents, stem cell therapy and medical devices such as implantable pacemakers, defibrillators, or cardiac resynchronization therapy.
[0182] The compounds of formula I may be used in combination with drugs used in the management of chronic kidney disease, including phosphate binders (e.g., sucroferric oxyhydroxide, sevelamer, calcium acetate), sodium bicarbonate, erythropoietin stimulators, oral or intravenous iron preparations (e.g., iron sucrose, ferric carboxymaltose, ferumoxytol), potassium binders, calcitriol, or SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, or other SGLT2 inhibitors listed herein).
[0183] In particular, when provided as a single dosage unit, there is a potential for chemical interaction between the combined active ingredients. For this reason, when the formula I compound and the second therapeutic agent are combined in a single dosage unit, they can be formulated so that the physical contact between the active ingredients is minimized (i.e., reduced) even when the active ingredients are combined in a single dosage unit. For example, one active ingredient can be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also to control the release of one of these ingredients in the gastrointestinal tract, so that these ingredients are not released in the stomach but are released in the intestine. One of the active ingredients can be coated with a material that also serves to achieve sustained release throughout the gastrointestinal tract and minimize the physical contact between the combined active ingredients. In addition, a sustained release component can be additionally enteric coated so that the release of this component occurs only in the intestine. Yet another approach would involve formulating a combination product in which one component is coated with a sustained and / or enteric release polymer to further separate the active ingredients, and the other component is also coated with a polymer such as low viscosity grades of hydroxypropylmethylcellulose (HPMC) or other suitable materials as known in the art. The polymer coating serves to form an additional barrier to interaction with the other component.
[0184] These and other techniques for minimizing contact between the components of the combination product, whether administered in a single dosage form or in separate forms but administered simultaneously by the same mode, will be readily apparent to those of skill in the art upon reading the present disclosure.
[0185] In combination therapy treatment, both the compounds of this invention and the other drug therapies are administered to mammals (eg, humans, male or female) by conventional methods.
[0186] The compounds of formula I of the present invention, their prodrugs and salts of such compounds and prodrugs are all adapted for therapeutic use as agents that inhibit and / or degrade BCKDK in mammals, particularly humans, and are therefore useful in the treatment of a variety of conditions in which such an effect is implicated, such as those described herein.
[0187] Diseases / conditions that may be treated with the compounds of formula I include, but are not limited to, NASH / NAFLD, diabetes, kidney disease, and heart failure and related diseases / conditions.
[0188] In particular, inhibition and / or degradation of BCKDK is associated with NASH / NAFLD and related diseases / conditions, as elevated BCAA levels have been observed in human NASH samples (Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ: Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015, 47:603-15). Decreased levels of PPM1K mRNA and increased levels of BCKDK protein were also observed in human NASH (Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ: Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015, 47:603-15).Treatment of obese mice or rats with BCKDK inhibitors and / or degraders reduced hepatic steatosis and triglyceride content, and overexpression of PPM1K in rats reduced hepatic triglyceride content. (White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, Grenier-Larouche T, An J, Lapworth AL, Astapova I, Hannou SA, George T, Arlotto M, Olson LB, Lai M, Zhang GF, Ilkayeva O, Herman MA, Wynn RM, Chuang DT, Newgard CB: The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. Cell Metab 2018, 27(6), 1281-1293). Furthermore, conditional approvals granted by regulatory agencies for Phase III studies in NASH are based on histological surrogate markers obtained by liver biopsy. These commonly accepted surrogates are i) resolution of NASH without worsening of fibrosis (i.e., a numerical increase in fibrosis stage); ii) reduction of one or more stages in fibrosis without worsening of NASH. Details can be found in Ratziu, A critical review of endpoints for non-cirrhotic NASH therapeutic trials, Journal of Hepatology, 2018, 68.353-361 and references therein.
[0189] Thus, in view of the positive correlation between activation of BCKDK and the occurrence of NASH / NAFLD and related diseases / conditions, the compounds of formula I of the present invention, their prodrugs and salts of such compounds and prodrugs, by their pharmacological action, are useful in preventing, arresting and / or regressing fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic steatohepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.
[0190] In addition, increased BCKDK is associated with heart failure and related diseases / conditions, as increased BCKA has been observed in hearts from patients with heart failure. (Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S, Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y:Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 2016, 133:2038-49).
[0191] In heart failure, the regulatory phosphatase that activates BCKDH (PPM1K) is downregulated and BCKDK is upregulated; thus, BCAA catabolism is likely impaired in heart failure. (Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S, Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y:Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 2016,133:2038-49).
[0192] Both BCKDH and BCKDK are ubiquitously expressed; however, the regulatory phosphatase PPM1K, which dephosphorylates BCKDH, is most highly expressed in cardiac tissue. Mice lacking PPM1K develop age-induced heart failure and have worse cardiac function when subjected to the transverse aortic constriction (TAC) model of heart failure. (Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S, Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y: Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 2016,133:2038-49).
[0193] Use of inhibitors and / or degraders of BCKDK improved cardiac function in three different preclinical heart failure models (TAC, left anterior descending artery ligation / myocardial infarction, and ischemia / reperfusion) (Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S, Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y: Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 2016, 133:2038-49; Wang W, Zhang F, Xia Y, Zhao S, Yan W, Wang H, Lee Y, Li C, Zhang L, Lian K, Gao E, Cheng H, Tao L:Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2016, 311:H1160-H9;Li T, Zhang Z, Kolwicz SC, Jr., Abell L, Roe ND, Kim M, Zhou B, Cao Y, Ritterhoff J, Gu H, Raftery D, Sun H, Tian R: Defective Branched-Chain Amino Acid Catabolism Disrupts Glucose Metabolism and Sensitizes the Heart to Ischemia-Reperfusion Injury. Cell Metab 2017, 25:374~85).
[0194] Therefore, inhibition and / or degradation of BCKDK in cardiac or peripheral tissues should demonstrate benefit for metabolic disease and cardiac function.
[0195] Thus, in view of the positive correlation between activation of BCKDK and the development of heart failure and related diseases / conditions, the compounds of formula I, their prodrugs and salts of such compounds and prodrugs, by their pharmacological action, are useful in preventing, terminating and / or reversing congestive heart failure, heart failure with New York Heart Association Class I-IV symptoms, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), heart failure with mid-range ejection fraction (HF-mrEF), unstable angina, peripheral arterial disease, pulmonary hypertension, vasculitis or, if the mammal has experienced a myocardial infarction (secondary prevention (second myocardial infarction)), the risk of cardiovascular death and hospitalization.
[0196] In addition, decreased BCAA catabolism is associated with diabetes and related diseases / conditions, as plasma BCAAs are upregulated in patients with elevated fasting glucose levels and a one standard deviation increase in plasma BCAA concentrations increases the likelihood of developing diabetes by more than 50%. (Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE: Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-53; Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Jr., Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.Cell Metab 2009、9:311~26; Menni C、Fauman E、Erte I、Perry JR、Kastenmuller G、Shin SY、Petersen AK、Hyde C、Psatha M、Ward KJ、Yuan W、Milburn M、Palmer CN、Frayling TM、Trimmer J、Bell JT、Gieger C、Mohney RP、Brosnan MJ、Suhre K、Soranzo N、Spector TD: Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013、62:4270~6;White PJ、McGarrah RW、Grimsrud PA、Tso SC、Yang WH、Haldeman JM、Grenier-Larouche T、An J、Lapworth AL、Astapova I、Hannou SA、George T、Arlotto M、Olson LB、Lai M、Zhang GF、Ilkayeva O、Herman MA、Wynn RM、Chuang DT、Newgard CB: The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. Cell Metab 2018、27(6)、1281~1293e7;Zhou M、Shao J、Wu C-Y、Shu L、Dong W、Liu Y、Chen M、Wynn RM、Wang J、Wang J、Gui W-J、Qi X、Lusis AJ、Li Z、Wang W、Ning G、Yang X、Chuang DT、Wang Y、Sun H:Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes 2019、68(9)、1730~1746.Sjogren, RJO, Rizo-Roca D, Chibalin AV, Chorell E, Furrer R, Katayma S, Harada J, Karlsson HKR, Handschin C, Moritz T, Krook A, Naslund E, Zierath JR. Diabetologia, 2021, 64, 2077~2091). .
[0197] Genetic analyses suggest that loss-of-function mutations at the PPM1K locus increase BCAA / BCKA levels and are associated with the development of type 2 diabetes (Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, Schmidt AF, Imamura F, Stewart ID, Perry JR, Marney L, Koulman A, Karoly ED, Forouhi NG, Sjogren RJ, Naslund E, Zierath JR, Krook A, Savage DB, Griffin JL, Chaturvedi N, Hingorani AD, Khaw KT, Barroso I, McCarthy MI, O'Rahilly S, Wareham NJ, Langenberg C: Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLoS Med 2016, 13:e1002179).
[0198] Treatment of diabetic obese mice or rats with BCKDK inhibitors and / or degraders improved fasting glycemia, glycemia in glucose tolerance tests, reduced insulin levels, and improved insulin sensitivity. Overexpression of PPM1K in rats also improved glycemia and reduced insulin levels (White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, Grenier-Larouche T, An J, Lapworth AL, Astapova I, Hannou SA, George T, Arlotto M, Olson LB, Lai M, Zhang GF, Ilkayeva O, Herman MA, Wynn RM, Chuang DT, Newgard CB: The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. Cell Metab 2018).
[0199] Therefore, in view of the positive correlation between BCKDK and the onset of diabetes and related diseases / conditions, the compounds of formula I of the present invention, their prodrugs and salts of such compounds and prodrugs, by their pharmacological action, are useful in the treatment of type I diabetes, type II diabetes mellitus, idiopathic type I diabetes (type Ib), latent autoimmune diabetes in adults (LADA), early onset type 2 diabetes (EOD), atypical diabetes of the young (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, interstitial pneumonia, and the like. Useful in the prevention, arrest and / or regression of intermittent claudication, myocardial infarction, dyslipidemia, postprandial lipemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, glucose metabolic disorders, skin and connective tissue disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and vascular compliance abnormalities, hyperapo B lipoproteinemia.
[0200] The administration of the compounds of the present invention can be via any method that delivers the compounds of the present invention systemically and / or locally. These methods include oral route, parenteral, intraduodenal route, oral, intranasal, etc. Generally, the compounds of the present invention are administered orally, but parenteral administration (e.g., intravenous, intramuscular, subcutaneous, or intramedullary) can be utilized, for example, when oral administration is inappropriate for the target or when the patient cannot ingest the drug.
[0201] In the administration to human patients, the oral daily dose of the compound herein can be in the range of 1mg to 5000mg, depending on the mode and frequency of administration, the disease state, and the age and condition of the patient, etc. The oral daily dose can be in the range of 3mg to 3000mg that can be used. Further oral daily dose can be in the range of 5mg to 1000mg. For convenience, the compound of formula I can be administered in unit dosage form. If desired, the unit dosage form can be used in multiple doses per day to increase the total daily dose. The unit dosage form may be, for example, a tablet or capsule containing about 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 500, or 1000 mg of the compound. The total daily dose may be administered in single or divided doses and, at the physician's discretion, may fall outside of the typical ranges given herein.
[0202] For administration to human patients, the daily injection dose of the compounds herein may be in the range of 1 mg to 2000 mg, depending, of course, on the mode and frequency of administration, the disease state, and the age and condition of the patient, etc. Further daily injection doses are in the range of 5 mg to 1000 mg. The total daily dose may be administered in single or divided doses and, at the physician's discretion, may be outside the typical ranges set forth herein.
[0203] These compounds may be administered to non-human animals, for example, for the indications detailed above. The exact dosage of each active ingredient administered will vary depending on any number of factors, including, but not limited to, the type of animal and type of condition being treated, the age of the animal, and the route of administration.
[0204] The dosage of the combined pharmaceutical agent used in conjunction with formula I compound is that which is effective for the indication being treated.Such dosage can be determined by standard assay such as those referred to above and provided herein.The combined agent can be administered simultaneously or sequentially in any order.
[0205] These dosages are based on an average human subject weighing about 60 kg to 70 kg. A physician will readily be able to determine dosages for subjects whose weight falls outside this range, such as infants and the elderly.
[0206] Dosage regimen can be adjusted to provide the optimum desired response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suitable as unitary dosages for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect together with the required pharmaceutical carrier. The specifications for the dosage unit form of the present invention are dictated by and directly depend on (a) the unique characteristics of the chemotherapeutic agent and the specific therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the technical field of compounding such active compounds for the treatment of susceptibility in individuals.
[0207] Therefore, based on the disclosure provided herein, those skilled in the art will understand that dosage and administration regimen can be adjusted according to the method well known in the art of treatment.That is, the maximum tolerated dose can be easily established, and the effective dose that provides detectable therapeutic benefit to the patient can be determined, as well as the primary requirement of administering each agent to provide detectable therapeutic benefit to the patient.Thus, although certain dosage and administration regimen are exemplified herein, these examples do not limit the dosage and administration regimen that can be provided to the patient.
[0208] It should be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It should be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to individual needs and the professional judgment of the person administering or supervising the administration of the composition, and that the dosage ranges specified herein are merely exemplary and are not intended to limit the scope or practice of the claimed compositions. For example, dosages may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include toxic effects and / or clinical effects such as laboratory values. Thus, intrapatient dose escalation may be used as determined by those skilled in the art. Determining appropriate dosages and regimens for administration of chemotherapeutic agents is well known in the relevant art, and will be understood to be encompassed by those skilled in the art, given the teachings disclosed herein.
[0209] The present application further includes the use of a compound of formula I for use as a medicament, such as a unit dose tablet or capsule. In another embodiment, the present application includes the use of a compound of formula I for the manufacture of a medicament, such as a unit dose tablet or capsule, for treating one or more of the conditions previously identified in the above section discussing methods of treatment.
[0210] The pharmaceutical composition of the present invention can be prepared, packaged or sold in bulk as a single unit dose or as a plurality of single unit doses.As used herein, "unit dose" is a discrete amount of pharmaceutical composition that contains a predetermined amount of active ingredient.The amount of active ingredient is generally equal to the dosage of active ingredient that will be administered to subject, or a convenient ratio of such dosage, such as half or one third of such dosage.
[0211] The compounds or combinations of the present invention may be administered alone, but will generally be administered in admixture with one or more suitable pharmaceutical additives, adjuvants, excipients or carriers known in the art and will be selected with respect to the intended route of administration and standard pharmaceutical practice.The compounds or combinations of the present invention may be formulated to provide immediate, delayed, adjusted, sustained, pulsed or controlled release dosage forms, depending on the specifics of the desired route of administration and release profile to meet the therapeutic needs.
[0212] Pharmaceutical compositions contain a compound or combination of the invention in an amount generally within the range of about 1% to about 75%, 80%, 85%, 90% or even 95% (by weight) of the composition, usually within the range of about 1%, 2% or 3% to about 50%, 60% or 70%, more often within the range of about 1%, 2% or 3% to less than 50%, for example within the range of about 25%, 30% or 35%.
[0213] Methods for preparing various pharmaceutical compositions with specific amounts of active compounds are known to those skilled in the art. See, for example, Remington: The Practice of Pharmacy, Lippincott Williams and Wilkins, Baltimore Md, 20th Edition, 2000.
[0214] Compositions suitable for parenteral injection generally include pharma- ceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers or excipients (including solvents and vehicles) include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, triglycerides, including vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. A preferred carrier is Miglyol® brand caprylic / capric esters (e.g., Miglyol® 812, Miglyol® 829, Miglyol® 840) with glycerin or propylene glycol, available from Condea Vista Co., Cranford, NJ. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0215] These compositions for parenteral injection may also contain additives such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial contamination of the compositions can be accomplished using various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents capable of delaying absorption, for example, aluminum monostearate and gelatin.
[0216] Solid dosage forms for oral administration include capsules, tablets, chewable tablets, lozenges, pills, powders and multiparticulate preparations (granules). In such solid dosage forms, the compound of formula I or combination is admixed with at least one inert additive, excipient or carrier. Suitable additives, excipients or carriers include materials such as sodium citrate or dicalcium phosphate, and / or (a) one or more fillers or extenders, such as microcrystalline cellulose (FMC), calcium carbonate, calcium phosphate ... (b) one or more binders (e.g., carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, gum arabic, ethylcellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, alginates, gelatin, polyvinylpyrrolidone, sucrose, acacia, etc.); (c) one or more humectants (e.g., glycerol, etc.); (d) one or more disintegrants (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, sodium carbonate, sodium lauryl sulfate, sodium starch glycolate (Edward Mendell Co.(available as Explotab® from Dow Jones Industrial Average Price), cross-linked polyvinylpyrrolidone, croscarmellose sodium type A (available as Ac-di-sol®), polyacrilin potassium (ion exchange resin), and the like; (e) one or more solution retardants (e.g., paraffin, and the like); (f) one or more absorption accelerators (e.g., quaternary ammonium compounds, and the like); (g) one or more wetting agents (e.g., cetyl alcohol, glycerol monostearate, and the like); (h) one or more adsorbents (e.g., kaolin, bentonite, and the like); and / or (i) one or more lubricants (e.g., talc, calcium stearate, magnesium stearate, stearic acid, polyoxyl stearate, cetanol, talc, hydrogenated castor oil, sucrose fatty acid esters, dimethylpolysiloxane, microcrystalline wax, yellow wax, white wax, solid polyethylene glycols, sodium lauryl sulfate, and the like). In the case of capsules and tablets, the dosage form may also comprise buffering agents.
[0217] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0218] Solid dosage forms such as tablets, dragees, capsules and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art.They can contain opacifiers and be of a composition that releases the compound of formula I and / or additional pharmaceutical agents in a delayed manner.Examples of embedding compositions that can be used are polymeric substances and waxes.Drugs can also be in microencapsulated form, where appropriate, with one or more of the additives mentioned above.
[0219] In tablets, the active agent will typically comprise less than 50% (by weight) of the formulation, e.g., less than about 10%, such as 5% or 2.5% by weight. The main part of the formulation will include fillers, excipients, disintegrants, lubricants, and may include flavorings. The composition of these additives is well known in the art. Frequently, the filler / excipient will comprise a mixture of two or more of the following ingredients: microcrystalline cellulose, mannitol, lactose (all types), starch, and dicalcium phosphate. The filler / excipient mixture will typically comprise less than 98%, preferably less than 95%, e.g., 93.5%, of the formulation. Preferred disintegrants include Ac-di-sol®, Explotab®, starch, and sodium lauryl sulfate. When present, the disintegrant will usually comprise less than 10% or less than 5%, e.g., about 3%, of the formulation. A preferred lubricant is magnesium stearate. If present, lubricants will usually comprise less than 5% or less than 3% of the formulation, for example about 1%.
[0220] Tablets can be manufactured by standard tabletting processes, such as direct compression or wet, dry or melt granulation, melt congealing processes and extrusion. Tablet cores can be single or multi-layered and can be coated with suitable protective films known in the art.
[0221] The liquid dosage form for oral administration includes pharmaceutically acceptable emulsion, solution, suspension, syrup and elixir.In addition to the compound of formula I or combination, liquid dosage form can contain inert excipients commonly used in the art, for example, water or other solvent, solubilizer and emulsifier, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (for example, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, sesame seed oil, etc.), Miglyole (registered trademark) (available from CONDEA Vista Co., Cranford, NJ), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid ester, or mixtures of these substances.
[0222] Besides such inert diluents, the composition can also include excipients, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0223] Oral liquid forms of the compounds or combinations of the present invention include solutions in which the active compounds are completely dissolved. Examples of solvents include all pharma- ceutical precedent solvents suitable for oral administration, especially those in which the compounds of the present invention show good solubility, such as polyethylene glycol, polypropylene glycol, edible oils, and glyceryl and glyceride-based systems. Glyceryl and glyceride-based systems are available, for example, from the following branded products (and corresponding generic products): Captex® 355EP (caprylic / capric glyceride, manufactured by Abitec, Columbus Ohio), Crodamol™ GTC / C (medium chain triglycerides, manufactured by Croda, Cowick Hall, UK) or Labrafac™ CC (medium chain triglycerides, manufactured by Gattefosse), Captex® 500P (glyceryl triacetate, i.e. triacetin, manufactured by Abitec), Capmul® MCM (medium chain mono- and diglycerides, manufactured by Abitec), Migyol® 812 (caprylic / capric triglyceride, manufactured by Condea, Cranford, England). NJ), Migyol® 829 (caprylic / capric / succinic triglyceride, ex Condea), Migyol® 840 (propylene glycol dicaprylate / dicaprate, ex Condea), Labrafil® M1944CS (oleoyl macrogol-6 glyceride, ex Gattefosse), Peceol™ (glyceryl monooleate, ex Gattefosse) and Maisine® 35-1 (glyceryl monooleate, ex Gattefosse). Of particular interest are medium chain (about C8 to C9) 10 ) triglyceride oils. These solvents frequently constitute the majority of the composition, i.e., more than about 50%, usually more than about 80%, for example more than about 95% or 99%. Adjuvants and additives may be included along with the solvents, mainly as taste masking agents, palatability and flavoring agents, antioxidants, stabilizers, texture and viscosity modifiers, and solubilizers.
[0224] Suspensions may further comprise, in addition to a compound of formula I or a combination, a carrier such as a suspending agent, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances.
[0225] Compositions for rectal or vaginal administration preferably include suppositories, which can be prepared by mixing a compound of formula I or a combination with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol or a suppository wax, which is solid at normal room temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity, thereby releasing the active ingredient.
[0226] Dosage forms for topical administration of a compound of formula I or a combination include ointments, creams, lotions, powders and sprays. The drug is mixed with a pharma- ceutically acceptable excipient, vehicle or carrier, and any preservatives, buffers or propellants that may be required.
[0227] Many of the compounds of the present invention have poor solubility in water, e.g., less than about 1 μg / mL, and therefore liquid compositions in solubilizing non-aqueous solvents such as the medium chain triglyceride oils discussed above are preferred dosage forms for these compounds.
[0228] Solid amorphous dispersions, including dispersions formed by spray drying processes, are also preferred dosage forms for the poorly soluble compounds of the present invention. By "solid amorphous dispersion" is meant a solid material in which at least a portion of the poorly soluble compound is in amorphous form and dispersed in a water-soluble polymer. By "amorphous" is meant that the poorly soluble compound is not crystalline. By "crystalline" is meant that the compound exhibits three-dimensional long-range order of at least 100 repeat units in each dimension. Thus, the term amorphous is intended to include not only materials that have no inherent order, but also materials that may have a small degree of order, but that order is less than three-dimensional and / or short-range. Amorphous materials can be characterized by techniques known in the art, for example, powder X-ray diffraction (PXRD) crystallography, solid-state NMR, or thermal techniques such as differential scanning calorimetry (DSC).
[0229] Preferably, at least the majority (i.e., at least about 60 wt%) of the poorly soluble compound in the solid amorphous dispersion is amorphous. The compound can exist in the solid amorphous dispersion in relatively pure amorphous domains or regions, as a solid solution of the compound homogeneously distributed throughout the polymer, or any combination of these states or intermediate states between them. Preferably, the solid amorphous dispersion is substantially homogeneous, so that the amorphous compound is dispersed as homogeneously as possible throughout the polymer. As used herein, "substantially homogeneous" means that the proportion of the compound present in the relatively pure amorphous domains or regions in the solid amorphous dispersion is relatively small, approximately less than 20 wt%, preferably less than 10 wt% of the total amount of drug.
[0230] Water-soluble polymers suitable for use in solid amorphous dispersions should be inert, in the sense that they do not chemically react in a deleterious manner with the poorly soluble compound, are pharma- ceutically acceptable, and have at least some solubility in aqueous solutions at physiologically relevant pH (e.g., 1-8). The polymers can be neutral or ionizable, and should have an aqueous solubility of at least 0.1 mg / mL over at least a portion of the pH range from 1 to 8.
[0231] Suitable water-soluble polymers for use in the compounds of formula I may be cellulosic or non-cellulosic. The polymers may be neutral or ionizable in aqueous solution. Of these, ionizable and cellulosic polymers are preferred, with ionizable cellulosic polymers being more preferred.
[0232] Exemplary water-soluble polymers include hydroxypropylmethylcellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate (HPMCP), carboxymethylethylcellulose (CMEC), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), polyvinylpyrrolidone (PVP), hydroxypropylcellulose (HPC), methylcellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO / PPO, also known as poloxamer), and mixtures thereof. Particularly preferred polymers include HPMCAS, HPMC, HPMCP, CMEC, CAP, CAT, PVP, poloxamer, and mixtures thereof. Most preferred is HPMCAS. See European Patent Application Publication No. 0901786A2, the disclosure of which is incorporated herein by reference.
[0233] The solid amorphous dispersion can be prepared according to any process for forming a solid amorphous dispersion that results in at least a majority (at least 60%) of the poorly soluble compound being in an amorphous state. Such processes include mechanical, thermal and solvent processes. Exemplary mechanical processes include milling and extrusion; melting processes, including high temperature melting, solvent-modified fusion and melt-solidification processes; and solvent processes, including non-solvent precipitation, spray coating and spray drying. For example, see the following U.S. patents, the relevant disclosures of which are incorporated herein by reference: 5,456,923 and 5,939,099, which describe forming a dispersion by an extrusion process; 5,340,591 and 4,673,564, which describe forming a dispersion by a milling process; and 5,707,646 and 4,894,235, which describe forming a dispersion by a melt-solidification process. In a preferred process, the solid amorphous dispersion is formed by spray drying, as disclosed in EP 0901786A2.In this process, the compound and polymer are dissolved in a solvent such as acetone or methanol, and then the solvent is rapidly removed from the solution by spray drying to form the solid amorphous dispersion.The solid amorphous dispersion can be prepared to contain up to about 99wt% of the compound, for example, 1wt%, 5wt%, 10wt%, 25wt%, 50wt%, 75wt%, 95wt%, or 98wt%, as desired.
[0234] The solid dispersion may be used as a dosage form by itself or may serve as a manufacturing use product (MUP) in the preparation of other dosage forms such as capsules, tablets, liquids or suspensions. An example of an aqueous suspension is an aqueous suspension of 1:1 (w / w) compound / HPMCAS-HF spray-dried dispersion containing 2.5 mg / mL of compound in 2% polysorbate-80. Solid dispersions for use in tablets or capsules will generally be mixed with other additives or adjuvants typically found in such dosage forms. For example, an exemplary filler for a capsule contains 2:1 (w / w) compound / HPMCAS-MF spray-dried dispersion (60%), lactose (fast flow) (15%), microcrystalline cellulose (e.g., Avicel.sup.(R0-102) (15.8%), sodium starch (7%), sodium lauryl sulfate (2%) and magnesium stearate (1%).
[0235] HPMCAS polymers are available in low, medium and high grades as Aqoat®-LF, Aqoat®-MF and Aqoat®-HF from Shin-Etsu Chemical Co., Ltd., Tokyo, Japan. The higher MF and HF grades are generally preferred.
[0236] The following paragraphs describe exemplary formulations, dosages, etc. useful in non-human animals.Administration of the combination of a compound of Formula I and an anti-obesity agent can be effected orally or parenterally.
[0237] The compound of formula I or the combination of the compound of formula I and another anti-obesity agent is administered in an amount such that an effective dose is administered. In general, the daily dose administered orally to an animal is between about 0.01 and about 1,000 mg / kg of body weight, for example, between about 0.01 and about 300 mg / kg, or between about 0.01 and about 100 mg / kg, or between about 0.01 and about 50 mg / kg of body weight, or between about 0.01 and about 25 mg / kg, or between about 0.01 and about 10 mg / kg, or between about 0.01 and about 5 mg / kg.
[0238] Conveniently, the compound of formula I (or combination) can be carried in drinking water such that a therapeutic dosage of the compound is ingested with the daily water supply. The compound can be metered directly into the drinking water, preferably in the form of a liquid, water-soluble concentrate (such as an aqueous solution of a water-soluble salt).
[0239] Advantageously, the compound (or combination) of formula I can be added directly to feed, as it is, or in the form of an animal feed supplement, also called premix or concentrated feed. To include the agent in feed, a premix or concentrated feed of the compound in an additive, excipient, or carrier is more commonly used. Suitable additives, excipients, or carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corn cob meal, and corn meal, molasses, urea, bone meal, and mineral mixes as commonly used in poultry feed. Particularly effective additives, excipients, or carriers are the individual animal feeds themselves; i.e., small amounts of such feeds. The carriers facilitate the uniform distribution of the compound in the final feed with which the premix is mixed. Preferably, the compound is thoroughly mixed into the premix and then into the feed. In this regard, the compound can be dispersed or dissolved in a suitable oily vehicle, such as soybean oil, corn oil, cottonseed oil, etc., or in a volatile organic solvent and then mixed with the carrier. It will be appreciated that the percentage of compound in the concentrated feed can vary widely, since the amount of compound in the final feed can be adjusted by blending the appropriate proportion of premix with the feed to obtain the desired level of compound.
[0240] To produce a concentrated supplement suitable for feeding directly to animals, feed manufacturers may blend high-potency concentrated feed with protein carriers such as soybean oil meal and other meals as described above. In such cases, animals are allowed to consume normal feed. Alternatively, such concentrated supplements can be added directly to the feed to produce a nutritionally balanced final feed containing therapeutically effective levels of the compound. The mixture is thoroughly blended by standard procedures, such as in a twin-shell blender, to ensure uniformity.
[0241] When the supplement is used as a top dressing for the feed, this also helps to ensure uniformity of distribution of the compound across the surface of the dressed feed.
[0242] In general, drinking water and feed effective for increasing lean meat accumulation and improving the lean meat to fat ratio are prepared by mixing a sufficient amount of a compound of formula I with animal feed to provide from about 0.001 to about 500 ppm of the compound in the feed or water.
[0243] Preferred medicated feeds for pigs, cattle, sheep, and goats generally contain from about 1 to about 400 grams of a compound of formula I (or combination) per ton of feed, with the optimum amount for these animals usually being from about 50 to about 300 grams per ton of feed.
[0244] Preferred poultry and domestic pet feeds will usually contain from about 1 to about 400 grams, preferably from about 10 to about 400 grams, of the compound (or combinations thereof) per ton of feed.
[0245] For parenteral administration in animals, the compound of formula I (or combination) can be prepared in the form of a paste or pellet and administered as an implant, usually subcutaneously in the head or ear, of an animal seeking to increase lean meat deposition and improve the lean meat to fat ratio.
[0246] Paste formulations can be prepared by dispersing the drug in a pharma- ceut oil, sesame oil, corn oil or the like.
[0247] Pellets containing an effective amount of a compound of formula I, pharmaceutical composition, or combination can be prepared by mixing the compound of formula I or combination with excipients such as carbowax, carnuba wax, etc., and lubricants such as magnesium stearate or calcium stearate can be added to improve the pelleting process.
[0248] It will of course be appreciated that more than one pellet can be administered to an animal to achieve the desired dosage level that results in the desired increased lean meat deposition and improved lean to fat ratio. Additionally, implants can be administered periodically during the animal's treatment period to maintain the proper drug levels in the animal's body.
[0249] Liposomes containing these agents and / or compounds of the present invention are prepared by methods known in the art, such as those described in U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be produced by the reverse phase evaporation method using a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
[0250] These agents and / or compounds of the invention may be encapsulated in microcapsules prepared, for example, by coacervation techniques, or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or macroemulsions, respectively. Such techniques are disclosed in Remington, The Science and Practice of Pharmacy, 20th Edition, Mack Publishing (2000).
[0251] Sustained release preparations can be used.Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the compound of the present invention, which matrices are in the form of shaped articles, for example, films or microcapsules.Examples of sustained release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides (US Pat. No. 3,773,919), copolymers of L-glutamic acid and L-7-ethyl glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, for example, those used in LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymers and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.
[0252] The preparations used for intravenous administration must be sterile. This can be easily accomplished, for example, by filtration through a sterile filtration membrane. The compound of the present invention is generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper that can be pierced by a hypodermic injection needle.
[0253] Suitable emulsions can be prepared using commercially available fat emulsions, such as Intralipid®, Liposyn®, Infonutrol™, Lipofundin® and Lipiphysan™. The active ingredient can either be dissolved in a premixed emulsion composition or, alternatively, dissolved in an emulsion formed upon mixing of oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and phospholipids (e.g., egg phospholipids, soybean phospholipids or soybean lecithin) with water. It will be appreciated that other ingredients, such as glycerol or glucose, may be added to adjust the isotonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example between 5 and 20%. The fat emulsions can contain fat droplets between 0.1 and 1.0 μm, particularly between 0.1 and 0.5 μm, and have a pH within the range of 5.5 to 8.0.
[0254] Emulsion compositions can be prepared by mixing a compound of the present invention with Intralipid™ or its components (soybean oil, egg phospholipids, glycerol and water).
[0255] Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable, aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable additives as specified above. In some embodiments, compositions are administered by oral or nasal respiratory route for local or systemic effect. Compositions, preferably in sterile pharma- ceutically acceptable solvents, may be nebulized by the use of gases. Nebulized solutions may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure respirator. Solution, suspension or powder compositions may be administered, preferably orally or intranasally, from a device that delivers the formulation in an appropriate manner.
[0256] The compound particles herein may be formulated in a form suitable for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration, or for administration by inhalation. The compounds of the present invention may also be formulated for sustained delivery.
[0257] Methods for preparing various pharmaceutical compositions with a particular amount of active ingredient are known or will be apparent to those skilled in the art in light of this disclosure. For examples of methods for preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, 20th Edition (Lippincott Williams & Wilkins, 2000).
[0258] Pharmaceutical compositions according to the invention may contain 0.1%-95%, preferably 1%-70%, of the compound of the invention. In any event, the composition administered will contain a quantity of a compound according to the invention in an amount effective to treat the disease / condition of the subject being treated.
[0259] Since the present application has an aspect related to the treatment of diseases / conditions described herein with compounds of active ingredients that can be administered separately, the present invention also relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: a compound of formula I, a prodrug thereof or a salt of such a compound or prodrug, and a second compound as described above. The kit comprises a means for containing the separate compositions, such as a container, a divided bottle or a divided foil packet. Typically, the kit comprises instructions for administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
[0260] An example of such a kit is the so-called blister pack. Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms (tablets, capsules, etc.). Blister packs generally consist of a sheet of relatively rigid material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape in which the tablets or capsules are packed. The tablets or capsules are then placed in the recesses and the sheet of relatively rigid material is sealed against the plastic foil on the face of the foil opposite to the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably, the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure to the recesses, which forms an opening in the sheet at the location of the recesses. The tablets or capsules can then be removed through said opening.
[0261] It may be desirable to provide a memory aid in the kit, for example in the form of a number next to the tablet or capsule that corresponds to the number of days in the regimen on which the tablet or capsule so designated should be taken. Another example of such a memory aid is, for example, a calendar printed on a card, for example as follows: "First week, Monday, Tuesday, etc....Second week, Monday, Tuesday,..." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several pills or capsules to be taken on a given day. Also, a daily dose of a compound of formula I may consist of one tablet or capsule, while a daily dose of a second compound may consist of several tablets or capsules, or vice versa. The memory aid should reflect this.
[0262] In another specific embodiment of the present invention, a dispenser is provided that is designed to dispense daily doses one at a time in the order of their intended use.Preferably, the dispenser is equipped with a memory aid, so as to further facilitate compliance with the regimen.An example of such a memory aid is a mechanical counter that indicates the number of daily doses dispensed.Another example of such a memory aid is a battery-powered microchip memory coupled with a liquid crystal display, or with an audible reminder signal, for example, that reads out the date that the previous daily dose was taken and / or reminds the date that the next dose should be taken.
[0263] Also, since the present application has aspects relating to the diseases / conditions described herein using combinations of active ingredients that may be administered together, the present invention also relates to combining separate pharmaceutical compositions in a single dosage form such as (but not limited to) a single tablet or capsule, bi-layer or multi-layer tablet or capsule, or by the use of segregated components or compartments within a tablet or capsule.
[0264] The active ingredient may be delivered as a solution in an aqueous or non-aqueous vehicle with or without additional solvents, co-solvents, additives or complexing agents selected from pharma- ceutically acceptable excipients, additives, vehicles or carriers.
[0265] The active ingredient may be formulated with pharma-ceutically acceptable excipients as a solid dispersion or as a self-emulsifying drug delivery system (SEDDS).
[0266] The active ingredient may be formulated as an immediate or modified release tablet or capsule. Alternatively, the active ingredient may be delivered alone as the active ingredient within a capsule shell without the addition of additional additives. EXAMPLES
[0267] Experimental procedure The following illustrates the synthesis of various compounds of the present invention. Additional compounds within the scope of the present invention can be prepared using the methods illustrated in these examples, either alone or in combination with techniques generally known in the art. All starting materials in these preparations and examples are either commercially available or can be prepared by methods known in the art or as described herein.
[0268] All reactions were carried out with continuous stirring under an atmosphere of nitrogen or argon gas unless otherwise noted. When appropriate, the reactor was dried under dynamic vacuum using a heat gun, and anhydrous solvents (Sure-Seal™ products from Aldrich Chemical Company, Milwaukee, Wisconsin, or DriSolv™ products from EMD Chemicals, Gibbstown, NJ) were used. In some cases, commercially available solvents were passed through columns packed with 4 Å molecular sieves until the following water QC criteria were reached: a) less than 100 ppm for dichloromethane, toluene, N,N-dimethylformamide, and tetrahydrofuran; b) less than 180 ppm for methanol, ethanol, 1,4-dioxane, and diisopropylamine. For highly sensitive reactions, solvents were further treated with sodium metal, calcium hydride, or molecular sieves and distilled immediately prior to use. Other commercially available solvents and reagents were used without further purification. In syntheses that refer to procedures in other examples or methods, reaction conditions (solvent, reaction time and / or temperature) may vary. The products were generally dried under vacuum before being carried forward to further reactions or sent for biological testing.
[0269] Where indicated, reactions were heated by microwave irradiation using a Biotage initiator or a Personal Chemistry Emries Optimizer microwave. Reaction progress was monitored using thin layer chromatography (TLC), liquid chromatography-mass spectrometry (LCMS), high performance liquid chromatography (HPLC), and / or gas chromatography-mass spectrometry (GCMS) analysis. TLC was performed on precoated silica gel plates with fluorescent indicators (254 nm excitation wavelength) and visualized under UV light and / or with I2, KMnO4, CoCl2, phosphomolybdic acid, and / or ceric ammonium molybdate stains. LCMS data was acquired on an Agilent 1100 series instrument using a Leap Technologies autosampler, a Gemini C18 column, an acetonitrile / water gradient, and either trifluoroacetic acid, formic acid, ammonium acetate, or ammonium hydroxide modifiers. Column eluates were analyzed using a Waters ZQ mass spectrometer scanning from 100 to 1200 Da in both positive and negative ion modes. Other similar instruments were also used. HPLC data were generally acquired on an Agilent 1100 series instrument using the indicated columns, acetonitrile / water gradients, and either trifluoroacetic acid or ammonium hydroxide modifiers. GCMS data were acquired using a Hewlett Packard 6890 oven with an HP6890 injector, HP-1 column (12 m x 0.2 mm x 0.33 μm), and helium carrier gas. Samples were analyzed on an HP5973 mass selective detector scanning from 50 to 550 Da using electron ionization. Purification was performed by medium pressure liquid chromatography (MPLC) using an Isco Combiflash Companion, AnaLogix IntelliFlash 280, Biotage SP1, or Biotage Isolela One instrument and pre-packed Isco RediSep or Biotage Snap Silica cartridges.Chiral purification was typically performed by chiral supercritical fluid chromatography (SFC) using a Berger or Thar instrument; columns such as ChiralPak-AD, -AS, -IC, Chiralcel-OD or -OJ columns; and CO2 mixtures with methanol, ethanol, propan-2-ol, or acetonitrile, alone or modified with trifluoroacetic acid or propan-2-amine. UV detection was used to trigger fraction collection. For syntheses that refer to procedures in other examples or methods, purification may vary: typically, the solvents and solvent ratios used for the eluents / gradients are selected from the appropriate R. fS or retention time was chosen to provide.
[0270] Mass spectrometry data are reported from LCMS analysis. Mass spectrometry (MS) was performed via atmospheric pressure chemical ionization (APCI), electrospray ionization (ESI), electron impact ionization (EI) or electron scattering ionization (ES) sources. Proton magnetic resonance spectroscopy ( 1 H NMR chemical shifts are reported in parts per million downfield from tetramethylsilane and were recorded on 300, 400, 500, or 600 MHz Varian, Bruker, or Jeol analyzers. Chemical shifts are expressed in parts per million (ppm, δ) referenced to deuterated solvent residual peaks (chloroform, 7.26 ppm; CD2HOD, 3.31 ppm; acetonitrile-d2, 1.94 ppm; dimethylsulfoxide-d5, 2.50 ppm; DHO, 4.79 ppm). Peak shapes are described as follows: s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet; brs, broad singlet; app, apparent. Analytical SFC data were acquired on a Berger analytical instrument as described above. Optical rotation data were typically acquired on a PerkinElmer Model 343 polarimeter using a 1 dm cell. Microanalysis was performed by Quantitative Technologies Inc. and was within 0.4% of calculated values.
[0271] Unless otherwise noted, chemical reactions were carried out at room temperature (approximately 23 degrees Celsius).
[0272] Unless otherwise noted, all reactants were commercially obtained and used without further purification or were prepared using methods known in the literature.
[0273] The terms "concentrated," "evaporated," and "concentrated in vacuum" refer to removal of solvent at reduced pressure in a rotary evaporator with a bath temperature below 60° C. The abbreviations "min" and "h" stand for "minutes" and "hours," respectively. The term "TLC" refers to thin layer chromatography, "room or ambient temperature" means a temperature between 18° C. and 25° C., "GCMS" refers to gas chromatography-mass spectrometry, "LCMS" refers to liquid chromatography-mass spectrometry, "UPLC" refers to ultra performance liquid chromatography, "HPLC" refers to high performance liquid chromatography, and "SFC" refers to supercritical fluid chromatography.
[0274] Hydrogenation can be carried out in a Parr shaker under pressurized hydrogen gas or in a Thales-nano H cube flow hydrogenator with full hydrogen and a flow rate between 1 and 2 mL / min at the specified temperature.
[0275] HPLC, UPLC, LCMS, GCMS, and SFC retention times were determined using the methods noted in the procedures.
[0276] In some examples, chiral separations were performed to separate the enantiomers, diastereoisomers, or atropisomers (or atropenantiomers) of certain compounds of the present invention (in some examples, the separated enantiomers are designated ENANT-1 and ENANT-2 according to their order of elution; similarly, the separated diastereoisomers are designated DIAST-1 and DIAST-2 according to their order of elution, and the separated atropisomers (or atropenantiomers) are designated ATROP-1 and ATROP-2 according to their order of elution). In some examples, the optical rotations of the enantiomers or atropisomers (or atropenantiomers) were measured using a polarimeter. According to its observed rotational data (or its specific rotational data), the enantiomer or atropisomer (or atropenantiomer) with clockwise rotation is designated as the (+)-enantiomer or (+)-atropisomer [or (+)-atropenantiomer], and the enantiomer or atropisomer (or atropenantiomer) with counterclockwise rotation is designated as the (-)-enantiomer or (-)-atropisomer [or (-)-atropenantiomer]. Racemates are designated either by the absence of drawn or written stereochemistry or by the presence of (+ / -) adjacent to the structure; in the latter case, the designated stereochemistry represents only one of the two enantiomers that make up the racemic mixture.
[0277] The compounds and intermediates described below were named using the naming conventions provided by ACD / ChemSketch 2019.1.1, file version C05H41, build 110712 (Advanced Chemistry Development, Inc., Toronto, Ontario, Canada). The naming conventions provided by ACD / ChemSketch 2019.1.1 are well known to those skilled in the art, and the naming conventions provided by ACD / ChemSketch 2019.1.1 are generally believed to conform to the IUPAC (International Union of Pure and Applied Chemistry) recommendations and CAS index rules for the nomenclature of organic compounds.
[0278] Preparation example P1 Methyl 3-bromo-6-fluoro-1-benzothiophene-2-carboxylate (P1)
[0279] [ka] Step 1. Synthesis of methyl 3-amino-6-fluoro-1-benzothiophene-2-carboxylate (C1). To an ice-cold solution of 2,4-difluorobenzonitrile (30.0 g, 216 mmol) in N,N-dimethylformamide (150 mL) was added methyl sulfanylacetate (25.2 g, 237 mmol) in a dropwise fashion. After the reaction mixture was stirred for 30 min at 0° C., an aqueous solution of sodium hydroxide (5 M; 64.7 mL, 324 mmol) was added whereupon stirring was continued for an additional 2 h. The resulting suspension was poured into ice water and the solid was collected by filtration; this material was combined with the products of two similar reactions carried out using 2,4-difluorobenzonitrile (20.0 g and 30.0 g, total 359 mmol) to give C1 as a white solid. Combined yield: 80.0 g, 355 mmol, 62%. LCMS m / z 226.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.59 (dd, J = 8.9, 4.9 Hz, 1H), 7.41 (dd, J = 8.7, 2.3 Hz, 1H), 7.12 (ddd, J = 8.8, 8.8, 2.3 Hz, 1H), 5.90 (br s, 2H), 3.89 (s, 3H).
[0280] Step 2. Synthesis of methyl 3-bromo-6-fluoro-1-benzothiophene-2-carboxylate (P1). To a solution of tert-butyl nitrite (23.3 g, 226 mmol) and copper(II) bromide (40.5 g, 181 mmol) in acetonitrile (500 mL) was added C1 (34.0 g, 151 mmol). After the reaction mixture was stirred at 20° C. for 3 h, it was combined with a similar reaction carried out using C1 (33.0 g, 146 mmol) and filtered. The filtrate was concentrated in vacuo and subjected to silica gel chromatography (eluent: petroleum ether) to give P1 as a white solid. Combined yield: 20 g, 69 mmol, 23%. GCMS m / z 290 (bromine isotope pattern observed) [M + ]. 1 H NMR (400 MHz, chloroform-d) δ 7.96 (dd, J = 9.0, 5.0 Hz, 1H), 7.52 (dd, J = 8.3, 2.3 Hz, 1H), 7.29 - 7.22 (m, 1H, estimated; partially obscured by solvent peak), 3.97 (s, 3H).
[0281] Preparation example P2 Methyl 6-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-benzothiophene-2-carboxylate (P2)
[0282] [ka] A mixture of P1 (25.0 g, 86.5 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (43.9 g, 173 mmol), potassium acetate (21.2 g, 216 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [Pd(dppf)Cl2; 3.16 g, 4.32 mmol] in 1,4-dioxane (450 mL) was degassed three times by alternating application of vacuum and nitrogen, then heated at 90° C. for 16 h. The reaction mixture was combined with a similar reaction carried out using P1 (1.0 g, 5.0 g, and 10.0 g; 55.3 mmol in total) and filtered; the filter cake was washed with petroleum ether (3×50 mL). After the combined filtrate was concentrated under vacuum, the residue was triturated with petroleum ether (500 mL) to give a black solid that was collected by filtration. This solid was purified using silica gel chromatography (gradient: 0% to 20% ethyl acetate in petroleum ether) to give P2 as a white solid. Combined yield: 20.5 g, 61.0 mmol, 43%. LCMS m / z 337.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.83 (dd, J = 8.9, 5.2 Hz, 1H), 7.52 (dd, J = 8.7, 2.4 Hz, 1H), 7.15 (ddd, J = 8.9, 8.9, 2.4 Hz, 1H), 3.93 (s, 3H), 1.48 (s, 12H).
[0283] Preparation example P3 Ethyl 3-bromo-6,7-difluoro-1-benzothiophene-2-carboxylate (P3)
[0284] [ka] Step 1. Synthesis of ethyl 3-amino-6,7-difluoro-1-benzothiophene-2-carboxylate (C2). Ethyl sulfanylacetate (0.768 mL, 7.00 mmol) was added dropwise to a 0° C. solution of 2,3,4-trifluorobenzonitrile (1.00 g, 6.37 mmol) in N,N-dimethylformamide (6.4 mL). After the reaction mixture was stirred at 0° C. for 30 min, an aqueous solution of sodium hydroxide (5 M; 1.91 mL, 9.55 mmol) was added and stirring was continued for 2 h. Water (30 mL) was then added and the resulting precipitate was collected by filtration, washed with water and dried in a vacuum oven. Chromatography on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) afforded C2 as a white solid. Yield: 788 mg, 3.06 mmol, 48%. 1 H NMR (400 MHz, chloroform-d) δ 7.37 (br dd, J = 8.8, 3.9 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.88 (br s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1Hz, 3H).
[0285] Step 2. Synthesis of ethyl 3-bromo-6,7-difluoro-1-benzothiophene-2-carboxylate (P3). To a 0° C. suspension of copper(II) bromide (417 mg, 1.87 mmol) and tert-butyl nitrite (0.280 mL, 2.35 mmol) in acetonitrile (15.5 mL) was added C2 (400 mg, 1.55 mmol) in portions. The reaction mixture was then stirred at 0° C. for 15 min and at room temperature (26° C.) for 1 h, whereupon it was poured into hydrochloric acid (0.5 M; 200 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed successively with water (200 mL) and saturated aqueous sodium chloride solution (200 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded P3 as a pale yellow solid. Yield: 334 mg, 1.04 mmol, 67%. 1H NMR (400 MHz, chloroform-d) δ 7.73 (ddd, J = 9.0, 4.0, 1.3 Hz, 1H), 7.37 (ddd, J = 10.1, 9.0, 7.0 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1Hz, 3H).
[0286] Preparation example P4 Ethyl 3-bromo-4,6-difluoro-1-benzothiophene-2-carboxylate (P4)
[0287] [ka] Step 1. Synthesis of ethyl 3-amino-4,6-difluoro-1-benzothiophene-2-carboxylate (C3). Ethyl sulfanylacetate (0.768 mL, 7.00 mmol) was added dropwise to a 0° C. solution of 2,4,6-trifluorobenzonitrile (1.00 g, 6.37 mmol) in N,N-dimethylformamide (6.4 mL). After the reaction mixture was stirred for 30 min at 0° C., an aqueous solution of sodium hydroxide (5 M; 1.91 mL, 9.55 mmol) was added and stirring was continued for 2 h. Water (30 mL) was then added and the resulting precipitate was collected by filtration, washed with water and dried in a vacuum oven; silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) afforded C3 as a white solid. Yield: 956 mg, 3.72 mmol, 58%. 1 H NMR (400 MHz, chloroform-d) δ 7.17 (br dd, J = 8.1, 2.1 Hz, 1H), 6.77 (ddd, J = 11.3, 9.0, 2.1 Hz, 1H), 6.28 (br s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H).
[0288] Step 2. Synthesis of ethyl 3-bromo-4,6-difluoro-1-benzothiophene-2-carboxylate (P4). To a 0° C. suspension of copper(II) bromide (996 mg, 4.46 mmol) and tert-butyl nitrite (0.668 mL, 5.62 mmol) in acetonitrile (37 mL) was added C3 (956 mg, 3.72 mmol) in portions. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature (26° C.) for 16 h, whereupon it was poured into hydrochloric acid (0.5 M; 200 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed successively with water (200 mL) and saturated aqueous sodium chloride solution (200 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded P4 as a white solid. Yield: 674 mg, 2.11 mmol, 57%. 1 H NMR (400 MHz, chloroform-d) δ 7.32 (ddd, J = 7.7, 2.2, 1.1 Hz, 1H), 6.93 (ddd, J = 11.3, 9.1, 2.2 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 3H).
[0289] Preparation example P5 Ethyl 3-bromo-6-chloro-5-fluoro-1-benzothiophene-2-carboxylate (P5)
[0290] [ka] Step 1. Synthesis of ethyl 3-amino-6-chloro-5-fluoro-1-benzothiophene-2-carboxylate (C4). Ethyl sulfanylacetate (0.284 mL, 2.59 mmol) was added dropwise to a 0° C. solution of 4-chloro-2,5-difluorobenzonitrile (450 mg, 2.59 mmol) in N,N-dimethylformamide (2 mL). After the reaction mixture was stirred for 30 min at 0° C., an aqueous solution of sodium hydroxide (5 M; 0.622 mL, 3.11 mmol) was added and stirring was continued at 20° C. for 1 h. The resulting suspension was poured into ice water; filtered to give C4 as a solid (500 mg). 1 H NMR analysis revealed this material to be impure; it was carried forward as is to the next step. 1 H NMR (400 MHz, chloroform-d), predicted product peaks only: δ 7.75 (d, J = 6.4 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 5.79 (br s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H).
[0291] Step 2. Synthesis of ethyl 3-bromo-6-chloro-5-fluoro-1-benzothiophene-2-carboxylate (P5). To a 0° C. suspension of copper(II) bromide (408 mg, 1.83 mmol) and tert-butyl nitrite (0.263 mL, 2.21 mmol) in acetonitrile (10 mL) was added C4 (from the previous step; 500 mg, <1.83 mmol) in portions. The reaction mixture was stirred at 0° C. for 15 min and at room temperature (28° C.) for 3 h, whereupon it was poured into hydrochloric acid (1 M; 2 mL) and extracted with ethyl acetate (10 mL). The organic layer was washed with water (5 mL) and with saturated aqueous sodium chloride solution (10 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded P5 as a white solid. Yield: 175 mg, 0.518 mmol, 20% for two steps. 1H NMR (400 MHz, chloroform-d) δ 7.88 (d, J = 6.3 Hz, 1H), 7.73 (d, J = 9.1 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1 Hz, 3H).
[0292] Preparation example P6 Methyl 6-fluoro-3-iodo-1-benzothiophene-2-carboxylate (P6)
[0293] [ka] Step 1. Synthesis of methyl [(2-cyano-5-fluorophenyl)sulfanyl]acetate (C5) and methyl 3-amino-6-fluoro-1-benzothiophene-2-carboxylate (C1). Methyl sulfanylacetate (356 mL, 3.98 mol) was added dropwise to a 0° C. solution of 2,4-difluorobenzonitrile (496 g, 3.57 mol) in N,N-dimethylformamide (2.4 L). After the mixture was stirred for 1 h at 0° C., an aqueous solution of sodium hydroxide (5 M; 1.07 L, 5.35 mol) was added dropwise over 2 h at a rate that maintained the reaction mixture at 20° C. to 50° C. Stirring was then continued for an additional 1 h at 25° C. whereupon the suspension was poured into ice water (6 L) and filtered. The filter cake was washed with water (3×1.5 L) to give the product, a light purple solid, as a mixture of C5 and C1; 1 H NMR analysis indicated that it consisted of approximately a 1:2 ratio of C5 to C1. The bulk of this material was used directly in the next step. Yield: 528 g, 2.34 mol, 66%. 1 H NMR (400 MHz, chloroform-d) δ 7.60 (major component; dd, J = 8.9, 5.0 Hz, 1H), 7.54 - 7.48 (minor component; m, 1H), 7.41 (principal component; dd, J = 8.7, 2.3 Hz, 1H), 7.18 - 7.13 (minor component; m, 2H), 7.16 - 7.08 (principal component; m, 1H), 5.89 (principal component; br s, 2H), 3.89 (principal component; s, 3H), 3.78 (minor component; s, 3H), 3.75 (minor component; s, 2H).
[0294] Isolation and characterization of C5 and C1 A portion of this mixture of C5 and C1 (644 mg, 2.86 mmol) was separated by reverse-phase HPLC (column: YMC-Actus Triart C18, 50×250 mm, 7 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: 34% to 74% B). Both components were isolated as pale yellow solids. C5 - Yield: 52mg, 0.23mmol. LCMS m / z 225.9 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.54 - 7.48 (m, 1H), 7.18 - 7.13 (m, 2H), 3.78 (s, 3H), 3.75 (s, 2H). Retention time: 4.38 min. [Column: Welch Ultisil XB-C18, 3.0×50 mm, 3 μm; Mobile phase A: water containing 0.1% trifluoroacetic acid; Mobile phase B: acetonitrile; Gradient: 1% to 5% B over 1.0 min, then 5% to 100% B over 5 min; Flow rate: 1.2 mL / min.]. C1 - Yield: 55 mg, 0.24 mmol. LCMS m / z 226.0 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.59 (dd, J = 8.9, 4.9 Hz, 1H), 7.41 (dd, J = 8.7, 2.4 Hz, 1H), 7.12 (ddd, J = 8.8, 8.8, 2.3 Hz, 1H), 5.89 (br s, 2H), 3.89 (s, 3H). Retention time: 4.70 min (analytical conditions identical to those used for C5).
[0295] Step 2. Synthesis of methyl 3-amino-6-fluoro-1-benzothiophene-2-carboxylate (C1). A mixture of C5 and C1 (from the previous step; 490 g, 2.18 mol), potassium carbonate (601 g, 4.35 mol), and 1,4,7,10,13,16-hexaoxacyclooctadecane (18-crown-6; 28.8 g, 109 mmol) in N,N-dimethylformamide (2 L) was heated to 98 °C and stirred at 98 °C for 16 h. The reaction mixture was cooled to 25 °C, added to ice water (6 L), and the resulting mixture was filtered. The filter cake was washed with water (3 x 1.5 L), then suspended in water (2 L), stirred at 25 °C for 12 h, and filtered to give C1 as a green solid. Yield: 382 g, 1.70 mol, 78%. 1 H NMR (400 MHz, chloroform-d) δ 7.59 (dd, J = 8.9, 4.9 Hz, 1H), 7.40 (dd, J = 8.7, 2.3 Hz, 1H), 7.11 (ddd, J = 8.8, 8.8, 2.3 Hz, 1H), 5.90 (br s, 2H), 3.88 (s, 3H).
[0296] Step 3. Synthesis of methyl 6-fluoro-3-iodo-1-benzothiophene-2-carboxylate (P6). To a solution of C1 (351 g, 1.56 mol) in acetonitrile (2 L) was added diiodomethane (188 mL, 2.33 mol) whereupon the mixture was heated to 70° C. 3-Methylbutyl nitrite (314 mL, 2.34 mol) was added over 1.5 h at a rate that maintained the reaction temperature between 70° C. and 80° C. Upon completion of the addition, the reaction mixture was stirred at 70° C. for an additional 2 h. Once it was cooled to 25° C., the reaction mixture was concentrated under vacuum and purified using silica gel chromatography (gradient: 0% to 2.5% ethyl acetate in petroleum ether). The resulting material was stirred with methanol (500 mL) at 25° C. for 1.5 h and filtered to give P6 as a light yellow solid. Yield: 184 g, 0.547 mmol, 35%. LCMS m / z 336.9 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.94 (dd, J = 9.0, 5.0 Hz, 1H), 7.52 (dd, J = 8.3, 2.3 Hz, 1H), 7.28 - 7.20 (m, 1H, estimated; partially obscured by solvent peak), 3.97 (s, 3H).
[0297] Preparation example P7 Ethyl 3-bromo-6-chloro-1-benzothiophene-2-carboxylate (P7)
[0298] [ka] Step 1. Synthesis of ethyl 3-amino-6-chloro-1-benzothiophene-2-carboxylate (C7). Ethyl sulfanylacetate (3.10 mL, 28.3 mmol) was added dropwise to a 0° C. solution of 4-chloro-2-fluorobenzonitrile (4.00 g, 25.7 mmol) in N,N-dimethylformamide (26 mL). After stirring for 30 min at 0° C., the reaction mixture was treated with an aqueous solution of sodium hydroxide (5 M; 7.71 mL, 38.6 mmol) and stirring was continued for an additional 2 h. Water (50 mL) was then added; the resulting precipitate was collected by filtration and lyophilized to give C7 as a white solid. Yield: 6.52 g, 25.5 mmol, 99%. 1 H NMR (400 MHz, chloroform-d) δ 7.71 (d, J = 1.9 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.33 (dd, J = 8.6, 1.9 Hz, 1H), 5.87 (br s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H).
[0299] Step 2. Synthesis of ethyl 3-bromo-6-chloro-1-benzothiophene-2-carboxylate (P7). To a 0° C. suspension of copper(II) bromide (3.69 g, 16.5 mmol) and tert-butyl nitrite (2.48 mL, 20.8 mmol) in acetonitrile (140 mL) was added C7 (3.52 g, 13.8 mmol) in portions. After the reaction mixture was stirred at 0° C. for 15 min, it was allowed to stir at room temperature (26° C.) for 1 h, whereupon it was poured into hydrochloric acid (0.5 M; 200 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with water (200 mL) and with saturated aqueous sodium chloride solution (200 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by silica gel chromatography (gradient: 0% to 5% ethyl acetate in petroleum ether) gave material that was combined with the product from a similar reaction carried out using C7 (3.00 g, 11.7 mmol) to give P7 as a yellow solid. Combined yield: 5.69g, 17.8mmol, 70%. LCMS m / z 320.7 (bromochloro isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.90 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 1.8 Hz, 1H), 7.46 (dd, J = 8.7, 1.9 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H).
[0300] Preparation example P8 Methyl 6-chloro-3-iodo-1-benzothiophene-2-carboxylate (P8)
[0301] [ka] Step 1. Synthesis of methyl 3-amino-6-chloro-1-benzothiophene-2-carboxylate (C8). A mixture of 4-chloro-2-fluorobenzonitrile (400 mg, 2.57 mmol), methyl sulfanylacetate (0.241 mL, 2.70 mmol), and triethylamine (1.11 mL, 7.96 mmol) in dimethylsulfoxide (1.2 mL) was irradiated in a Biotage initiator+microwave synthesizer for 20 min at 130° C. After the reaction mixture was cooled to room temperature in a compressed air stream, it was poured into ice water; the resulting solid was collected by filtration and washed with water to give C8 as a grey solid, which was used in further chemistry without purification. Yield: 560 mg, 2.32 mmol, 90%. LCMS m / z 242.0 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.15 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 1.9 Hz, 1H), 7.46 (dd, J = 8.7, 2.0 Hz, 1H), 7.22 (br s, 2H), 3.79 (s, 3H).
[0302] Step 2. Synthesis of methyl 6-chloro-3-iodo-1-benzothiophene-2-carboxylate (P8). tert-Butyl nitrite (0.372 mL, 3.10 mmol) was added dropwise to a suspension of C8 (500 mg, 2.07 mmol) and copper(I) iodide (591 mg, 3.10 mmol) in acetonitrile (10 mL). After stirring the reaction mixture at 20° C. for 16 h, the pH was adjusted to approximately 3 and the reaction mixture was extracted with ethyl acetate (3×15 mL). The combined organic layers were washed with saturated aqueous sodium chloride (50 mL), concentrated in vacuo, and purified using silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to give P8 as a white solid. Yield: 200 mg, 0.567 mmol, 27%. 1H NMR (400 MHz, DMSO-d6) δ 8.30 (d, J = 1.9 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.61 (dd, J = 8.7, 2.0 Hz, 1H), 3.91 (s, 3H).
[0303] Preparation Example P9 Ethyl 6-fluoro-3-iodo-1-benzofuran-2-carboxylate (P9)
[0304] [ka] Step 1. Synthesis of ethyl (2-cyano-5-fluorophenoxy)acetate (C9). To a mixture of 4-fluoro-2-hydroxybenzonitrile (8.50 g, 62.0 mmol) in acetonitrile (200 mL) was added potassium carbonate (17.1 g, 124 mmol), followed by ethyl bromoacetate (12.4 g, 74.3 mmol). After the reaction mixture was stirred at 15° C. for 3 h, it was filtered; the filtrate was concentrated under vacuum to give C9 as a yellow solid. Yield: 14.9 g, assumed quantitative. LCMS m / z 224.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.59 (dd, J = 8.6, 6.2 Hz, 1H), 6.78 (ddd, J = 8.6, 7.8, 2.3 Hz, 1H), 6.56 (dd, J = 10.1, 2.3 Hz, 1H), 4.75 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H).
[0305] Step 2. Synthesis of ethyl 3-amino-6-fluoro-1-benzofuran-2-carboxylate (C10). A solution of C9 (8.00 g, 35.8 mmol) in tetrahydrofuran (50 mL) was added dropwise to a 0° C. solution of potassium tert-butoxide (6.44 g, 57.4 mmol) in tetrahydrofuran (100 mL) and the reaction mixture was stirred at 0° C. for 2 h. It was then diluted with water and extracted with ethyl acetate (3×150 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (2×150 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give C10 as a yellow solid. Yield: 6.68 g, 29.9 mmol, 84%. LCMS m / z 224.0 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.49 (dd, J = 8.7, 5.3 Hz, 1H), 7.15 (dd, J = 8.9, 2.3 Hz, 1H), 7.01 (ddd, J = 8.9, 8.9, 2.2 Hz, 1H), 4.98 (br s, 2H), 4.43 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H).
[0306] Step 3. Synthesis of ethyl 6-fluoro-3-iodo-1-benzofuran-2-carboxylate (P9). To a suspension of copper(I) iodide (2.56 g, 13.4 mmol) and C10 (2.00 g, 8.96 mmol) in acetonitrile (60 mL) was added tert-butyl nitrite (1.61 mL, 13.5 mmol) in portions, whereupon the reaction mixture was stirred at 0° C. for 15 min and at room temperature (15° C.) for 16 h. It was then poured into hydrochloric acid (1 M; 15 mL) and extracted with ethyl acetate (50 mL). The organic layer was washed successively with aqueous sodium sulfite (3×40 mL) and saturated aqueous sodium chloride (2×30 mL), dried over sodium sulfate, filtered, concentrated under vacuum, and purified by chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to give P9 as a yellow solid. Yield: 190 mg, 0.569 mmol, 6%. 1H NMR (400 MHz, chloroform-d) δ 7.50 (dd, J = 8.7, 5.3 Hz, 1H), 7.29 (dd, J = 8.5, 2.2 Hz, 1H), 7.15 (ddd, J = 9.0, 9.0, 2.2 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 1.47 (t, J = 7.1 Hz, 3H).
[0307] Preparation example P10 Ethyl 6-chloro-3-iodo-1-benzofuran-2-carboxylate (P10)
[0308] [ka] Step 1. Synthesis of ethyl (5-chloro-2-cyanophenoxy)acetate (C11). To a solution of 4-chloro-2-hydroxybenzonitrile (9.00 g, 58.6 mmol) in acetonitrile (290 mL) was added potassium carbonate (16.2 g, 117 mmol) followed by ethyl bromoacetate (11.7 g, 70.1 mmol) and the reaction mixture was stirred at 15° C. for 16 h. It was then filtered; the filtrate was concentrated under vacuum to give C11 as a white solid. Yield: 13.5 g, 56.3 mmol, 96%. 1 H NMR (400 MHz, chloroform-d) δ 7.53 (d, J = 8.3 Hz, 1H), 7.06 (dd, J = 8.3, 1.8 Hz, 1H), 6.84 (d, J = 1.8 Hz, 1H), 4.76 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H).
[0309] Step 2. Synthesis of ethyl 3-amino-6-chloro-1-benzofuran-2-carboxylate (C12). A solution of C11 (13.5 g, 56.3 mmol) in tetrahydrofuran (25 mL) was added dropwise to a 0° C. solution of potassium tert-butoxide (10.1 g, 90.0 mmol) in tetrahydrofuran (200 mL). After the reaction mixture was stirred at 0° C. for 2 h, it was diluted with water (50 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with saturated aqueous sodium chloride (2×50 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to give C12 as a solid. Yield: 8.70 g, 36.3 mmol, 64%. LCMS m / z 239.9 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.50 - 7.44 (m, 2H), 7.24 (dd, J = 8.4, 1.8 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1 Hz, 3H).
[0310] Step 3. Synthesis of ethyl 6-chloro-3-iodo-1-benzofuran-2-carboxylate (P10). A suspension of C12 (7.40 g, 30.9 mmol) and copper(I) iodide (8.82 g, 46.3 mmol) in acetonitrile (150 mL) was heated to 45° C. whereupon a solution of tert-butyl nitrite (5.55 mL, 46.7 mmol) in acetonitrile (4 mL) was added. After the reaction mixture was stirred at 45° C. for 2 h, it was concentrated under vacuum and treated with dilute hydrochloric acid until the pH of the mixture was approximately 3. After extraction with ethyl acetate (3×50 mL), the combined organic layers were washed with saturated aqueous sodium chloride (2×50 mL), concentrated under reduced pressure and purified by chromatography on silica gel (gradient: 0% to 20% ethyl acetate in petroleum ether) to give P10 as a white solid. Yield: 1.12 g, 3.20 mmol, 10%. LCMS m / z 350.9 [M+H] + . 1H NMR (400 MHz, chloroform-d) δ 7.58 (d, J = 1.7 Hz, 1H), 7.47 (d, half of the AB quartet, J = 8.4 Hz, 1H), 7.36 (dd, components of the ABX system, J = 8.5, 1.7 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 1.47 (t, J = 7.1 Hz, 3H).
[0311] Preparation example P11 5,7-Difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran (P11)
[0312] [ka] Step 1. Synthesis of ethyl (2E)-3-(2,4-difluoro-6-hydroxyphenyl)prop-2-enoate (C13). Ethyl(triphenyl-λ) in dichloromethane (50 mL) 5 A solution of 2,4-difluoro-6-hydroxybenzaldehyde (50%; 7.00 g, 22 mmol) was added in portions to a solution of 2,4-difluoro-6-hydroxybenzaldehyde (50%; 7.00 g, 22 mmol) in dichloromethane (100 mL). After the reaction mixture was stirred at 25° C. overnight, it was concentrated under vacuum; the residue was purified by silica gel chromatography (gradient: 0% to 25% ethyl acetate in petroleum ether) to give C13 as a yellow solid. Yield: 2.71 g, 11.9 mmol, 54%. 1 H NMR (400 MHz, chloroform-d) δ 9.03 (br s, 1H), 7.96 (d, J = 16.4 Hz, 1H), 6.93 (d, J = 16.5 Hz, 1H), 6.49 (ddd, J = 9.7, 2, 2 Hz, 1H), 6.41 (ddd, J = 11.0, 9.0, 2.5 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H).
[0313] Step 2. Synthesis of ethyl 3-(2,4-difluoro-6-hydroxyphenyl)propanoate (C14). Nickel(II) chloride hexahydrate (3.39 g, 14.3 mmol) was added to a 0° C. solution of C13 (2.71 g, 11.9 mmol) in a mixture of tetrahydrofuran (90 mL) and methanol (16 mL). After nickel(II) chloride hexahydrate was completely dissolved, sodium borohydride (1.80 g, 47.6 mmol) was added slowly in small portions and the reaction mixture was allowed to stir at 0° C. for 1 h. Water (50 mL) was carefully added and the resulting mixture was extracted with ethyl acetate (2×80 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (2×50 mL), dried over sodium sulfate, filtered, and concentrated under vacuum to give C14 as a yellow oil. Yield: 2.88 g; corrected for residual ethyl acetate: 2.35 g, 10.2 mmol; 86%. 1 H NMR (400 MHz, chloroform-d) δ 8.42 (br s, 1H), 6.47 (ddd, J = 10.1, 2.6, 1.8 Hz, 1H), 6.38 (ddd, J = 10.0, 8.9, 2.6 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 2.87 - 2.81 (m, 2H), 2.73 - 2.67 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H).
[0314] Step 3. Synthesis of 5,7-difluoro-3,4-dihydro-2H-1-benzopyran-2-one (C15). To a solution of C14 (from the previous step; 2.88 g, 10.2 mmol, containing 2.35 g of C14) in toluene (60 mL) was added p-toluenesulfonic acid (215 mg, 1.25 mmol), whereupon the reaction mixture was stirred at 130° C. for 16 h. After the mixture was concentrated under vacuum, it was treated with water (50 mL) and extracted with ethyl acetate (3×60 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (2×50 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by silica gel chromatography [gradient: 0% to 20% ethyl acetate in (5:1 petroleum ether / dichloromethane)] afforded C15 as a yellow solid. Yield: 1.70 g, 9.23 mmol, 90%. 1 H NMR (400 MHz, chloroform-d) δ 6.68 - 6.61 (m, 2H), 3.03 - 2.96 (m, 2H), 2.82 - 2.76 (m, 2H).
[0315] Step 4. Synthesis of 5,7-difluoro-3,4-dihydro-2H-1-benzopyran-2-ol (C16). A solution of diisobutylaluminum hydride in toluene (DIBAL, 1M; 7.82 mL, 7.82 mmol) was slowly added to a −78° C. solution of C15 (1.20 g, 6.52 mmol) in dichloromethane (30 mL). The reaction mixture was stirred at −78° C. for 2.5 h whereupon it was added to hydrochloric acid (1M; 20 mL) at 0° C.; the resulting mixture was extracted with dichloromethane (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride (26 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel [gradient: 0% to 20% ethyl acetate in (5:1 petroleum ether / dichloromethane)] afforded C16 as a yellow oil. Yield: 700 mg, 3.76 mmol, 58%. 1 H NMR (400 MHz, chloroform-d) δ 6.44 - 6.34 (m, 2H), 5.64 - 5.60 (m, 1H), 3.15 (br d, J = 3.5 Hz, 1H), 2.85 - 2.67 (m, 2H), 2.10 - 2.00 (m, 1H), 1.99 - 1.87 (m, 1H).
[0316] Step 5. Synthesis of 3,5-difluoro-2-(3-hydroxybutyl)phenol (C17). A solution of methylmagnesium bromide in diethyl ether (3.0 M; 3.76 mL, 11.3 mmol) was added dropwise to a 0° C. solution of C16 (700 mg, 3.76 mmol) in tetrahydrofuran (18 mL). The reaction mixture was stirred at 0° C. for 20 min and then at 25° C. for 2.5 h whereupon it was poured into hydrochloric acid (1 M; 15 mL) and extracted with ethyl acetate (2×12 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum to give C17 as a yellow oil. Yield: 540 mg, 2.67 mmol, 71%. 1 H NMR (400 MHz, chloroform-d) δ 6.43 (ddd, J = 10.2, 2.1, 2.1 Hz, 1H), 6.41 - 6.34 (m, 1H), 3.78 - 3.68 (m, 1H), 2.85 - 2.65 (m, 2H), 1.82 - 1.63 (m, 2H), 1.25 (d, J = 6.2 Hz, 3H).
[0317] Step 6. Synthesis of 5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran (P11). To a solution of C17 (540 mg, 2.67 mmol) in acetic acid (6 mL), sulfuric acid (50%; 6 mL) was added and the reaction mixture was stirred at 100° C. for 3 h. It was then diluted with water (10 mL) and extracted with a mixture of petroleum ether and ethyl acetate (5:1 ratio; 3×6 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (15 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give P11 as a brown oil. Yield: 350 mg, 1.90 mmol, 71%. 1 H NMR (400 MHz, chloroform-d) δ 6.38 - 6.29 (m, 2H), 4.17 - 4.07 (m, 1H), 2.83 - 2.72 (m, 1H), 2.67 - 2.54 (m, 1H), 2.05 - 1.96 (m, 1H), 1.72 - 1.59 (m, 1H), 1.39 (d, J = 6.2 Hz, 3H).
[0318] Alternative preparation of P11 5,7-Difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran (P11)
[0319] [ka] Step 1. Synthesis of 5,7-difluoro-2-methyl-2,3-dihydro-4H-1-benzopyran-4-one (C18). (2E)-But-2-enoic acid (1.72 g, 20.0 mmol) was added to a solution of 3,5-difluorophenol (2.60 g, 20.0 mmol) in methanesulfonic acid (50 mL). The reaction mixture was stirred at 110° C. for 16 h whereupon it was diluted with water (150 mL) and extracted with ethyl acetate (3×60 mL). The combined organic layers were washed successively with aqueous sodium bicarbonate (2×50 mL) and saturated aqueous sodium chloride (60 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel (0% to 10% ethyl acetate in petroleum ether) afforded C18 as a yellow oil. Yield: 569 mg, 2.87 mmol, 14%. 1 H NMR (400 MHz, chloroform-d) δ 6.53 - 6.41 (m, 2H), 4.66 - 4.54 (m, 1H), 2.69 - 2.64 (m, 2H), 1.51 (d, J = 6.3 Hz, 3H).
[0320] Step 2. Synthesis of 5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran (P11). To a solution of C18 (569 mg, 2.87 mmol) in trifluoroacetic acid (10 mL) was added triethylsilane (2.29 mL, 14.3 mmol), whereupon the reaction mixture was stirred at 25° C. for 3 days. After adjusting the pH to 7 by addition of aqueous sodium bicarbonate, the reaction mixture was extracted with ethyl acetate (3×6 mL) and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (eluent: petroleum ether) afforded P11 as a colorless oil. Yield: 416 mg, 2.26 mmol, 79%. 1 H NMR (400 MHz, chloroform-d), performed from a similar, smaller scale reaction using C18: δ 6.37 - 6.30 (m, 2H), 4.12 (dqd, J = 10.1, 6.3, 2.1 Hz, 1H), 2.82 - 2.72 (m, 1H), 2.66 - 2.55 (m, 1H), 2.00 (dddd, J = 13.8, 6.3, 3.1, 2.2 Hz, 1H), 1.65 (dddd, J = 13.7, 11.3, 10.1, 5.8 Hz, 1H), 1.39 (d, J = 6.3 Hz, 3H).
[0321] Preparation example P12 Methyl 3-bromo-6-chloro-1-benzothiophene-2-carboxylate (P12)
[0322] [ka] To a 0° C. solution of tert-butyl nitrite (0.385 mL, 3.24 mmol) in acetonitrile (10 mL) was added copper(II) bromide (806 mg, 3.61 mmol), followed by portionwise addition of C8 (560 mg, 2.32 mmol). The reaction mixture was then warmed to 25° C. and stirred at that temperature for 2 h whereupon it was treated with hydrochloric acid (1 M; 30 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with hydrochloric acid (1 M; 2×10 mL), dried over sodium sulfate, filtered, concentrated under vacuum, and purified by silica gel chromatography (gradient: 0% to 2% ethyl acetate in petroleum ether) to give P12 as a white solid. Yield: 350 mg, 1.15 mmol, 50%. LCMS m / z 304.9 (bromochloro isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.91 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 1.9 Hz, 1H), 7.47 (dd, J = 8.8, 1.8 Hz, 1H), 3.97 (s, 3H).
[0323] Preparation example P13 5-Fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P13)
[0324] [ka] Step 1. Synthesis of 2-bromo-1-(3-bromopropoxy)-3-fluorobenzene (C19). Potassium carbonate (6.51 g, 47.1 mmol) and 1,3-dibromopropane (7.17 mL, 70.6 mmol) were added to a solution of 2-bromo-3-fluorophenol (4.50 g, 23.6 mmol) in acetonitrile (45 mL), whereupon the reaction mixture was stirred at 80° C. for 16 h. It was then concentrated under vacuum, diluted with water (50 mL), and extracted with ethyl acetate (2×40 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography on silica gel (gradient: 0% to 1% ethyl acetate in petroleum ether) afforded C19 as a colorless oil. Yield: 5.56 g, 17.8 mmol, 75%. 1 H NMR (400 MHz, chloroform-d) δ 7.23 (ddd, J = 8.3, 8.3, 6.4 Hz, 1H), 6.78 (ddd, J = 8.3, 8.1, 1.2 Hz, 1H), 6.71 (br d, J = 8.4 Hz, 1H), 4.18 (t, J = 5.7 Hz, 2H), 3.68 (t, J = 6.3 Hz, 2H), 2.42 - 2.34 (m, 2H).
[0325] Step 2. Synthesis of 5-fluoro-3,4-dihydro-2H-1-benzopyran (C20). To a -78°C solution of C19 (5.56 g, 17.8 mmol) in tetrahydrofuran (15 mL) was added a solution of n-butyllithium in hexanes (2.5 M; 9.27 mL, 23.2 mmol) and the reaction mixture was stirred at -78°C for 2 h. It was then warmed to 25°C and stirred at that temperature for 16 h, whereupon LCMS analysis showed conversion to C20: LCMS m / z 153.1 [M+H]. + Water (30 mL) was added and the resulting mixture was extracted with methyl tert-butyl ether (3×50 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated in vacuo to give C20 as a yellow oil. Yield: 2.70 g, 17.7 mmol, 99%. 1 H NMR (400 MHz, chloroform-d) δ 7.06 - 6.99 (m, 1H), 6.62 - 6.54 (m, 2H), 4.20 - 4.15 (m, 2H), 2.74 (t, J = 6.6 Hz, 2H), 2.04 - 1.96 (m, 2H).
[0326] Step 3. Synthesis of 6-bromo-5-fluoro-3,4-dihydro-2H-1-benzopyran (C21). N-Bromosuccinimide (2.34 g, 13.1 mmol) was added to a solution of C20 (2.00 g, 13.1 mmol) in acetonitrile (20 mL). After the mixture was stirred at 25° C. for 16 h, it was concentrated under reduced pressure, diluted with water (10 mL), and extracted with methyl tert-butyl ether (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum, followed immediately by silica gel chromatography (gradient: 0% to 1% ethyl acetate in petroleum ether) to give C21 as a colorless oil. Yield: 1.60 g, 6.92 mmol, 53%. 1 H NMR (400 MHz, chloroform-d) δ 7.21 (br dd, J = 8.8, 8.0 Hz, 1H), 6.53 (dd, J = 8.8, 1.6 Hz, 1H), 4.19 - 4.13 (m, 2H), 2.77 (t, J = 6.6 Hz, 2H), 2.03 - 1.95 (m, 2H).
[0327] Step 4. Synthesis of 5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P13). A mixture of C21 (200 mg, 0.866 mmol), potassium acetate (297 mg, 3.03 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (330 mg, 1.30 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (63 mg, 86 μmol) in N,N-dimethylformamide (2 mL) was stirred at 100 °C for 16 h, whereupon the reaction mixture was diluted with ethyl acetate (20 mL) and filtered. The filtrate was washed with water (30 mL) and with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated under vacuum, and purified using chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to give P13 as a white solid. Yield: 120 mg, 0.431 mmol, 50%. LCMS m / z 279.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.45 (dd, J = 8, 8 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 4.18 (dd, J = 5.8, 4.5 Hz, 2H), 2.73 (t, J = 6.6 Hz, 2H), 2.02 - 1.94 (m, 2H), 1.34 (s, 12H).
[0328] Preparation example P14 3-Methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P14)
[0329] [ka] Step 1. Synthesis of 7-bromo-3-methyl-2,3-dihydro-4H-1-benzopyran-4-one (C22). A solution of lithium diisopropylamide was prepared as follows: to a −78° C. solution of diisopropylamine (4.31 mL, 30.8 mmol) in tetrahydrofuran (50 mL) was added a solution of n-butyllithium (2.4 M; 11.9 mL, 28.6 mmol), whereupon the reaction mixture was stirred at −60° C. for 1 h.
[0330] A solution of 7-bromo-2,3-dihydro-4H-1-benzopyran-4-one (5.00 g, 22.0 mmol) and N,N,N',N',N",N"-hexamethylphosphoric triamide (HMPA; 19.1 mL, 110 mmol) in tetrahydrofuran (70 mL) was cooled to -78°C and treated with the lithium diisopropylamide solution prepared above. After stirring the reaction mixture at -78°C for 1 h, a solution of iodomethane (15.6 g, 110 mmol) in tetrahydrofuran (20 mL) was added dropwise. At the end of the addition, the reaction mixture was warmed to 0°C and stirred at 0°C for 2 h. After addition of saturated aqueous ammonium chloride (50 mL), the resulting mixture was extracted with ethyl acetate (3 x 40 mL) and the combined organic layers were washed with saturated aqueous sodium chloride and concentrated under vacuum. Purification by silica gel chromatography (gradient: 0% to 15% ethyl acetate in petroleum ether) afforded C22 as a yellow solid. Yield: 2.50 g, 10.4 mmol, 47%. LCMS m / z 240.9 (bromine isotope pattern observed) [M+H] + . 1H NMR (400 MHz, chloroform-d) δ 7.75 (d, J = 8.3 Hz, 1H), 7.19 - 7.13 (m, 2H), 4.51 (dd, J = 11.4, 5.1 Hz, 1H), 4.15 (dd, J = 11.3, 11.1 Hz, 1H), 2.92 - 2.80 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H).
[0331] Step 2. Synthesis of 7-bromo-3-methyl-3,4-dihydro-2H-1-benzopyran (C23). To a solution of C22 (3.50 g, 14.5 mmol) in trifluoroacetic acid (30 mL) was added triethylsilane (25 mL, 160 mmol). The reaction mixture was stirred at 50° C. for 16 h whereupon it was concentrated under vacuum and partitioned between ethyl acetate (20 mL) and saturated aqueous sodium bicarbonate (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum; the residue was purified using chromatography on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) to give C23 as a white solid. Yield: 3.01 g, 13.3 mmol, 92%. 1 H NMR (400 MHz, chloroform-d) δ 6.98 - 6.92 (m, 2H), 6.87 (br d, half of AB quartet, J = 7.8 Hz, 1H), 4.16 (ddd, J = 10.6, 3.4, 2.0 Hz, 1H), 3.67 (dd, J = 10.6, 9.4 Hz, 1H), 2.77 (ddd, J = 16.2, 5.2, 2.0 Hz, 1H), 2.36 (dd, J = 16.2, 9.8 Hz, 1H), 2.19 - 2.05 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H).
[0332] Step 3. Synthesis of 3-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P14). A mixture of C23 (3.0 g, 13 mmol), potassium acetate (4.54 g, 46.3 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (5.03 g, 19.8 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (967 mg, 1.32 mmol) in N,N-dimethylformamide (60 mL) was stirred at 100 °C for 16 h. Ethyl acetate (150 mL) was then added and the resulting mixture was filtered. After the filtrate was washed with water (2 x 300 mL) and with saturated aqueous sodium chloride, it was dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by chromatography on silica gel (gradient: 0% to 15% ethyl acetate in petroleum ether) gave P14 as a white solid. Yield: 2.70g, 9.85mmol, 76%. LCMS m / z 275.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.29 - 7.23 (m, 2H), 7.03 (br d, J = 7.4 Hz, 1H), 4.16 (ddd, J = 10.6, 3.4, 2.0 Hz, 1H), 3.67 (dd, J = 10.6, 9.4 Hz, 1H), 2.84 (ddd, J = 16.4, 5.3, 1.9 Hz, 1H), 2.45 (dd, J = 16.5, 9.7 Hz, 1H), 2.20 - 2.07 (m, 1H), 1.32 (s, 12H), 1.03 (d, J = 6.7 Hz, 3H).
[0333] Preparation example P15 2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P15)
[0334] [ka] Step 1. Synthesis of 6-bromo-2-methyl-2,3-dihydro-4H-1-benzopyran-4-one (C24). Pyrrolidine (3.31 g, 46.5 mmol) was added to a solution of 1-(5-bromo-2-hydroxyphenyl)ethan-1-one (10.0 g, 46.5 mmol) in ethanol (200 mL). After the reaction mixture was stirred at 20° C. for 30 min, it was heated to 70° C. whereupon a solution of acetaldehyde (5.0 M in tetrahydrofuran; 46.5 mL, 232 mmol) in ethanol (100 mL) was added dropwise over 1.5 h. At the end of the addition, stirring was continued at 70° C. for 1 h. LCMS analysis at this point showed conversion to C24: LCMS m / z 241.1 (bromine isotope pattern observed) [M+H] + The reaction mixture was concentrated under vacuum and the residue was added to water (300 mL); the resulting mixture was extracted with ethyl acetate (3×150 mL) and the combined organic layers were washed successively with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under vacuum. Silica gel chromatography (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded a mixture of solids and oils that was taken up in hot heptane and cooled to give C24 after filtration as a yellow solid. Yield: 2.44 g, 10.1 mmol, 22%. 1 H NMR (400 MHz, chloroform-d) δ 7.98 (d, J = 2.4 Hz, 1H), 7.54 (dd, J = 8.8, 2.6 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 4.64 - 4.52 (m, 1H), 2.73 - 2.60 (m, 2H), 1.52 (d, J = 6.3 Hz, 3H).
[0335] Step 2. Synthesis of 6-bromo-2-methyl-3,4-dihydro-2H-1-benzopyran (C25). Triethylsilane (25 mL, 160 mmol) was added to a solution of C24 (3.94 g, 16.3 mmol) in trifluoroacetic acid (25 mL). After the reaction mixture was heated at 50° C. for 16 h, it was concentrated under vacuum, diluted with ethyl acetate (100 mL), and basified to pH 8 by addition of saturated aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (50 mL), and the combined organic layers were washed with water and with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Silica gel chromatography (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded C25 as a pale yellow solid. Yield: 3.00 g, 13.2 mmol, 81%. 1 H NMR (400 MHz, chloroform-d) δ 7.18 - 7.13 (m, 2H), 6.67 (d, J = 9.3 Hz, 1H), 4.11 (dqd, J = 10.1, 6.2, 2.1 Hz, 1H), 2.83 (br ddd, ABXY components, J = 16.6, 11.5, 6.1 Hz, 1H), 2.71 (ddd, ABXY components, J = 16.7, 5.6, 3.1 Hz, 1H), 1.97 (dddd, J = 13.6, 6.1, 3.2, 2.2 Hz, 1H), 1.68 (dddd, J = 13.6, 11.5, 10.1, 5.6 Hz, 1H), 1.39 (d, J = 6.2 Hz, 3H).
[0336] Step 3. Synthesis of 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P15). 4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi-1,3,2-dioxaborolane (5.03 g, 19.8 mmol), potassium acetate (4.55 g, 46.4 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (964 mg, 1.32 mmol) were added to a solution of C25 (3.00 g, 13.2 mmol) in N,N-dimethylformamide (40 mL). The reaction vessel was then evacuated and charged with nitrogen; this evacuation cycle was repeated twice, whereupon the reaction mixture was heated at 90° C. for 16 h. After addition of water (100 mL) and ethyl acetate (100 mL), the resulting mixture was filtered and the aqueous layer was extracted with ethyl acetate (2×50 mL). The combined organic layers were washed successively with water and saturated aqueous sodium chloride, dried over sodium sulfate, filtered and concentrated under vacuum. Silica gel chromatography (gradient: 5% to 10% ethyl acetate in petroleum ether) afforded P15 as a pale yellow solid. Yield: 2.56 g, 9.34 mmol, 71%. LCMS m / z 275.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.57 - 7.50 (m, 2H), 6.78 (d, J = 8.6 Hz, 1H), 4.16 (dqd, J = 10.1, 6.3, 2.2 Hz, 1H), 2.84 (br ddd, ABXY component, J = 16.4, 11.3, 5.9 Hz, 1H), 2.75 (ddd, ABXY component, J = 16.4, 5.5, 3.2 Hz, 1H), 1.99 (dddd, J = 13.6, 5.8, 3.3, 2.2 Hz, 1H), 1.71 (dddd, J = 13.6, 11.4, 10.0, 5.7 Hz, 1H), 1.39 (d, J = 6.3 Hz, 3H), 1.33 (s, 12H).
[0337] Preparation example P16 4-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P16)
[0338] [ka] Step 1. Synthesis of 6-bromo-4-methyl-3,4-dihydro-2H-1-benzopyran-4-ol (C26). (III) Cerium chloride (2.17 g, 8.80 mmol) was added to a solution of 6-bromo-2,3-dihydro-4H-1-benzopyran-4-one (4.00 g, 17.6 mmol) in tetrahydrofuran (50 mL), whereupon the mixture was cooled to -50°C and treated dropwise with a solution of methylmagnesium chloride in diethyl ether (3.0 M; 17.6 mL, 52.8 mmol). After completion of the addition, the reaction mixture was warmed to 25°C over 16 hours and then stirred at 25°C for 2 days. Saturated aqueous ammonium chloride solution (80 mL) was added; the resulting mixture was extracted with ethyl acetate (2 x 60 mL) and the combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by chromatography on silica gel (gradient: 0% to 20% ethyl acetate in petroleum ether) afforded C26 as a white solid. Yield: 2.60 g, 10.7 mmol, 61%. 1 H NMR (400 MHz, chloroform-d) δ 7.58 (d, J = 2.5 Hz, 1H), 7.25 (dd, J = 8.7, 2.4 Hz, 1H), 6.71 (d, J = 8.7 Hz, 1H), 4.32 - 4.17 (m, 2H), 2.08 - 2.03 (m, 2H), 1.85 (br s, 1H), 1.61 (s, 3H).
[0339] Step 2. Synthesis of 6-bromo-4-methyl-3,4-dihydro-2H-1-benzopyran (C27). Boron trifluoride diethyl etherate (98%, 2.14 g, 14.8 mmol) was added dropwise to a 0° C. solution of C26 (1.20 g, 4.94 mmol) and triethylsilane (2.87 g, 24.7 mmol) in dichloromethane (10 mL). After the reaction mixture was stirred at 0° C. for 30 min, it was treated with saturated aqueous sodium bicarbonate; the aqueous layer was extracted with dichloromethane (3×30 mL) and the combined organic layers were washed with saturated aqueous sodium chloride (20 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (gradient: 0% to 1% ethyl acetate in petroleum ether) afforded C27 as a clear, colorless liquid. Yield: 801 mg, 3.53 mmol, 71%. GCMS m / z 226 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.25 (dd, J = 2.4, 1.0 Hz, 1H), 7.16 (ddd, J = 8.7, 2.4, 0.7 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H), 4.24 - 4.10 (m, 2H), 2.98 - 2.86 (m, 1H), 2.11 - 2.00 (m, 1H), 1.76 - 1.65 (m, 1H), 1.32 (d, J = 7.0 Hz, 3H).
[0340] Step 3. Synthesis of 4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P16). A mixture of C27 (300 mg, 1.32 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (839 mg, 3.30 mmol), and potassium acetate (259 mg, 2.64 mmol) in 1,4-dioxane (12 mL) was degassed with nitrogen for 1 min, whereupon [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (96.7 mg, 0.132 mmol) was added and the reaction mixture was heated at 100° C. for 16 h. It was then filtered and the filtrate was concentrated under vacuum, diluted with water (40 mL), and extracted with ethyl acetate (2×30 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (40 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure; chromatography on silica gel (eluent: petroleum ether) afforded P16 as a clear yellow liquid. Yield: 350 mg.
[0341] Preparation Example P17 8-Fluoro-3-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P17)
[0342] [ka] Step 1. Synthesis of 1-bromo-2,3-difluoro-4-(2-methylprop-2-en-1-yl)benzene (C28). A solution of (propan-2-yl)magnesium chloride (2M; 4.08 mL, 8.16 mmol) was added dropwise to a −20° C. solution of 1-bromo-2,3-difluoro-4-iodobenzene (2.00 g, 6.27 mmol) in tetrahydrofuran (10 mL). After the reaction mixture was stirred for 10 min, it was warmed to 0° C. and stirred for an additional 50 min, whereupon copper(I) iodide (299 mg, 1.57 mmol) was added and stirring was continued at 0° C. for 10 min. Then 3-bromo-2-methylprop-1-ene (931 mg, 6.90 mmol) was added; the reaction mixture was warmed to 25° C. and stirred for 16 h. It was then treated with saturated aqueous ammonium chloride solution (30 mL), diluted with petroleum ether (8 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with saturated aqueous sodium chloride (20 mL), dried over sodium sulfate, filtered and concentrated in vacuo to afford C28 as a yellow oil. Yield: 1.48 g, 5.99 mmol, 96%. 1 H NMR (400 MHz, chloroform-d) δ 7.23 (ddd, J = 8.3, 6.1, 2.1 Hz, 1H), 6.89 - 6.83 (m, 1H), 4.85 (br s, 1H), 4.69 (br s, 1H), 3.33 (s, 2H), 1.71 (s, 3H).
[0343] Step 2. Synthesis of 3-(4-bromo-2,3-difluorophenyl)-2-methylpropan-1-ol (C29). To a 0° C. solution of C28 (1.48 g, 5.99 mmol) in tetrahydrofuran (10 mL) was added a solution of borane in tetrahydrofuran (1 M; 8.39 mL, 8.39 mmol) in a dropwise manner. After the reaction mixture was stirred for 30 min, it was warmed to room temperature, stirred for 2 h, and cooled back to 0° C. An aqueous solution of sodium hydroxide (3 M; 9.98 mL, 29.9 mmol) was added, followed by hydrogen peroxide (30% in water; 3.06 mL, 30.0 mmol), and stirring was continued for 30 min, whereupon the reaction mixture was heated to 60° C. and stirred at that temperature for an additional 1.5 h. After it was cooled to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (3×20 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by silica gel chromatography (Gradient: 0% to 30% ethyl acetate in petroleum ether) afforded C29 as a colorless oil. Yield: 800 mg, 3.02 mmol, 50%. 1 H NMR (400 MHz, chloroform-d) δ 7.22 (ddd, J = 8.2, 6.1, 2.0 Hz, 1H), 6.85 (ddd, J = 8.3, 6.9, 2.0 Hz, 1H), 3.51 (dd, J = 5.5, 5.5 Hz, 2H), 2.81 (ddd, J = 13.5, 6.1, 1.6 Hz, 1H), 2.48 (ddd, J = 13.6, 8.2, 1.6 Hz, 1H), 2.01 - 1.90 (m, 1H), 1.48 - 1.36 (m, 1H), 0.92 (d, J = 6.8 Hz, 3H).
[0344] Step 3. Synthesis of 7-bromo-8-fluoro-3-methyl-3,4-dihydro-2H-1-benzopyran (C30). Sodium hydride (60% dispersion in mineral oil; 315 mg, 7.88 mmol) was added to a 0° C. solution of C29 (950 mg, 3.58 mmol) in a mixture of toluene (16 mL) and N,N-dimethylformamide (4 mL), whereupon the reaction mixture was stirred at 25° C. for 16 h. Saturated aqueous ammonium chloride solution (10 mL) was added, and the resulting mixture was diluted with water (15 mL) and petroleum ether (9 mL), and extracted with petroleum ether (3×9 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum to give crude C30 as a yellow solution (2.7 mL). A portion of this solution was carried on directly to the next step.
[0345] The product of a similar reaction carried out using C29 was subjected to silica gel chromatography (eluent: petroleum ether) to give a purified sample of C30: 1 H NMR (400 MHz, chloroform-d) δ 6.96 (dd, J = 8.4, 6.2 Hz, 1H), 6.69 (br d, J = 8.3 Hz, 1H), 4.28 (ddd, J = 10.7, 3.5, 1.9 Hz, 1H), 3.74 (dd, J = 10.6, 9.4 Hz, 1H), 2.81 (ddd, J = 16.4, 5.1, 1.9 Hz, 1H), 2.40 (dd, J = 16.3, 9.7 Hz, 1H), 2.23 - 2.10 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H).
[0346] Step 4. Synthesis of 8-fluoro-3-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (P17). To a mixture of C30 (part of the solution from the previous step; 1.8 mL, ≦2.39 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (361 mg, 1.42 mmol) in toluene (10 mL) was added potassium acetate (232 mg, 2.36 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (86.6 mg, 0.118 mmol). The reaction vessel was then evacuated and charged with nitrogen; this evacuation cycle was repeated twice, whereupon the reaction mixture was stirred at 100° C. for 16 h. It was then filtered, and the filtrate was concentrated under vacuum and purified using chromatography on silica gel (eluent: petroleum ether) to give P17 as a yellow oil. Yield: 189 mg, 0.647 mmol, 27% for two steps. 1 H NMR (400 MHz, chloroform-d) δ 7.12 (dd, J = 7.6, 5.2 Hz, 1H), 6.79 (br d, J = 7.6 Hz, 1H), 4.25 (ddd, J = 10.5, 3.5, 2.0 Hz, 1H), 3.71 (dd, J = 10.6, 9.5 Hz, 1H), 2.85 (br dd, ABX component, J = 16.6, 5.0 Hz, 1H), 2.45 (dd, ABX system, J = 16.7, 9.7 Hz, 1H), 2.24 - 2.09 (m, 1H), 1.34 (s, 12H), 1.04 (d, J = 6.8 Hz, 3H).
[0347] Preparation example P18 2-(3-ethyl-2,4,5-trifluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (P18)
[0348] [ka] Step 1. Synthesis of 1-(3-bromo-2,5,6-trifluorophenyl)ethan-1-ol (C31). A solution of methylmagnesium bromide (3M; 4.58 mL, 13.7 mmol) was added dropwise to a −78° C. solution of 3-bromo-2,5,6-trifluorobenzaldehyde (2.19 g, 9.16 mmol) in tetrahydrofuran (30 mL). The reaction mixture was stirred at −78° C. for 30 min and then at 0° C. for 1.5 h, whereupon it was poured into aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (50 mL). The combined organic layers were washed with saturated aqueous sodium chloride (100 mL), dried over sodium sulfate, filtered, and concentrated under vacuum; silica gel chromatography (gradient: 0% to 7% ethyl acetate in petroleum ether) afforded C31, which was combined with the product of a similar reaction carried out using 3-bromo-2,5,6-trifluorobenzaldehyde (500 mg, 2.09 mmol) to give C31 as a colorless oil. Combined yield: 2.40 g, 9.41 mmol, 84%. 1 H NMR (400 MHz, chloroform-d) δ 7.34 (ddd, J = 8.6, 8.5, 6.4 Hz, 1H), 5.32 - 5.21 (m, 1H), 2.27 (br d, J = 8.3 Hz, 1H), 1.64 (d, J = 6.8 Hz, 3H).
[0349] Step 2. Synthesis of 1-(3-bromo-2,5,6-trifluorophenyl)ethyl methanesulfonate (C32). A solution of methanesulfonyl chloride (0.824 mL, 10.6 mmol) in dichloromethane (12 mL) was added dropwise to an ice-cold solution of C31 (1.90 g, 7.45 mmol) and triethylamine (2.07 mL, 14.9 mmol) in dichloromethane (25 mL). After the reaction mixture was stirred at 0° C. for 30 min, it was partitioned between dichloromethane (50 mL) and water (100 mL). The organic layer was dried over sodium sulfate, filtered, concentrated in vacuo, and purified using chromatography on silica gel (gradient: 0% to 16% ethyl acetate in petroleum ether) to give C32 as a colorless oil. Yield: 2.40 g, 7.20 mmol, 97%. 1 H NMR (400 MHz, chloroform-d) δ 7.44 (ddd, J = 8.9, 8.1, 6.3 Hz, 1H), 6.08 (q, J = 6.8 Hz, 1H), 2.98 (s, 3H), 1.81 (d, J = 6.8 Hz, 3H).
[0350] Step 3. Synthesis of 1-bromo-3-ethyl-2,4,5-trifluorobenzene (C33). To an ice-cold solution of C32 (2.40 g, 7.20 mmol) in tetrahydrofuran (24 mL) was added a solution of lithium triethylborohydride (1 M; 14.4 mL, 14.4 mmol) in a dropwise manner. The reaction mixture was stirred at 0° C. for 30 min, then treated dropwise with water (50 mL) at 0° C. and diluted with petroleum ether (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure at 20° C. Silica gel chromatography (eluent: petroleum ether) afforded C33 as a colorless oil. Yield: 1.31 g, 5.48 mmol, 76%. 1 H NMR (400 MHz, chloroform-d) δ 7.24 (ddd, J = 9, 8, 6.5 Hz, 1H), 2.75 (qt, J = 7.6, 1.4 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H).
[0351] Step 4. Synthesis of 2-(3-ethyl-2,4,5-trifluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (P18). A mixture of C33 (400 mg, 1.67 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (850 mg, 3.35 mmol), potassium acetate (328 mg, 3.34 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (122 mg, 0.167 mmol) in 1,4-dioxane (8.4 mL) was degassed with nitrogen for 2 min and then heated at 95° C. for 16 h. Concentration in vacuo gave a residue that was purified using chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to give P18 as a yellow oil. Yield: 330 mg, 1.15 mmol, 69%. 1 H NMR (400 MHz, chloroform-d) δ 7.34 (ddd, J = 9.7, 9.7, 5.2 Hz, 1H), 2.70 (qt, J = 7.5, 1.6 Hz, 2H), 1.35 (s, 12H), 1.20 (t, J = 7.6 Hz, 3H).
[0352] Preparation example P19 3-Chloro-1,5-difluoro-2-iodo-4-methoxybenzene (P19)
[0353] [ka] Step 1. Synthesis of 1-chloro-3,5-difluoro-4-iodo-2-methoxybenzene (C34). A solution of n-butyllithium (2.5 M; 2.67 mL, 6.68 mmol) was added dropwise to a −65° C. solution of 1-chloro-3,5-difluoro-2-methoxybenzene (1.09 g, 6.10 mmol) in tetrahydrofuran (33 mL). After stirring the reaction mixture at −65° C. for 1 h, iodine (1.56 g, 6.15 mmol) was added and the reaction mixture was warmed to room temperature and stirred at 20° C. for 2 h. Aqueous ammonium chloride solution (10 mL) was added and the resulting mixture was extracted with petroleum ether (3×10 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL), dried over sodium sulfate, filtered, and concentrated under vacuum to give C34 as a brown oil. Yield: 1.68 g, 5.52 mmol, 90%. 1 H NMR (400 MHz, chloroform-d) δ 6.99 (dd, J = 7.3, 2.3 Hz, 1H), 3.92 (d, J = 1.0 Hz, 3H).
[0354] Step 2. Synthesis of 3-chloro-1,5-difluoro-2-iodo-4-methoxybenzene (P19). To a -65°C solution of C34 (1.68g, 5.52mmol) in tetrahydrofuran (30mL) was added a solution of lithium diisopropylamide (2M; 3.59mL, 7.18mmol) and the reaction mixture was stirred at 20°C for 2 hours. After the reaction was quenched by the addition of aqueous ammonium chloride (5mL), the resulting mixture was extracted with petroleum ether (3x3mL). The combined organic layers were washed with saturated aqueous sodium chloride (6mL), dried over sodium sulfate, filtered and concentrated under vacuum to give P19 as a yellow oil. Yield: 1.23g, 4.04mmol, 73%. 1 H NMR (400 MHz, chloroform-d) δ 6.91 (dd, J = 10.4, 7.6 Hz, 1H), 3.92 (d, J = 1.0 Hz, 3H).
[0355] Preparation example P20 3-Fluoro-6-iodo-2-methoxybenzonitrile (P20)
[0356] [ka] Step 1. Synthesis of 3-fluoro-6-iodo-2-methoxybenzoic acid (C35). Palladium(II) acetate (66.0 mg, 0.294 mmol) was added to a mixture of 3-fluoro-2-methoxybenzoic acid (1.00 g, 5.88 mmol), (diacetoxyiodo)benzene (1.89 g, 5.87 mmol), and iodine (1.49 g, 5.87 mmol) in N,N-dimethylformamide (30 mL), whereupon the reaction mixture was stirred at 120° C. for 16 h. It was then diluted with aqueous sodium sulfate (40 mL), and the resulting mixture was adjusted to a pH of approximately 4. After extraction with ethyl acetate (3×25 mL), the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (gradient: 0% to 50% ethyl acetate in petroleum ether) afforded C35 as a colorless gum (1.20 g); this material was 1 H NMR analysis showed it contained impurities. A portion of this lot was used in the next step. 1 H NMR (400 MHz, chloroform-d), product peak only: δ 7.49 (dd, J = 8.7, 4.3 Hz, 1H), 6.92 (dd, J = 11.2, 8.7 Hz, 1H), 3.99 (d, J = 2.0Hz, 3H).
[0357] Step 2. Synthesis of 3-fluoro-6-iodo-2-methoxybenzamide (C36). A mixture of C35 (from the previous step; 200 mg, <0.676 mmol), 1H-benzotriazol-1-ol (274 mg, 2.03 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (298 mg, 1.55 mmol) in tetrahydrofuran (3.5 mL) was stirred at 15° C. for 1 h, whereupon 4-methylmorpholine (226 mg, 2.23 mmol) and aqueous ammonium hydroxide (1.5 mL) were added; stirring was continued at 15° C. for 16 h. The reaction mixture was then diluted with water (4 mL) and extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with saturated aqueous sodium chloride (5 mL), dried over sodium sulfate, filtered, concentrated in vacuo, and purified by chromatography on silica gel (gradient: 0% to 20% ethyl acetate in petroleum ether) to give C36 as a white solid. Yield: 86 mg, 0.29 mmol, 30% for two steps. 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (br s, 1H), 7.63 (br s, 1H), 7.55 (dd, J = 8.7, 4.5 Hz, 1H), 7.10 (dd, J = 11.5, 8.7 Hz, 1H), 3.83 (d, J = 1.3 Hz, 3H).
[0358] Step 3. Synthesis of 3-fluoro-6-iodo-2-methoxybenzonitrile (P20). Trifluoroacetic anhydride (306 mg, 1.46 mmol) was added to a 15° C. mixture of C36 (86.0 mg, 0.29 mmol) and pyridine (0.236 mL, 2.92 mmol) in dichloromethane (2.0 mL). After the reaction mixture was stirred at 15° C. for 16 h, it was concentrated under reduced pressure, diluted with water (5 mL), and extracted with ethyl acetate (3×2 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (3 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (gradient: 0% to 20% ethyl acetate in petroleum ether) afforded P20 as a colorless gum. Yield: 79 mg, 0.285 mmol, 98%. 1 H NMR (400 MHz, DMSO-d6) δ 7.70 (dd, J = 8.7, 4.4 Hz, 1H), 7.45 (dd, J = 12.1, 8.7 Hz, 1H), 4.06 (d, J = 2.8 Hz, 3H).
[0359] Example 1 3-(5,7-difluoro-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (1)
[0360] [ka] Step 1. Synthesis of 6-bromo-5,7-difluoro-3,4-dihydro-2H-1-benzopyran (C37). N-Bromosuccinimide (819 mg, 4.60 mmol) was added to a 0° C. mixture of 5,7-difluoro-3,4-dihydro-2H-1-benzopyran (783 mg, 4.60 mmol) in acetonitrile (20 mL). After the reaction mixture was stirred at 25° C. for 16 h, it was diluted with water and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum; purification was performed using silica gel chromatography (eluent: petroleum ether) to give C37 as a white solid. Yield: 855 mg, 3.43 mmol, 75%. 1 H NMR (400 MHz, chloroform-d) δ 6.46 (dd, J = 9.8, 2.1 Hz, 1H), 4.20 - 4.15 (m, 2H), 2.75 - 2.69 (m, 2H), 2.02 - 1.94 (m, 2H).
[0361] Step 2. Synthesis of (5,7-difluoro-3,4-dihydro-2H-1-benzopyran-6-yl)boronic acid (C38). A reaction flask containing C37 (920 mg, 3.69 mmol), potassium acetate (906 mg, 9.23 mmol), sodium tert-butoxide (4 mg, 40 μmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2; 29 mg, 37 μmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos; 53 mg, 0.11 mmol) was purged with nitrogen. Methanol (20 mL), ethane-1,2-diol (2 mL) and tetrahydroxydiborane (364 mg, 4.06 mmol) were added and nitrogen was bubbled through the reaction mixture for 10 min whereupon it was heated to 50° C. (internal temperature) for 6 h. The reaction mixture was then concentrated under vacuum, diluted with water (20 mL) and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (30 mL), dried over sodium sulfate, filtered and concentrated under vacuum. After chromatography on silica gel (gradient: 0% to 50% ethyl acetate in petroleum ether), C38 was obtained as a yellow solid. 1 This material contained an impurity by H NMR analysis. Yield: 243 mg, <1.14 mmol, <31%. 1 H NMR (400 MHz, DMSO-d6), characteristic peak: δ 6.40 (dd, J = 9.9, 1.5 Hz, 1H), 4.18 - 4.10 (m, 2H), 2.62 - 2.56 (m, 2H), 1.94 - 1.85 (m, 2H).
[0362] Step 3. Synthesis of methyl 3-(5,7-difluoro-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylate (C39). To a solution of methyl 3-chloro-6-fluoro-1-benzothiophene-2-carboxylate (114 mg, 0.466 mmol) in 1,4-dioxane (1.5 mL) was added C38 (100 mg, 0.47 mmol), tripotassium phosphate (198 mg, 0.933 mmol), bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) [Pd(amphos)2Cl2; 33 mg, 47 μmol], and water (0.25 mL). After bubbling nitrogen through the reaction mixture for 2 min, it was stirred at 110° C. for 16 h, whereupon LCMS analysis showed the presence of C39: LCMS m / z 379.3 [M+H]. + The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (2×15 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and chromatographed on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) to afford C39 as a white solid. Yield: 10 mg, 26 μmol, 6%. 1 H NMR (400 MHz, methanol-d4) δ 7.75 (dd, J = 8.8, 2.3 Hz, 1H), 7.48 (br dd, J = 9.2, 5.2 Hz, 1H), 7.23 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 6.54 (dd, J = 10.8, 1.9 Hz, 1H), 4.27 (dd, J = 5.9, 4.5 Hz, 2H), 3.80 (s, 3H), 2.75 (br dd, J = 6.5, 6.5 Hz, 2H), 2.09 - 2.00 (m, 2H).
[0363] Step 4. Synthesis of 3-(5,7-difluoro-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (1). A solution of lithium hydroxide (3.8 mg, 0.16 mmol) in water (1.0 mL) was added to a solution of C39 (10 mg, 26 μmol) in a mixture of methanol (1.0 mL) and tetrahydrofuran (1.0 mL). The reaction mixture was stirred at 60° C. for 16 h whereupon it was diluted with water (20 mL), concentrated under vacuum to remove methanol and tetrahydrofuran, and washed with dichloromethane (3×25 mL). The aqueous layer was adjusted to a pH of 4 by the addition of 1 M hydrochloric acid, then extracted with ethyl acetate (3×15 mL). The combined ethyl acetate layers were dried over sodium sulfate, filtered, and concentrated under vacuum to give 3-(5,7-difluoro-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (1) as a yellow solid. Yield: 2.6 mg, 7.1 μmol, 27%. LCMS m / z 365.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.72 (dd, J = 8.8, 2.4 Hz, 1H), 7.44 (br dd, J = 9.0, 5.1 Hz, 1H), 7.20 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 6.51 (dd, J = 10.7, 1.9 Hz, 1H), 4.28 - 4.22 (m, 2H), 2.75 (br dd, J = 6.5, 6.5 Hz, 2H), 2.08 - 2.00 (m, 2H).
[0364] Example 2 6-Fluoro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (2)
[0365] [ka] Step 1. Synthesis of 1,3,5-trifluoro-2-iodo-4-methoxybenzene (C40). A solution of n-butyllithium in hexane (2.5 M; 9.50 mL, 23.8 mmol) was added dropwise to a −70° C. to −75° C. solution of 1,3,5-trifluoro-2-methoxybenzene (3.5 g, 22 mmol) in tetrahydrofuran (40 mL). The reaction mixture was stirred at −75° C. for 75 min, whereupon it was treated dropwise with a solution of iodine (9.97 g, 39.3 mmol) in tetrahydrofuran (22 mL). The reaction mixture was stirred for an additional 20 min whereupon it was warmed to room temperature, diluted with diethyl ether, and washed with saturated aqueous sodium thiosulfate. The aqueous layer was extracted once with diethyl ether, and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum at a bath temperature of 35° C.; yielding C40 as a yellow oil. Yield: 6.15 g, 21.4 mmol, 97%. GCMS m / z 288.1 [M + ]. 1 H NMR (400 MHz, methanol-d4) δ 7.03 (ddd, J = 10.7, 8.0, 2.4 Hz, 1H), 3.92 (br s, 3H).
[0366] Step 2. Synthesis of methyl 6-fluoro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (C41). A suspension of C40 (100 mg, 0.347 mmol), P2 (117 mg, 0.348 mmol), potassium fluoride (40.3 mg, 0.694 mmol), and tris(dibenzylideneacetone)dipalladium(0) [Pd2(dba)3; 15.9 mg, 17.4 μmol] in a mixture of 1,4-dioxane (3 mL) and water (0.3 mL) was degassed with nitrogen for 1 min, whereupon tri-tert-butylphosphine (7.02 mg, 34.7 μmol) was added. The reaction mixture was stirred at 75° C. for 16 h, then concentrated in vacuo and purified by chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to give C41 as a colorless gum. Yield: 40.0 mg, 0.108 mmol, 31%. 1H NMR (400 MHz, chloroform-d) δ 7.58 (dd, J = 8.5, 2.4 Hz, 1H), 7.44 (br dd, J = 9.1, 5.1 Hz, 1H), 7.17 (ddd, J = 8.9, 8.8, 2.3 Hz, 1H), 6.86 (ddd, J = 11.0, 9.1, 2.3 Hz, 1H), 4.00 (br s, 3H), 3.84 (s, 3H).
[0367] Step 3. Synthesis of 6-fluoro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (2). Lithium hydroxide (25.9 mg, 1.08 mmol) was added to a solution of C41 (40.0 mg, 0.108 mmol) in a mixture of tetrahydrofuran (2 mL), methanol (1 mL), and water (1 mL). The reaction mixture was stirred at 25° C. for 2 h, whereupon it was acidified to a pH of approximately 3 by the addition of hydrochloric acid. After the resulting mixture was extracted with ethyl acetate (3×3 mL), the combined organic layers were concentrated under vacuum and purified by reverse-phase HPLC (column: Phenomenex Gemini C18, 50×250 mm, 10 μm; mobile phase A: water containing 0.225% formic acid; mobile phase B: acetonitrile; gradient: B 48% to 68%; flow rate: 25 mL / min) to give 6-fluoro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (2) as a white solid. Yield: 10.4 mg, 29.2 μmol, 27%. LCMS m / z 354.9 [MH] - . 1 H NMR (400 MHz, chloroform-d) δ 7.60 (dd, J = 8.4, 2.3 Hz, 1H), 7.45 (br dd, J = 9.0, 5.0 Hz, 1H), 7.18 (ddd, J = 8.8, 8.8, 2.4 Hz, 1H), 6.86 (ddd, J = 10.8, 9.0, 2.2 Hz, 1H), 4.00 (s, 3H).
[0368] Example 3 3-(5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (3)
[0369] [ka] Step 1. Synthesis of 5,7-difluoro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1-benzopyran (C42). A solution of n-butyllithium in hexane (2.5 M; 1.63 mL, 4.08 mmol) was added dropwise to a −65° C. solution of P11 (300 mg, 1.63 mmol) in tetrahydrofuran (8 mL). After stirring the reaction mixture at −65° C. for 1 h, 4,4,5,5-tetramethyl-2-(propan-2-yloxy)-1,3,2-dioxaborolane (909 mg, 4.89 mmol) was added and the reaction mixture was warmed to 25° C. and stirred at that temperature for 1 h. Aqueous ammonium chloride (15 mL) was added and the resulting mixture was extracted with ethyl acetate (3×20 mL); the combined organic layers were washed with saturated aqueous sodium chloride (30 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (0% to 10% ethyl acetate in petroleum ether) afforded C42 as a yellow oil. Yield: 350 mg, 1.13 mmol, 69%. 1 H NMR (400 MHz, chloroform-d) δ 6.31 (dd, J = 10.6, 1.7 Hz, 1H), 4.18 - 4.10 (m, 1H), 2.82 - 2.71 (m, 1H), 2.65 - 2.51 (m, 1H), 2.03 - 1.95 (m, 1H), 1.70 - 1.58 (m, 1H), 1.38 (d, J = 6.4 Hz, 3H), 1.36 (s, 12H).
[0370] Step 2. Synthesis of methyl 3-(5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylate (C43). A suspension of P1 (110 mg, 0.380 mmol), potassium fluoride (72.9 mg, 1.25 mmol), and C42 (165 mg, 0.532 mmol) in a mixture of tetrahydrofuran (2.0 mL) and water (0.2 mL) was degassed with nitrogen for 2 min, whereupon tris(dibenzylideneacetone)dipalladium(0) (6.97 mg, 7.61 μmol) and tri-tert-butylphosphine (80 mg, 0.4 mmol) were added. The reaction mixture was stirred at 60° C. for 18 h before it was filtered. The filtrate was concentrated under vacuum and purified by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to give C43 as a colorless gum. 1 Examination of the H NMR spectrum suggested that this material existed as a mixture of rotamers. Yield: 110 mg, 0.280 mmol, 74%. 1 H NMR (400 MHz, chloroform-d) δ 7.55 (dd, J = 8.5, 2.3 Hz, 1H), 7.51 - 7.45 (m, 1H), 7.17 - 7.10 (m, 1H), 6.55 - 6.49 (m, 1H), 4.25 - 4.17 (m, 1H), [3.84 (s) and 3.83 (s), total 3H], 2.90 - 2.78 (m, 1H), 2.77 - 2.64 (m, 1H), 2.11 - 2.01 (m, 1H), 1.80 - 1.65 (m, 1H), 1.44 (d, J = 6.3 Hz, 3H).
[0371] Step 3. Synthesis of 3-(5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (3). To a solution of C43 (110 mg, 0.280 mmol) in a mixture of tetrahydrofuran (1 mL), methanol (1 mL), and water (0.2 mL) was added lithium hydroxide monohydrate (82.3 mg, 1.96 mmol). After the reaction mixture was stirred at 25° C. for 16 h, it was adjusted to a pH of approximately 4 and extracted with ethyl acetate (3×4 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (8 mL), dried over sodium sulfate, filtered, concentrated under vacuum, and purified by preparative thin layer chromatography (eluent: 1:1 petroleum ether / ethyl acetate) to give 3-(5,7-difluoro-2-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (3) as a white solid. Yield: 100 mg, 0.26 mmol, 93%. LCMS m / z 379.0 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.60 (dd, J = 8.9, 2.4 Hz, 1H), 7.36 - 7.29 (m, 1H), 7.10 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 6.45 (dd, J = 10.7, 1.8 Hz, 1H), 4.25 - 4.13 (m, 1H), 2.90 - 2.76 (m, 1H), 2.76 - 2.61 (m, 1H), 2.13 - 2.03 (m, 1H), 1.74 - 1.61 (m, 1H), 1.41 (br d, J = 6.3 Hz, 3H).
[0372] Example 4 6,7-Difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (4)
[0373] [ka] Step 1. Synthesis of ethyl 6,7-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (C44). To a suspension of phenylboronic acid (190 mg, 1.56 mmol) and P3 (334 mg, 1.04 mmol) in a mixture of 1,4-dioxane (8 mL) and water (2 mL) was added cesium carbonate (1.02 g, 3.13 mmol) and tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.104 mmol). The reaction was stirred at 90° C. for 16 h whereupon it was concentrated in vacuo and purified by silica gel chromatography (eluent: petroleum ether) to give C44 as a white solid. Yield: 67.7 mg, 0.213 mmol, 20%. 1 H NMR (400 MHz, chloroform-d), characteristic peak: δ 7.29 - 7.24 (m, 1H, estimated; partially obscured by solvent peak), 7.20 (ddd, J = 9.8, 9.2, 6.8 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H).
[0374] Step 2. Synthesis of 6,7-difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (4). To a suspension of C44 (67.7 mg, 0.213 mmol) in a mixture of methanol (1 mL) and tetrahydrofuran (1 mL) was added a solution of sodium hydroxide (42.5 mg, 1.06 mmol) in water (0.5 mL). After the reaction mixture was stirred at room temperature (26° C.) for 16 h, it was concentrated under vacuum and the residue was acidified to a pH of approximately 6 by the addition of 1 M hydrochloric acid. Filtration of the resulting suspension gave a solid, which was purified using reverse-phase HPLC (column: Phenomenex Gemini NX-C18, 30×75 mm, 3 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 0% to 32%; flow rate: 25 mL / min) to give 6,7-difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (4) as a white solid. Yield: 15.3mg, 52.7μmol, 25%. LCMS m / z 291.0 [M+H] + .1 H NMR (400 MHz, DMSO-d6) δ 7.57 - 7.43 (m, 4H), 7.43 - 7.38 (m, 2H), 7.24 (br dd, J = 9, 4 Hz, 1H).
[0375] Example 5 Ammonium 4,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (5)
[0376] [ka] Step 1. Synthesis of ethyl 4,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (C45). Cesium carbonate (1.22 g, 3.74 mmol) and tetrakis(triphenylphosphine)palladium(0) (144 mg, 0.125 mmol) were added to a suspension of P4 (400 mg, 1.25 mmol) and phenylboronic acid (228 mg, 1.87 mmol) in a mixture of 1,4-dioxane (8.0 mL) and water (2.0 mL). After stirring the reaction mixture at 90° C. for 16 h, LCMS analysis showed the presence of C45: LCMS m / z 318.9 [M+H]. + The solvent was removed in vacuo and the residue was purified by silica gel chromatography (eluent: petroleum ether) to give C45 as a white solid. Yield: 282 mg, 0.886 mmol, 71%.
[0377] Step 2. Synthesis of ammonium 4,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (5). To a suspension of C45 (282 mg, 0.886 mmol) in a mixture of methanol (4 mL) and tetrahydrofuran (4 mL), a solution of sodium hydroxide (177 mg, 4.42 mmol) in water (2 mL) was added, and the reaction mixture was stirred at room temperature (26 °C) for 16 h. It was then concentrated under vacuum, and the residue was acidified to a pH of approximately 6 by the addition of 1 M hydrochloric acid. A solid was obtained by filtration, which was purified by reverse-phase HPLC (column: Phenomenex Gemini NX-C18, 30 × 75 mm, 3 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 0% to 31%; flow rate: 25 mL / min) to give ammonium 4,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (5) as a white solid. Yield: 91.4 mg, 0.315 mmol, 36%. LCMS m / z 288.9 [MH] - . 1 H NMR (400 MHz, DMSO-d6) δ 7.67 (dd, J = 8.7, 2.3 Hz, 1H), 7.35 - 7.23 (m, 5H), 7.05 (ddd, J = 11.9, 9.6, 2.3 Hz, 1H), 6.74 (br s, approx. 4H).
[0378] Example 6 6-Chloro-5-fluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (6)
[0379] [ka] Step 1. Synthesis of ethyl 6-chloro-5-fluoro-3-phenyl-1-benzothiophene-2-carboxylate (C46). A suspension of P5 (150 mg, 0.444 mmol), phenylboronic acid (54.2 mg, 0.444 mmol), and cesium carbonate (434 mg, 1.33 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was degassed with nitrogen for 1 min, whereupon tetrakis(triphenylphosphine)palladium(0) (103 mg, 89.1 μmol) was added. The reaction mixture was stirred at 80° C. for 16 h before it was filtered; the filtrate was concentrated in vacuo and purified by chromatography on silica gel (gradient: 0% to 1% ethyl acetate in petroleum ether) to give C46 as a colorless gum. Yield: 110 mg, 0.329 mmol, 74%. 1 H NMR (400 MHz, chloroform-d) δ 7.91 (d, J = 6.4 Hz, 1H), 7.53 - 7.44 (m, 3H), 7.38 - 7.33 (m, 2H), 7.27 (d, J = 9.4 Hz, 1H, estimated; partially obscured by solvent peak), 4.23 (q, J = 7.1 Hz, 2H), 1.19 (t, J = 7.1 Hz, 3H).
[0380] Step 2. Synthesis of 6-chloro-5-fluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (6). A suspension of C46 (110 mg, 0.329 mmol) in a mixture of methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) was treated with lithium hydroxide monohydrate (138 mg, 3.29 mmol). After stirring the reaction mixture at 25° C. for 16 h, the pH was adjusted to approximately 3 using hydrochloric acid (1 M; 2 mL), whereupon the mixture was extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum. Reverse phase HPLC (column: Welch Xtimate C18, 30×100 mm, 3 μm; mobile phase A: water containing 0.225% formic acid; mobile phase B: acetonitrile; gradient: B 45% to 85%; flow rate: 30 mL / min) afforded 6-chloro-5-fluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (6) as a white solid. Yield: 31.6 mg, 0.103 mmol, 31%. LCMS m / z 261.1 (chlorine isotope pattern observed) [M-CO2H] - . 1 H NMR (400 MHz, methanol-d4) δ 8.14 (d, J = 6.6 Hz, 1H), 7.54 - 7.44 (m, 3H), 7.40 - 7.35 (m, 2H), 7.22 (d, J = 9.8 Hz, 1H).
[0381] Example 7 3-(4,5-dichloro-2-fluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (7)
[0382] [ka] Step 1. Synthesis of methyl 3-(4,5-dichloro-2-fluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylate (C47). A reaction vessel containing a suspension of P1 (175 mg, 0.605 mmol), 2-(4,5-dichloro-2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (211 mg, 0.725 mmol), potassium fluoride (105 mg, 1.81 mmol), a solution of tri-tert-butylphosphine in toluene (1 M; 60.5 μL, 60.5 μmol), and tris(dibenzylideneacetone)dipalladium(0) (55.4 mg, 60.5 μmol) in a mixture of tetrahydrofuran (5 mL) and water (1 mL) was evacuated and backfilled with nitrogen. This evacuation cycle was repeated twice whereupon the reaction mixture was heated at 60° C. overnight. It was then filtered; the filtrate was concentrated in vacuo and chromatographed on silica gel (gradient: 0% to 30% ethyl acetate in heptane) to give C47 as a yellow oil. Yield: 214 mg, 0.573 mmol, 95%. 1 H NMR (400 MHz, methanol-d4) δ 7.77 (dd, J = 8.8, 2.4 Hz, 1H), 7.61 - 7.53 (m, 2H), 7.50 (br dd, J = 9.0, 5.1 Hz, 1H), 7.25 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 3.80 (s, 3H).
[0383] Step 2. Synthesis of 3-(4,5-dichloro-2-fluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (7). A mixture of C47 (214 mg, 0.573 mmol), an aqueous solution of lithium hydroxide (1.0 M; 1.15 mL, 1.15 mmol), and tetrahydrofuran (2.9 mL) was heated at 80° C. overnight. The reaction mixture was then partitioned between ethyl acetate and 1 M hydrochloric acid; the organic layer was washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was triturated with heptane containing a small amount of diethyl ether before being purified by silica gel chromatography (gradient: 0% to 20% methanol in dichloromethane). The resulting material was triturated with heptane to give 3-(4,5-dichloro-2-fluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (7) as a white solid. Yield: 94.8 mg, 0.264 mmol, 46%. LCMS m / z 358.8 (dichloro isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.77 (dd, J = 8.8, 2.4 Hz, 1H), 7.58 (d, J = 6.8 Hz, 1H), 7.54 (d, J = 8.9 Hz, 1H), 7.49 (br dd, J = 9.0, 5.0 Hz, 1H), 7.25 (ddd, J = 9.0, 9.0, 2.4Hz, 1H).
[0384] Example 8 3-(3,5-difluoro-2-methylpyridin-4-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (8)
[0385] [ka] Step 1. Synthesis of 3,5-difluoro-4-iodo-2-methylpyridine (C48). A solution of lithium diisopropylamide (2M; 2.28 mL, 4.56 mmol) was added to a −78° C. solution of 3,5-difluoro-4-iodopyridine (1.00 g, 4.15 mmol) in tetrahydrofuran (15 mL). The reaction mixture was stirred at −78° C. for 1 h, followed by a solution of iodomethane (648 mg, 4.56 mmol) in tetrahydrofuran (20 mL) was added. Stirring was continued at −78° C. for 1 h, followed by 25° C. for 16 h, whereupon the reaction mixture was poured into aqueous ammonium chloride solution (15 mL) and extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (15 mL), dried over sodium sulfate, filtered, concentrated under vacuum, and purified by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to give C48 as a white solid (140 mg). 1 By 1 H NMR, this material was mostly starting material but contained C48 (approximately 4:1 ratio starting material / C48). 1 H NMR (400 MHz, chloroform-d), product peak only: δ 8.13 (s, 1H), 2.29 (dd, J = 1.7, 1.7 Hz, 3H).
[0386] Step 2. Synthesis of methyl 3-(3,5-difluoro-2-methylpyridin-4-yl)-6-fluoro-1-benzothiophene-2-carboxylate (C49). To a suspension of C48 (from the previous step; 140 mg), P2 (185 mg, 0.550 mmol), and potassium fluoride (95.7 mg, 1.65 mmol) in a mixture of tetrahydrofuran (10 mL) and water (1.0 mL) was added tris(dibenzylideneacetone)dipalladium(0) (25.1 mg, 27.4 μmol), followed by a solution of tri-tert-butylphosphine in toluene (1 M; 54.9 μL, 54.9 μmol). The reaction mixture was heated at 60° C. for 16 h, whereupon it was poured into water (20 mL) and extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (30 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Preparative thin layer chromatography (eluent: 15:1 petroleum ether / ethyl acetate) afforded C49 as a yellow solid. Yield: 40.0 mg, 0.119 mmol, 3% for two steps. LCMS m / z 337.9 [M+H] + .
[0387] Step 3. Synthesis of 3-(3,5-difluoro-2-methylpyridin-4-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (8). Lithium hydroxide (28.4 mg, 1.19 mmol) was added to a suspension of C49 (40.0 mg, 0.119 mmol) in a mixture of tetrahydrofuran (3.0 mL), methanol (1.5 mL), and water (1.5 mL). The reaction mixture was stirred at 25° C. for 16 h whereupon it was concentrated under reduced pressure, diluted with water (30 mL), and acidified to a pH of approximately 5 by the addition of 1 M hydrochloric acid. The resulting mixture was extracted with ethyl acetate (2×15 mL) and the combined organic layers were concentrated under vacuum and purified by reverse phase HPLC (column: YMC-Actus Triart C18, 30×150 mm, 5 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: 20% to 40% B; flow rate: 35 mL / min) to give 3-(3,5-difluoro-2-methylpyridin-4-yl)-6-fluoro-1-benzothiophene-2-carboxylic acid (8) as a white solid. Yield: 2.78 mg, 8.60 μmol, 7%. LCMS m / z 324.0 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.34 (s, 1H), 7.66 (dd, J = 8.9, 2.4 Hz, 1H), 7.42 (dd, J = 8.9, 5.2 Hz, 1H), 7.12 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 2.34 (dd, J = 1.6, 1.6 Hz, 3H).
[0388] Example 9 6-Fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (9)
[0389] [ka] Step 1. Synthesis of 1,2-dibromo-3,4,6-trifluoro-5-methoxybenzene (C50). 1,2-Dibromo-3,4,5,6-tetrafluorobenzene (25.0 g, 81.2 mmol) was added to a mixture of sodium methoxide in methanol (25% by weight; 37.1 mL, 162 mmol) and methanol (125 mL). After the reaction was stirred at room temperature overnight, it was diluted with water and extracted three times with dichloromethane. The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum to give C50 as a pale yellow oil. This material was assumed to show quantitative conversion and was carried on directly to the next step. 1 H NMR (400 MHz, methanol-d4) δ 4.06 (t, J = 1.3 Hz, 3H).
[0390] Step 2. Synthesis of 1-bromo-2,4,5-trifluoro-3-methoxybenzene (C51). A solution of n-butyllithium in hexane (2.5 M; 32.5 mL, 81.2 mmol) was added to a −78° C. solution of C50 (26 g, 81 mmol) in diethyl ether (813 mL) and the reaction mixture was stirred at −78° C. for 5 h. It was then diluted with water and extracted three times with diethyl ether; the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, and filtered through a prepacked hydrogenator filter cartridge containing silica gel. The filtrate was concentrated under vacuum using a 30° C. bath to give C51 as a clear yellow oil (20 g, assumed quantitative). This material was carried on to the next step. 1 H NMR (400 MHz, methanol-d4) δ 7.36 (ddd, J = 9.7, 7.8, 6.1 Hz, 1H), 4.04 (t, J = 1.2 Hz, 3H).
[0391] Step 3. Synthesis of (2,4,5-trifluoro-3-methoxyphenyl)boronic acid (C52). A reaction vessel containing C51 (from the previous step; 20 g, ≦81 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (52.7 g, 208 mmol), potassium acetate (16.3 g, 166 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (6.07 g, 8.30 mmol) in 1,4-dioxane (830 mL) was evacuated and charged with nitrogen. This evacuation cycle was repeated twice whereupon the reaction mixture was heated at 100° C. overnight. It was then filtered through a cartridge packed with diatomaceous earth, and the cartridge was rinsed with ethyl acetate. The combined filtrate was concentrated to near dryness under vacuum and then treated with 1 M hydrochloric acid. The resulting mixture was stirred for approximately 10 minutes and extracted three times with dichloromethane. The combined extracts were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give C52 as a black oil (17.1 g). This material was used as is in the next step. LCMS m / z 205.1 [MH] - .
[0392] Step 4. Synthesis of methyl 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (C53). A reaction vessel containing a suspension of P6 (20.0 g, 59.5 mmol), C52 (from step 3; 17.1 g, ≦81 mmol), methanesulfonyl[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) [P(t-Bu)3Pd G3; 3.40 g, 5.94 mmol], aqueous cesium fluoride (1 M; 89.3 mL, 89.3 mmol), and tri-tert-butylphosphonium tetrafluoroborate (17.3 g, 59.6 mmol) in tetrahydrofuran was evacuated and charged with nitrogen. This evacuation cycle was repeated twice whereupon the reaction mixture was heated at 70° C. overnight. It was then poured into ethyl acetate and washed with water; the aqueous layer was extracted twice with ethyl acetate, and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, and filtered through a cartridge packed with diatomaceous earth. The filtrate was concentrated in vacuo and purified twice by silica gel chromatography (gradient: 0% to 10% ethyl acetate in heptane) to give C53 as a light brown oil. Yield: 17.3 g, 46.7 mmol, 78%. LCMS m / z 339.1 [M-OCH3] + . 1 H NMR (400 MHz, chloroform-d) δ 7.58 (dd, J = 8.4, 2.3 Hz, 1H), 7.46 (br dd, J = 8.9, 5.1 Hz, 1H), 7.16 (ddd, J = 8.9, 8.9, 2.3 Hz, 1H), 6.86 (ddd, J = 9.9, 8.1, 6.0 Hz, 1H), 4.09 (t, J = 1.2 Hz, 3H), 3.84 (s, 3H).
[0393] Step 5. Synthesis of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (9). An aqueous solution of sodium hydroxide (50% by weight; 12.9 mL, 244 mmol) was added to a solution of C53 (43.4 g, 117 mmol) in a mixture of ethanol (360 mL) and 2-methyltetrahydrofuran (239 mL), whereupon the reaction mixture was heated at 55° C. for 1 h. It was then cooled to room temperature, diluted with ethyl acetate, and added to a 1:1 mixture of 1 M hydrochloric acid and saturated aqueous sodium chloride. After the aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum. The resulting material, containing a small amount of residual solvent from the concentration, was triturated with heptane and then purified by supercritical fluid chromatography {Column: Chiral Technologies Chiralpak AD-H, 50.0×250 mm, 5 μm; Mobile phase: 85:15 carbon dioxide / [methanol containing 0.2% (7 M ammonia in methanol)]; Flow rate: 225 mL / min; Back pressure: 175 bar} to give the ammonium salt of 9 as a white solid. Yield: 32.7 g, 87.6 mmol, 75%. Retention time 2.22 min [Analytical conditions. Column: Chiral Technologies Chiralpak AD-H, 4.6 x 250 mm, 5 μm; mobile phase A: carbon dioxide; mobile phase B: methanol containing 0.2% (7 M ammonia in methanol); gradient: 5% B over 1.00 min, then 5% to 100% B over 7.50 min; flow rate: 3.0 mL / min; back pressure: 120 bar].
[0394] This material was combined with the product of a similar reaction carried out using C53 (22.4 g, 60.5 mmol), dissolved in ethyl acetate, and added to a 1:1 mixture of 1 M hydrochloric acid and saturated aqueous sodium chloride. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue, which contained a small amount of residual ethyl acetate from the concentration, was triturated with heptane to give 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (9) as a white solid. Combined yield: 44.67 g, 125.4 mmol, 71%. LCMS m / z 311.0 [M-CO2H] - . 1 H NMR (400 MHz, DMSO-d6) δ 13.59 (br s, 1H), 8.07 (dd, J = 9.2, 2.4 Hz, 1H), 7.56 (br dd, J = 9.0, 5.1 Hz, 1H), 7.44 - 7.32 (m, 2H), 4.02 (br s, 3H).
[0395] Preparation of Crystalline Form 1, Anhydrous 6-Fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic Acid (Example 9)
[0396] [ka] Step 1. Synthesis of (3-bromo-2,5,6-trifluorophenyl)boronic acid (C54). A solution of 1-bromo-2,4,5-trifluorobenzene (29.5 kg, 140 mol) in methyl tert-butyl ether (65.5 kg) was cooled to −60° C. to −55° C. whereupon it was treated dropwise with lithium diisopropylamide (2.0 M solution in a mixture of tetrahydrofuran and hexane; 57.1 kg, 147 mol) and the reaction mixture was maintained at −60° C. to −55° C. After stirring for 2 hours at −55° C., trimethyl borate (18.9 kg, 182 mol) was added dropwise at −60° C. to −55° C. and the reaction mixture was stirred for 2 hours at −60° C. to −55° C. Then it was quenched with hydrochloric acid (1 M; 700 kg, 707 mol) at 0° C. and extracted with methyl tert-butyl ether (2×218 kg). The organic layers were combined and concentrated under vacuum below 30° C. to 177 kg whereupon heptane (383 kg) was added. At this point a second round of concentration in the same manner to approximately 380 kg was continued with the addition of heptane (383 kg); the resulting mixture was stirred at 20° C. for 1 hour. The solids were collected by filtration, followed by washing the filter cake with heptane (30-60 kg) to give C54 as a solid. Yield: 24 kg, 94 mol, 67%. Data from a similar reaction carried out using 1-bromo-2,4,5-trifluorobenzene: 1 H NMR (400 MHz, chloroform-d) δ 7.53 (ddd, J = 8.7, 8.7, 6.8 Hz, 1H).
[0397] Step 2. Synthesis of 3-bromo-2,5,6-trifluorophenol (C55). An aqueous solution of hydrogen peroxide (30%, 15.2 kg, 134 mol) was added dropwise to a 30° C. to 40° C. solution of C54 (22.8 kg, 89.5 mol) in dichloromethane (159 kg). After the reaction mixture was stirred at 35° C. to 40° C. for 16 hours, it was cooled to −10° C. and treated dropwise with a 10% aqueous solution of sodium bisulfite (98 kg, 392 mmol) at a rate that maintained the temperature of the mixture between −15° C. to −10° C. The resulting mixture was extracted with dichloromethane (2×336 kg); the combined organic layers were concentrated under vacuum at 30° C. to give a solution of C55 in dichloromethane (70 kg, assayed 30.3% C55 by weight). This material was used in the next reaction. Data from a similar reaction carried out using C54: LCMS m / z 224.9 (bromine isotope pattern observed) [MH] + . 1 H NMR (400 MHz, chloroform-d) δ 6.96 (ddd, J = 9.3, 7.7, 6.1 Hz, 1H).
[0398] Step 3. Synthesis of 1-bromo-2,4,5-trifluoro-3-methoxybenzene (C51). A solution of C55 (from the previous step; ≦89.5 mol) in acetone (94.8 kg) was treated with potassium carbonate (38.7 kg, 280 mmol) and cooled to −10° C. to 0° C. whereupon iodomethane (19.9 kg, 140 mol) was added dropwise at −10° C. to 0° C. The reaction mixture was allowed to stir at 25° C. to 30° C. for 16 hours and then filtered. The filter cake was rinsed with heptane (55 kg) and the combined filtrate was exchanged into heptane by repeatedly diluting with heptane followed by removing the solvent under reduced pressure to a final weight of approximately 100 kg. The heptane solution was washed with water (64 kg) and with aqueous sodium sulfate (5%, 64 kg), filtered through silica gel (11 kg) and concentrated under vacuum below 30° C. to give C51 as a solution in heptane (35.2 kg, assayed as 51.4% C51 by weight). Yield: 18 kg, 75 mol, 84% for two steps. Data from a similar reaction carried out using C55: GCMS m / z 240.0 (bromine isotope pattern observed) [M + ]. 1 H NMR (400 MHz, methanol-d4) δ 7.37 (ddd, J = 9.7, 7.9, 6.1 Hz, 1H), 4.04 (t, J = 1.2 Hz, 3H).
[0399] Step 4. Synthesis of (2,4,5-trifluoro-3-methoxyphenyl)boronic acid (C52). A solution of (propan-2-yl)magnesium chloride (2M; 45 L, 90 mol) was added dropwise to a −70° C. to −65° C. solution of C51 (18.1 kg, 75.1 mol) in tetrahydrofuran (161 kg). After stirring the reaction mixture at −70° C. to −65° C. for 2 to 3 hours, trimethyl borate (10.1 kg, 97.2 mol) was added dropwise at a rate that maintained the internal reaction temperature between −70° C. and −65° C. The reaction mixture was stirred at −50° C. to −40° C. for 1 to 2 hours, whereupon it was quenched with hydrochloric acid (1M; 375 kg, 379 mol) at 0° C. to 5° C. The resulting mixture was extracted with methyl tert-butyl ether (161 kg); the combined organic layers were washed successively with water (90 kg) and aqueous sodium sulfate (10%, 90 kg) and concentrated under vacuum. The solvent was exchanged with tetrahydrofuran (180-360 kg) and the resulting mixture was filtered. The filtrate was concentrated under vacuum below 30° C. to a volume of 55 L, then treated with heptane (90 kg) and concentrated in the same manner to 55 L. Heptane (90 kg) was again added and the mixture was stirred at 15° C. to 25° C. for 1-2 h, at which point the solid was collected by filtration and slurried with heptane (36 kg). Isolation of the resulting solid by filtration afforded C52 as a solid. Yield: 10.2 kg, 49.5 mol, 66%. LCMS m / z 205.1 [MH] - . 1 H NMR (400 MHz, chloroform-d) δ 7.36 - 7.27 (br ddd, J = 9, 9, 5.4 Hz, 1H), 5.07 - 5.02 (m, 2H), 4.03 (apparent br t, J = 1 Hz, 3H).
[0400] Step 5. Synthesis of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (9). A mixture of P6 (1.00 g, 2.98 mmol), C52 (735 mg, 3.57 mmol), and potassium fluoride (520 mg, 8.95 mmol) in tetrahydrofuran (11 mL) and water (5 mL) was sparged with nitrogen for 2 min, whereupon tri-tert-butylphosphonium tetrafluoroborate (99%, 34.0 mg, 0.116 mmol) and allylpalladium(II) chloride dimer (10.7 mg, 29.2 μmol) were added. Sparging was continued for 1 min, and then the reaction mixture was placed in a 50° C. heating block with 700 rpm magnetic stirring. After stirring the reaction mixture at 50° C. for 1 h, the organic layer was washed with a solution of sodium chloride in water (23.5 wt %; 3 mL, 14 mmol). It was then treated with a solution of sodium bisulfite (99%, 600 mg, 5.7 mmol) in water (2.4 mL) and stirred at 60° C. for 1 h; the organic layer was washed with a solution of sodium chloride in water (23.5 wt %; 3 mL, 14 mmol) by stirring at 60° C. for 2 min. SiliCycle SiliaMetS®Thiol (Si-Thiol; 300 mg) was added to the organic layer and the resulting mixture was stirred at 60° C. for 1 h whereupon it was cooled to 20° C. and filtered through a pad of diatomaceous earth. The filter cake was washed with tetrahydrofuran (6 mL) and the combined filtrate was concentrated under vacuum. The resulting material was dissolved in tetrahydrofuran (2 mL) and methanol (2 mL) and treated with an aqueous solution of sodium hydroxide (3.0 M; 1.5 mL, 4.5 mmol). The reaction mixture was heated in a 50° C. heating block with magnetic stirring at 700 rpm for 1 h, then cooled to 20° C., acidified by addition of hydrochloric acid (3.0 M, 2.0 mL, 6.0 mmol), extracted with methyl tert-butyl ether (5 mL, then 3 mL); the combined organic layers were concentrated under reduced pressure, treated with propan-2-ol (7 mL), and concentrated again. The resulting oil was dissolved in propan-2-ol (4 mL) and water (4 mL) was added slowly to give a slurry that was stirred at 20° C. and 500 rpm for 17 h. The mixture was cooled in an ice bath and stirred for 10 min before it was filtered.The filter cake was washed with an ice-cold mixture of propan-2-ol (1 mL) and water (1 mL) and dried in vacuum at 50° C. to give 9 as an off-white solid, Form 1. Yield: 0.912 g, 99.3% by mass (determined by quantitative NMR), 2.54 mmol, 85%. 1 H NMR (400 MHz, DMSO-d6) δ 13.58 (br s, 1H), 8.06 (dd, J = 9.1, 2.4 Hz, 1H), 7.56 (dd, J = 9.0, 5.2 Hz, 1H), 7.44 - 7.31 (m, 2H), 4.02 (s, 3H). This material was analyzed for powder X-ray diffraction as described herein.
[0401] Amorphous Form 3 of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid was prepared by heating Form 1 anhydrous 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid to 205° C., holding isothermal for approximately 2 minutes, and then cooling to ambient temperature to obtain a glass. This material was analyzed for powder X-ray diffraction as described herein.
[0402] Example 10 6-Chloro-3-(2,4,5-trifluoro-3-methylphenyl)-1-benzothiophene-2-carboxylic acid (10)
[0403] [ka] Step 1. Synthesis of 4,4,5,5-tetramethyl-2-(2,4,5-trifluoro-3-methylphenyl)-1,3,2-dioxaborolane (C56). A mixture of 1-bromo-2,4,5-trifluoro-3-methylbenzene (250 mg, 1.11 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (564 mg, 2.22 mmol), potassium acetate (218 mg, 2.22 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (81.3 mg, 0.111 mmol) in 1,4-dioxane (5.6 mL) was degassed with nitrogen for 2 min whereupon it was heated at 100° C. for 16 h. The reaction mixture was concentrated under vacuum, diluted with ethyl acetate (20 mL), filtered, and concentrated under vacuum. Chromatography on silica gel (gradient: 0% to 6% ethyl acetate in petroleum ether) afforded C56 as a pale yellow oil. Yield: 167 mg, 0.614 mmol, 55%. 1 H NMR (400 MHz, chloroform-d) δ 7.33 (ddd, J = 9.7, 9.7, 5.2 Hz, 1H), 2.20 (dd, J = 1.9, 1.9 Hz, 3H), 1.35 (s, 12H).
[0404] Step 2. Synthesis of ethyl 6-chloro-3-(2,4,5-trifluoro-3-methylphenyl)-1-benzothiophene-2-carboxylate (C57). A suspension of P7 (200 mg, 0.626 mmol), C56 (167 mg, 0.614 mmol), potassium fluoride (109 mg, 1.88 mmol), and tris(dibenzylideneacetone)dipalladium(0) (57.3 mg, 62.6 μmol) in a mixture of tetrahydrofuran (6 mL) and water (1.5 mL) was degassed with nitrogen for 1 min, whereupon a solution of tri-tert-butylphosphine in toluene (1 M; 62.6 μL, 62.6 μmol) was added. After the reaction mixture was heated at 60° C. for 16 h, it was concentrated under vacuum and purified using silica gel chromatography (eluent: petroleum ether) to give C57 as a yellow oil. Yield: 221 mg, 0.574 mmol, 92%. LCMS m / z 385.0 (chlorine isotope pattern observed) [M+H] + .
[0405] Step 3. Synthesis of 6-chloro-3-(2,4,5-trifluoro-3-methylphenyl)-1-benzothiophene-2-carboxylic acid (10). Lithium hydroxide monohydrate (241 mg, 5.74 mmol) was added to a solution of C57 (221 mg, 0.574 mmol) in a mixture of tetrahydrofuran (4 mL), methanol (2 mL), and water (2 mL), and the reaction mixture was stirred at 22° C. for 16 h. It was then concentrated under vacuum, diluted with water (20 mL), and acidified to a pH of approximately 5 by the addition of hydrochloric acid; filtered to obtain a solid, which was subjected to reverse phase HPLC (column: YMC-Actus Triart C18, 50×250 mm, 7 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 43% to 83%; flow rate: 60 mL / min) to obtain 6-chloro-3-(2,4,5-trifluoro-3-methylphenyl)-1-benzothiophene-2-carboxylic acid (10) as a white solid. Yield: 109 mg, 0.306 mmol, 53%. LCMS m / z 310.8 [M-COOH] - . 1 H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 1.7 Hz, 1H), 7.57 - 7.48 (m, 1H), 7.49 (dd, ABX system, J = 8.7, 1.8 Hz, 1H), 7.46 (d, half of AB quartet, J = 8.8 Hz, 1H), 2.27 (br s, 3H).
[0406] Example 11 5,6-Difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (11)
[0407] [ka] Step 1. Synthesis of 3-bromo-5,6-difluoro-1-benzothiophene (C58). A solution of 5,6-difluoro-1-benzothiophene (R. Acharya et al.; see WO2016100184 A1, June 23, 2016; 1.60 g, 9.40 mmol) in acetic acid (47 mL) was treated portionwise with N-bromosuccinimide (2.01 g, 11.3 mmol). The reaction mixture was stirred at 80° C. for 16 h whereupon it was diluted with water and extracted with petroleum ether (3×30 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (eluent: petroleum ether) afforded C58 as a white solid. Yield: 1.26 g, 5.06 mmol, 54%. 1 H NMR (400 MHz, chloroform-d) δ 7.64 (dd, J = 9.5, 6.9 Hz, 1H), 7.60 (dd, J = 10.3, 7.4 Hz, 1H), 7.46 (s, 1H).
[0408] Step 2. Synthesis of 5,6-difluoro-3-phenyl-1-benzothiophene (C59). To a suspension of C58 (640 mg, 2.57 mmol) and phenylboronic acid (313 mg, 2.57 mmol) in a mixture of 1,4-dioxane (20 mL) and water (2 mL) was added cesium carbonate (2.51 g, 7.70 mmol) and tetrakis(triphenylphosphine)palladium(0) (297 mg, 0.257 mmol). The reaction mixture was stirred at 85° C. for 16 h before it was filtered. The filtrate was concentrated under vacuum and purified by silica gel chromatography (eluent: petroleum ether) to give C59 as a gum. Yield: 561 mg, 2.28 mmol, 89%. 1 H NMR (400 MHz, chloroform-d) δ 7.70 - 7.62 (m, 2H), 7.56 - 7.47 (m, 4H), 7.46 - 7.40 (m, 2H).
[0409] Step 3. Synthesis of 2-bromo-5,6-difluoro-3-phenyl-1-benzothiophene (C60). A solution of N-bromosuccinimide (425 mg, 2.39 mmol) in ethanol (1 mL) was added in portions to a solution of C59 (560 mg, 2.27 mmol) in a mixture of dichloromethane (20 mL) and ethanol (0.5 mL). The reaction mixture was stirred at 25° C. for 16 h and then at 35° C. for 3 h, whereupon it was diluted with water and extracted with dichloromethane (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (2×15 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (eluent: petroleum ether) afforded C60 as a colorless oil. Yield: 260 mg, 0.800 mmol, 35%. 1 H NMR (400 MHz, chloroform-d) δ 7.59 - 7.41 (m, 6H), 7.32 (dd, J = 10.8, 7.5 Hz, 1H).
[0410] Step 4. Synthesis of methyl 5,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylate (C61). To a solution of C60 (260 mg, 0.800 mmol) and N,N-diisopropylethylamine (0.221 mL, 1.27 mmol) in methanol (5 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane complex (65.3 mg, 80.0 μmol), whereupon the atmosphere was replaced with carbon monoxide. The reaction mixture was stirred at 70 °C for 16 h, at which time analysis by thin layer chromatography indicated that the starting material had not been consumed. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give a material which was then subjected to a second reaction: the residue was diluted with methanol (15 mL), treated with N,N-diisopropylethylamine (0.221 mL, 1.27 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane complex (65.3 mg, 80.0 μmol) and placed under an atmosphere of carbon monoxide. The reaction mixture was stirred at 80° C. for 3 h and filtered; the filtrate was concentrated under reduced pressure and subjected to silica gel chromatography (eluent: petroleum ether) to give C61 as a colorless gum. Yield: 52.0 mg, 0.171 mmol, 21%. 1 H NMR (400 MHz, chloroform-d) δ 7.65 (dd, J = 9.5, 7.0 Hz, 1H), 7.54 - 7.46 (m, 3H), 7.39 - 7.34 (m, 2H), 7.29 (dd, J = 10.7, 7.6 Hz, 1H), 3.78 (s, 3H)
[0411] Step 5. Synthesis of 5,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (11). To a solution of C61 (52.0 mg, 0.171 mmol) in a mixture of methanol (1 mL), tetrahydrofuran (1 mL), and water (0.5 mL), lithium hydroxide monohydrate (71.7 mg, 1.71 mmol) was added whereupon the reaction mixture was stirred at 20° C. for 4 h. Water was added and the resulting mixture was washed with petroleum ether (2×8 mL); the aqueous layer was then adjusted to a pH of approximately 3 by the addition of hydrochloric acid (1 mL). This aqueous mixture was extracted with ethyl acetate (3×8 mL) and the combined ethyl acetate layers were dried over sodium sulfate, filtered, and concentrated under vacuum. Purification by reverse phase HPLC (column: Boston Prime C18, 30×150 mm, 5 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: 13% to 43% B; flow rate: 30 mL / min) gave 5,6-difluoro-3-phenyl-1-benzothiophene-2-carboxylic acid (11) as a white solid. Yield: 26.5 mg, 91.3 μmol, 53%. LCMS m / z 291.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.86 (dd, J = 10.2, 7.2 Hz, 1H), 7.51 - 7.36 (m, 5H), 7.24 (dd, J = 11.2, 7.6 Hz, 1H).
[0412] Example 12 Ammonium 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (12)
[0413] [ka] Step 1. Synthesis of 4,4,5,5-tetramethyl-2-(2,4,5-trifluoro-3-methoxyphenyl)-1,3,2-dioxaborolane (C62). A mixture of C51 (400.0 mg, 1.66 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (1.05 g, 4.13 mmol), and potassium acetate (326 mg, 3.32 mmol) in 1,4-dioxane (12 mL) was degassed with nitrogen for 1 min, whereupon [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (121 mg, 0.165 mmol) was added and the reaction mixture was heated at 100° C. for 16 h. After filtration, the filtrate was concentrated under vacuum and purified using chromatography on silica gel (gradient: 0% to 8% ethyl acetate in petroleum ether) to give C62 as a gum. Yield: 500 mg, estimated quantitative. 1 H NMR (400 MHz, chloroform-d) δ 7.22 (ddd, J = 9.8, 8.8, 4.6 Hz, 1H), 4.03 (t, J = 1.1 Hz, 3H), 1.37 (s, 12H).
[0414] Step 2. Synthesis of methyl 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (C63). A suspension of C62 (200 mg, 0.694 mmol), P8 (200 mg, 0.567 mmol), and potassium carbonate (235 mg, 1.70 mmol) in 1,4-dioxane (2 mL) was degassed with nitrogen for 1 min, whereupon [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (41.5 mg, 56.7 μmol) was added. The reaction mixture was stirred at 80° C. for 16 h and then filtered; the filtrate was concentrated in vacuo and purified by chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to give C63 as a colorless gum. Yield: 160 mg, 0.414 mmol, 73%. 1 H NMR (400 MHz, chloroform-d) δ 7.89 (br d, J = 1.9 Hz, 1H), 7.42 (br d, half of the AB quadruplet, J = 8.7 Hz, 1H), 7.37 (dd, component of the ABX system, J = 8.7, 1.8 Hz, 1H), 6.85 (ddd, J = 9.9, 8.1, 6.0 Hz, 1H), 4.09 (t, J = 1.2 Hz, 3H), 3.84 (s, 3H).
[0415] Step 3. Synthesis of ammonium 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (12). To a solution of C63 (160 mg, 0.414 mmol) in a mixture of methanol (2.0 mL) and tetrahydrofuran (2.0 mL) was added a solution of lithium hydroxide monohydrate (174 mg, 4.15 mmol) in water (1.0 mL). After the reaction mixture was stirred at room temperature for 16 h, it was diluted with water (5 mL) and adjusted to a pH of 4. The resulting mixture was extracted with ethyl acetate (3×5 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, concentrated under vacuum, and purified by reverse-phase HPLC (column: YMC-Actus Triart C18, 30×150 mm, 7 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 3% to 43%; flow rate: 25 mL / min). Ammonium 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (12) was isolated as a white solid. Yield: 71.4 mg, 0.183 mmol, 44%. LCMS m / z 370.8 (chlorine isotope pattern observed) [MH] - . 1 H NMR (400 MHz, DMSO-d6) δ 8.12 (br s, 1H), 7.37 (dd, ABX component, J = 8.7, 1.8 Hz, 1H), 7.34 (d, half of the AB quartet, J = 8.8 Hz, 1H), 7.25 (br s, approximately 3H), 7.22 (ddd, J = 10.8, 8.5, 6.1 Hz, 1H), 4.00 (br s, 3H).
[0416] (Example 13) 6-Chloro-3-(2,4-difluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (13)
[0417] [ka] Step 1. Synthesis of 2-(2,4-difluoro-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (C64). A mixture of 1-bromo-2,4-difluoro-3-methoxybenzene (330 mg, 1.48 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (752 mg, 2.96 mmol), and potassium acetate (290 mg, 2.95 mmol) in 1,4-dioxane (7 mL) was degassed with nitrogen for 1 min, whereupon [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (108 mg, 0.148 mmol) was added and the reaction mixture was heated at 95° C. for 16 h. It was then filtered; the filtrate was concentrated under vacuum and purified by silica gel chromatography (eluent: petroleum ether) to give C64 as a yellow gum. Yield: 370 mg, 1.37 mmol, 93%. 1 H NMR (400 MHz, chloroform-d) δ 7.37 (ddd, J = 8.5, 6.3, 6.3 Hz, 1H), 6.88 (ddd, J = 10.1, 8.5, 1.6 Hz, 1H), 3.97 (s, 3H), 1.35 (s, 12H).
[0418] Step 2. Synthesis of ethyl 6-chloro-3-(2,4-difluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylate (C65). A suspension of C64 (370 mg, 1.37 mmol), P7 (390 mg, 1.22 mmol), and potassium fluoride (193 mg, 3.32 mmol) in a mixture of tetrahydrofuran (10 mL) and water (1 mL) was treated with tris(dibenzylideneacetone)dipalladium(0) (50.8 mg, 55.5 μmol), followed by a solution of tri-tert-butylphosphine in toluene (1 M; 0.111 mL, 0.111 mmol). After the reaction mixture was heated at 65° C. for 16 h, it was filtered, concentrated in vacuo, and purified by silica gel chromatography (gradient: 0% to 2% ethyl acetate in petroleum ether) to give C65 as a gum. Yield: 240 mg, 0.627 mmol, 51%. 1 H NMR (400 MHz, chloroform-d) δ 7.88 (d, J = 1.8 Hz, 1H), 7.41 (br d, AB quadruplet component, J = 8.7 Hz, 1H), 7.34 (dd, ABX component, J = 8.7, 1.9 Hz, 1H), 7.03 (ddd, ABXY component, J = 10.1, 8.7, 1.6 Hz, 1H), 6.95 (ddd, ABXY system components, J = 8.7, 7.1, 5.9 Hz, 1H), 4.32 - 4.21 (m, 2H), 4.05 (br s, 3H), 1.25 (t, J = 7.1 Hz, 3H).
[0419] Step 3. Synthesis of 6-chloro-3-(2,4-difluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (13). A solution of lithium hydroxide monohydrate (263 mg, 6.27 mmol) in water (1 mL) was added to a solution of C65 (240 mg, 0.627 mmol) in a mixture of methanol (2.5 mL) and tetrahydrofuran (2.5 mL). After the reaction mixture was stirred at 25° C. for 2.5 h, it was adjusted to a pH of approximately 3 and then extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (2×15 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was treated with acetonitrile and water and then lyophilized to give 6-chloro-3-(2,4-difluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid (13) as a green solid. Yield: 160 mg, 0.451 mmol, 72%. LCMS m / z 372.0 (chlorine isotope pattern observed) [M+NH4 + ]. 1 H NMR (400 MHz, methanol-d4) δ 8.05 (br d, J = 1.6 Hz, 1H), 7.44 (br d, half of the AB quartet, J = 8.7 Hz, 1H), 7.41 (dd, components of the ABX system, J = 8.8, 1.8 Hz, 1H), 7.12 (ddd, ABXY component, J = 10.4, 8.7, 1.6 Hz, 1H), 7.05 (ddd, ABXY component, J = 8.7, 7.2, 5.8 Hz, 1H), 4.00 (br s, 3H).
[0420] (Examples 14, 15, and 16) 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (14), 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-1 (15), and 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-2 (16).
[0421] [ka] Step 1. Synthesis of 2-(6-chloro-2,4-difluoro-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (C66). A solution of n-butyllithium (2.5 M; 10.1 mL, 25.2 mmol) was added dropwise to a −65° C. solution of 5-chloro-1,3-difluoro-2-methoxybenzene (1.80 g, 10.1 mmol) in tetrahydrofuran (50.4 mL). After the reaction mixture was stirred at −65° C. for 1 h, it was treated with 4,4,5,5-tetramethyl-2-(propan-2-yloxy)-1,3,2-dioxaborolane (5.63 g, 30.3 mmol) and warmed to 0° C. over 1 h. Aqueous ammonium chloride (100 mL) was added and the resulting mixture was extracted with ethyl acetate (3×50 mL); these organic layers were combined with those from a similar reaction carried out using 5-chloro-1,3-difluoro-2-methoxybenzene (1.00 g, 5.60 mmol), washed with saturated aqueous sodium chloride (50 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. Silica gel chromatography (Gradient: 0% to 10% ethyl acetate in petroleum ether) afforded C66 as a colorless oil. Combined yield: 3.10 g, 10.2 mmol, 65%. 1 H NMR (400 MHz, chloroform-d) δ 6.92 (dd, J = 10.3, 2.0 Hz, 1H), 3.94 (t, J = 1.0 Hz, 3H), 1.39 (s, 12H).
[0422] Step 2. Synthesis of methyl 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylate (C67). To a mixture of P1 (1.80 g, 6.23 mmol), C66 (3.03 g, 9.95 mmol), and tripotassium phosphate (3.96 g, 18.7 mmol) in toluene (30 mL), tris(dibenzylideneacetone)dipalladium(0), chloroform complex (322 mg, 0.311 mmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos; 383 mg, 0.933 mmol) were added whereupon the reaction mixture was stirred at 100° C. for 2 h. It was then concentrated under vacuum and purified by chromatography on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) to give C67 as a colorless oil (1.80 g). 1 1 H NMR analysis showed the product contained aliphatic impurities; it was carried on directly to the next step. 1 H NMR (400 MHz, chloroform-d), product peak only: δ 7.59 (dd, J = 8.4, 2.3 Hz, 1H), 7.36 (dd, J = 9.0, 5.0 Hz, 1H), 7.19 - 7.12 (m, 2H), 4.03 (br s, 3H), 3.83 (s, 3H).
[0423] Step 3. Synthesis of 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (14). To a solution of C67 (from the previous step; 1.80 g, <4.65 mmol) in a mixture of water (4 mL), tetrahydrofuran (6 mL), and methanol (8 mL) was added lithium hydroxide monohydrate (976 mg, 23.3 mmol). The reaction mixture was stirred at 20° C. for 16 h, whereupon LCMS analysis showed conversion to 14: LCMS m / z 370.9 [MH]. -After the reaction mixture was concentrated under vacuum, it was diluted with water (50 mL), acidified to a pH of approximately 4 by the addition of 1 M hydrochloric acid, and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were concentrated under reduced pressure and purified by reverse-phase HPLC (column: YMC-Actus Triart C18, 50 x 250 mm, 7 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 7% to 47%; flow rate: 60 mL / min). The fractions containing 14 were combined and concentrated under vacuum to remove acetonitrile, followed by acidification to a pH of approximately 4 by the addition of 1 M hydrochloric acid. The resulting mixture was extracted with ethyl acetate (2 x 40 mL) and the combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (14) as a white solid. Yield: 1.01 g, 2.71 mmol, 43% for two steps. LCMS m / z 373.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) 7.78 (dd, J = 8.8, 2.4 Hz, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.31 (dd, J = 10.7, 2.1 Hz, 1H), 7.23 (ddd, J = 9.0, 8.9, 2.4 Hz, 1H), 4.00 (t, J = 0.9 Hz, 3H).
[0424] Step 4. Isolation of 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-1 (15) and 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-2 (16). The product 14 (1.00 g, 2.68 mmol) from the previous step was separated into its component atropisomers using supercritical fluid chromatography (column: Chiral Technologies Chiralpak AD-H, 30×250 mm, 5 μm; mobile phase: 4:1 carbon dioxide / methanol; back pressure: 100 bar; flow rate: 80 mL / min). The first eluting atropisomer, an off-white solid, was designated 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-1 (15), and the second eluting atropisomer, a white solid, was designated 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-2 (16). 15 - Yield: 0.45g, 1.2mmol, 45% isolated. LCMS m / z 373.2 (Chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 13.66 (br s, 1H), 8.08 (dd, J = 9.1, 2.4 Hz, 1H), 7.65 (dd, J = 11.0, 2.0 Hz, 1H), 7.46 (dd, ABX component, J = 9.0, 5.2 Hz, 1H), 7.35 (ddd, ABXY component, J = 9.0, 9.0, 2.4 Hz, 1H), 3.97 (s, 3H). Retention time: 1.16 min (analytical conditions: Column: Chiral Technologies Chiralpak AD-H, 4.6×100 mm, 3 μm; Mobile phase A: carbon dioxide; Mobile phase B: methanol; Gradient: 5% B over 0.25 min, then 5% to 70% B over 2.25 min; Back pressure: 100 bar; Flow rate: 2.5 mL / min). 16 - Yield: 0.49g, 1.3mmol, 49% isolated. LCMS m / z 373.3 (Chlorine isotope pattern observed) [M+H] + .1 H NMR (400 MHz, DMSO-d6) δ 13.66 (br s, 1H), 8.08 (dd, J = 9.2, 2.4 Hz, 1H), 7.65 (dd, J = 11.0, 2.0 Hz, 1H), 7.46 (dd, ABX component, J = 8.9, 5.2 Hz, 1H), 7.35 (ddd, ABXY component, J = 9.0, 9.0, 2.5 Hz, 1H), 3.97 (s, 3H). Retention time: 1.34 min (same analytical conditions as used for 15).
[0425] (Example 17) 6-Fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (17)
[0426] [ka] Step 1. Synthesis of ethyl 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylate (C68). To a mixture of C62 (194 mg, 0.673 mmol), P9 (150 mg, 0.449 mmol), and tripotassium phosphate (286 mg, 1.35 mmol) in toluene (3.0 mL) was added tris(dibenzylideneacetone)dipalladium(0) (20.6 mg, 22.5 μmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos; 27.6 mg, 67.2 μmol). The reaction mixture was stirred at 100° C. for 2 h whereupon it was filtered. The filtrate was concentrated under vacuum and subjected to silica gel chromatography (gradient: 0% to 8% ethyl acetate in petroleum ether) to give C68 as an orange solid. Yield: 134 mg, 0.364 mmol, 81%. LCMS m / z 369.0 [M+H] + . 1H NMR (400 MHz, chloroform-d) δ 7.43 (br dd, J = 8.8, 5.4 Hz, 1H), 7.35 (dd, J = 8.5, 2.3 Hz, 1H), 7.12 (ddd, J = 9.0, 9.0, 2.3 Hz, 1H), 7.00 (ddd, J = 10.0, 8.1, 6.0 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 1.2 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H).
[0427] Step 2. Synthesis of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (17). A solution of lithium hydroxide monohydrate (148 mg, 3.53 mmol) in water (1 mL) was added to a solution of C68 (130 mg, 0.353 mmol) in a mixture of methanol (2 mL) and tetrahydrofuran (2 mL). After the reaction mixture was stirred at room temperature for 4 h, it was diluted with water (5 mL) and washed with petroleum ether (2×8 mL). The aqueous layer was acidified to a pH of 4 by addition of hydrochloric acid (1 M; 3 mL) and extracted with ethyl acetate (3×8 mL); the combined ethyl acetate layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum. Reverse phase HPLC (column: Boston Prime C18, 30×150 mm, 5 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: 8% to 38% B; flow rate: 30 mL / min) afforded 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (17) as a white solid. Yield: 48.4 mg, 0.142 mol, 40%. LCMS m / z 338.9 [MH] - . 1 H NMR (400 MHz, methanol-d4) δ 7.45 - 7.37 (m, 2H), 7.19 - 7.07 (m, 2H), 4.05 (br s, 3H).
[0428] (Example 18) 6-Chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (18)
[0429] [ka] Step 1. Synthesis of ethyl 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylate (C69). A suspension of P10 (73.0 mg, 0.208 mmol), C62 (50 mg, 0.17 mmol), and potassium carbonate (72.0 mg, 0.521 mmol) in 1,4-dioxane (1 mL) was degassed with nitrogen for 1 min, whereupon [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (12.7 mg, 17.4 μmol) was added. The reaction mixture was stirred at 80° C. for 16 h before it was filtered; the filtrate was concentrated under vacuum and purified using silica gel chromatography (gradient: 0% to 7% ethyl acetate in petroleum ether) to give C69 as a colorless gum. Yield: 39.6 mg, 0.103 mmol, 61%. 1 H NMR (400 MHz, chloroform-d) δ 7.65 (d, J = 1.7 Hz, 1H), 7.40 (br d, Half of the AB quadruplet, J = 8.7 Hz, 1H), 7.33 (dd, component of the ABX system, J = 8.5, 1.7 Hz, 1H), 6.99 (ddd, J = 10.0, 8.1, 6.0 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 1.2 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H).
[0430] Step 2. Synthesis of 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (18). A solution of C69 (84.0 mg, 0.218 mmol) in a mixture of methanol (1 mL) and tetrahydrofuran (1 mL) was treated with a solution of lithium hydroxide monohydrate (91.6 mg, 2.18 mmol) in water (0.5 mL). The reaction mixture was stirred at room temperature for 1.5 h whereupon it was diluted with water (5 mL) and washed with petroleum ether (4 mL). The aqueous layer was acidified to pH 4 by addition of hydrochloric acid (1 M; 3 mL) and extracted with ethyl acetate (3×5 mL); the combined ethyl acetate layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum. Reverse phase HPLC (column: YMC-Actus Triart C18, 30×150 mm, 7 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: 25% to 50% B; flow rate: 25 mL / min) followed by supercritical fluid chromatography [column: Chiral Technologies Chiralpak AD, 30×250 mm, 10 μm; mobile phase: 3:1 carbon dioxide / (propan-2-ol containing 0.1% ammonium hydroxide); flow rate: 70 mL / min] gave 6-chloro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzofuran-2-carboxylic acid (18) as a white solid. Yield: 9.71 mg, 27.2 μmol, 12%. LCMS m / z 356.9 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.72 (d, J = 1.8 Hz, 1H), 7.45 (br d, half of the AB quadruplet, J = 8.5 Hz, 1H), 7.35 (dd, component of the ABX system, J = 8.5, 1.8 Hz, 1H), 7.17 (ddd, J = 10.6, 8.3, 6.0 Hz, 1H), 4.06 (br s, 3H).
[0431] (Example 19) 6-Fluoro-3-(2,3,4-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (19)
[0432] [ka] Step 1. Synthesis of methyl 6-fluoro-3-(2,3,4-trifluorophenyl)-1-benzothiophene-2-carboxylate (C70). To a mixture of methyl 3-chloro-6-fluoro-1-benzothiophene-2-carboxylate (70 mg, 0.29 mmol) in toluene (3 mL) was added (2,3,4-trifluorophenyl)boronic acid (55 mg, 0.31 mmol), potassium bicarbonate (85.8 mg, 0.857 mmol), bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) [Pd(amphos)2Cl2; 10 mg, 14 μmol), and water (0.5 mL). The reaction vessel was evacuated and charged with nitrogen; this evacuation cycle was repeated twice whereupon the reaction mixture was heated at 120° C. for 16 h. It was then diluted with water (10 mL) and extracted with ethyl acetate (2×10 mL). The combined organic layers were washed successively with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under vacuum. Chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) afforded C70 as a gum. Yield: 70 mg, 0.21 mmol, 72%. LCMS m / z 341.0 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.59 (dd, J = 8.4, 2.3 Hz, 1H), 7.44 (dd, J = 9.0, 5.1 Hz, 1H), 7.16 (ddd, J = 8.8, 8.8, 2.4 Hz, 1H), 7.15 - 7.02 (m, 2H), 3.83 (s, 3H).
[0433] Step 2. Synthesis of 6-fluoro-3-(2,3,4-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (19). A solution of lithium hydroxide (24.7 mg, 1.03 mmol) in water (1 mL) was added to a solution of C70 (70 mg, 0.21 mmol) in a mixture of methanol (5 mL) and tetrahydrofuran (1 mL). After the reaction mixture was stirred at 25° C. for 16 h, it was concentrated under vacuum, diluted with water (10 mL), and washed with dichloromethane (2×10 mL). The aqueous layer was adjusted to pH 2 whereupon it was extracted with ethyl acetate (3×50 mL). The combined ethyl acetate layers were washed with water and with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 6-fluoro-3-(2,3,4-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (19) as a solid. Yield: 11.5 mg, 35.2 μmol, 17%. LCMS m / z 327.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.01 (br d, J = 9.1 Hz, 1H), 7.52 - 7.37 (m, 2H), 7.37 - 7.23 (m, 2H).
[0434] (Example 20) 6-Chloro-3-(4-chloro-3-fluorophenyl)-1-benzothiophene-2-carboxylic acid (20)
[0435] [ka] Step 1. Synthesis of (4-chloro-2-fluorophenyl)(4-chloro-3-fluorophenyl)methanone (C71). A solution of n-butyllithium in hexane (2.4 M; 0.44 mL, 1.1 mmol) was added dropwise to a −78° C. solution of 4-bromo-1-chloro-2-fluorobenzene (200 mg, 0.955 mmol) in tetrahydrofuran (3 mL). The reaction mixture was stirred at −78° C. for 30 min, after which a solution of 4-chloro-2-fluoro-N-methoxy-N-methylbenzamide (208 mg, 0.956 mmol) in tetrahydrofuran (2 mL) was added dropwise. Stirring was continued at −78° C. for 1 h, whereupon the reaction mixture was warmed to 20° C. and stirred at 20° C. for 2 h. Hydrochloric acid (1 M; 3 mL, 3 mmol) and water (10 mL) were then added and the resulting aqueous layer was extracted with ethyl acetate (2×15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo; chromatography on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) afforded C71 as a white solid. Yield: 120 mg, 0.418 mmol, 44%. LCMS m / z 287.1 [M+H] + .
[0436] Step 2. Synthesis of ethyl 6-chloro-3-(4-chloro-3-fluorophenyl)-1-benzothiophene-2-carboxylate (C72). To a solution of C71 (120 mg, 0.418 mmol) in N,N-dimethylformamide (2 mL) was added ethyl sulfanylacetate (75 mg, 0.62 mmol) and potassium carbonate (173 mg, 1.25 mmol). The reaction mixture was heated at 100° C. for 16 h whereupon it was diluted with water and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with water and with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under vacuum; silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) followed by preparative thin layer chromatography (eluent: 20:1 petroleum ether / ethyl acetate) afforded C72 as a white solid. This material was carried on directly to the next step. Yield: 15 mg, 41 μmol, 10%. LCMS m / z 369.0 (dichloro isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.89 (d, J = 1.9 Hz, 1H), 7.55 - 7.49 (m, 1H), 7.40 (d, half of the AB quartet, J = 8.7 Hz, 1H), 7.34 (dd, components of the ABX system, J = 8.7, 1.8 Hz, 1H), 7.25 - 7.18 (m, 2H), 4.34 - 4.17 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H).
[0437] Step 3. Synthesis of 6-chloro-3-(4-chloro-3-fluorophenyl)-1-benzothiophene-2-carboxylic acid (20). A solution of lithium hydroxide (10 mg, 0.42 mmol) in water (1.0 mL) was added to a solution of C72 (15 mg, 41 μmol) in a mixture of tetrahydrofuran (1.0 mL) and methanol (1.0 mL), and the reaction mixture was stirred at 20° C. for 16 h. After removing the volatiles by concentration under vacuum, the residue was purified using reverse-phase HPLC (column: Nouryon Kromasil® C18, 21.2×100 mm, 5 μm; mobile phase A: water containing 0.1% formic acid; mobile phase B: acetonitrile; gradient: B 60% to 70%) to give 6-chloro-3-(4-chloro-3-fluorophenyl)-1-benzothiophene-2-carboxylic acid (20) as a white solid. Yield: 3.2 mg, 9.4 μmol, 23%. LCMS m / z 294.9 (dichloro isotope pattern observed) [M-COOH] - . 1 H NMR (400 MHz, DMSO-d6) δ 8.30 (br s, 1H), 7.74 - 7.66 (m, 1H), 7.52 - 7.32 (m, 4H).
[0438] Example 21 3-(2,6-difluoro-4-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (21)
[0439] [ka] Step 1. Synthesis of 2-(2,6-difluoro-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (C73). This three-step sequence was carried out in library format. A solution of 1,3-difluoro-5-methoxybenzene (29 mg, 0.20 mmol) in tetrahydrofuran (2 mL) was treated with (1,5-cyclooctadiene)(methoxy)iridium(I) dimer {[IrOMe(cod)]2; 6.6 mg, 10 μmol} and 4,4'-di-tert-butyl-2,2'-bipyridine (1.34 mg, 4.99 μmol) followed by 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (approximately 290 mg, 2 mmol), whereupon the reaction vial was capped and the reaction mixture was stirred at 80° C. for 16 h. The solvent was removed using a Speedvac concentrator to give C73, which was carried on directly to the next step.
[0440] Step 2. Synthesis of methyl 3-(2,6-difluoro-4-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylate (C74). A solution of P1 in 1,4-dioxane (0.1 M; 1.0 mL, 0.1 mmol) was added to C73 (from the previous step; ≦0.20 mmol). Water (0.2 mL) and potassium fluoride (174 mg, 2.99 mmol) were then added, followed by chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) [P(t-Bu)3Pd G2; 2.6 mg, 5.1 μmol). The reaction vial was capped and shaken at 80° C. for 16 h, whereupon the volatiles were removed using a Speedvac concentrator. The residue was diluted with water (1 mL) and extracted with ethyl acetate (3×1 mL); the combined organic layers were evaporated using a Speedvac concentrator to give C74, which was taken directly into the next step.
[0441] Step 3. Synthesis of 3-(2,6-difluoro-4-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (21). Tetrahydrofuran (1 mL) and aqueous lithium hydroxide (1 M; 1.0 mL, 1.0 mmol) were added to C74 (from the previous step; ≦0.20 mmol) followed by methanol (0.4 mL) whereupon the reaction vial was capped and the vial was shaken at 30° C. for 2 h. After evaporation using a Speedvac concentrator, the residue was purified by reverse-phase HPLC (column: Boston Prime C18, 30×150 mm, 5 μm; mobile phase A: water containing ammonium hydroxide (pH 10); mobile phase B: acetonitrile; gradient: 12% to 52% B; flow rate: 30 mL / min) to give 3-(2,6-difluoro-4-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (21). Yield: 8.4 mg, 25 μmol, 25% for two steps. LCMS m / z 339 [M+H] + Retention time: 3.16 min (analysis conditions: Column: Waters XBridge C18, 2.1×50 mm, 5 μm; Mobile phase A: water containing 0.0375% trifluoroacetic acid; Mobile phase B: acetonitrile containing 0.01875% trifluoroacetic acid; Gradient: 10% B over 0.50 min; 10% to 100% B over 3.5 min; Flow rate: 0.8 mL / min.
[0442] Example 22 6-Fluoro-3-(2,4,5-trifluoro-3-hydroxyphenyl)-1-benzothiophene-2-carboxylic acid (22)
[0443] [ka] A solution of boron tribromide in dichloromethane (1M; 4.21 mL, 4.21 mmol) was slowly added to a 0° C. solution of 9 (0.500 g, 1.40 mmol) in dichloromethane (30 mL). The reaction mixture was then warmed to room temperature and stirred at that temperature for 16 h, whereupon it was cooled to 0° C. and a solution of boron tribromide in dichloromethane (1M, 2.81 mmol, 2.81 mL) was added again. The reaction mixture was warmed to room temperature; after it was stirred at room temperature for another 16 h, it was poured into a mixture of cold water (200 mL) and dichloromethane (100 mL). The resulting solid was collected by filtration, washed with dichloromethane (3×15 mL), then dissolved in a mixture of dichloromethane and methanol (9:1, 20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in a mixture of dichloromethane and methanol (9:1, 10 mL) and subjected to silica gel chromatography [gradient: 5% to 15% (5% acetic acid in methanol) in dichloromethane] to give 6-fluoro-3-(2,4,5-trifluoro-3-hydroxyphenyl)-1-benzothiophene-2-carboxylic acid (22) as a white solid. Yield: 217 mg, 0.634 mmol, 45%. LCMS m / z 343.0 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.75 (dd, J = 8.8, 2.4 Hz, 1H), 7.49 (dd, J = 9.0, 5.1 Hz, 1H), 7.23 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H), 6.73 (ddd, J = 10.5, 8.1, 6.0 Hz, 1H).
[0444] (Example 23) 6-Fluoro-3-(2,4,5-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (23)
[0445] [ka] Step 1. Synthesis of methyl 6-fluoro-3-(2,4,5-trifluorophenyl)-1-benzothiophene-2-carboxylate (C75). To a suspension of P2 (200 mg, 0.595 mmol), 1-bromo-2,4,5-trifluorobenzene (151 mg, 0.716 mmol), and potassium fluoride (104 mg, 1.79 mmol) in a mixture of tetrahydrofuran (10 mL) and water (1 mL) was added tris(dibenzylideneacetone)dipalladium(0) (27.2 mg, 29.7 μmol), followed by a solution of tri-tert-butylphosphine in toluene (1 M; 59.5 μL, 59.5 μmol). The reaction mixture was heated at 60° C. for 16 h whereupon it was diluted with water (20 mL) and extracted with ethyl acetate (2×15 mL). The combined organic layers were washed with saturated aqueous sodium chloride (40 mL), dried over sodium sulfate, filtered, concentrated under vacuum, and purified by chromatography on silica gel (gradient: 0% to 6% ethyl acetate in petroleum ether) to give C75 as a yellow solid. Yield: 180 mg, 0.529 mmol, 89%. 1 H NMR (400 MHz, chloroform-d) δ 7.58 (dd, J = 8.4, 2.4 Hz, 1H), 7.46 (dd, J = 9.0, 5.0 Hz, 1H), 7.23 - 7.13 (m, 2H), 7.09 (ddd, J = 10.1, 8.7, 6.6 Hz, 1H), 3.83 (s, 3H).
[0446] Step 2. Synthesis of 6-fluoro-3-(2,4,5-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (23). A mixture of C75 (180 mg, 0.529 mmol) in a mixture of tetrahydrofuran (2 mL), methanol (2 mL), and water (1 mL) was treated with lithium hydroxide (127 mg, 5.30 mmol). After the reaction mixture was stirred at 25° C. for 16 h, it was concentrated under reduced pressure; the residue was diluted with water (30 mL) and adjusted to a pH of approximately 5 by the addition of 1 M hydrochloric acid. The resulting suspension was filtered and the collected solid was purified by reverse-phase HPLC (column: Phenomenex Gemini NX-C18, 30×75 mm, 3 μm; mobile phase A: water containing 0.05% ammonium hydroxide (v / v); mobile phase B: acetonitrile; gradient: B 13% to 53%; flow rate: 25 mL / min) to give 6-fluoro-3-(2,4,5-trifluorophenyl)-1-benzothiophene-2-carboxylic acid (23) as a white solid. Yield: 84.8mg, 0.260mmol, 49%. LCMS m / z 280.9 [M-COOH] - . 1 H NMR (400 MHz, methanol-d4) δ 7.65 (dd, J = 8.9, 2.4 Hz, 1H), 7.39 (ddd, J = 9.0, 5.1, 1.2 Hz, 1H), 7.31 (ddd, J = 10.8, 8.9, 6.5 Hz, 1H), 7.23 (ddd, J = 10.8, 9.0, 6.8 Hz, 1H), 7.14 (ddd, J = 9.0, 9.0, 2.4 Hz, 1H).
[0447] (Example 24) 3-(3-chloro-2,4,5-trifluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid (24)
[0448] [ka] To a -65°C solution of 23 (164 mg, 0.503 mmol) in tetrahydrofuran (3 mL) was added lithium diisopropylamide (2M; 0.528 mL, 1.06 mmol). After the reaction mixture was stirred at -60°C for 1 h, a solution of N-chlorosuccinimide (67.1 mg, 0.503 mmol) in tetrahydrofuran (2 mL) was added slowly at -60°C. The reaction mixture was then stirred at room temperature for 16 h whereupon it was treated with aqueous ammonium chloride (10 mL), dil...
Claims
1. Compounds of Formula I 【Chemistry 1】 [In the formula, Z is O or S; A is, 【Chemistry 2】 and X 1 is CR 11 or N, X 2 and X 3 are each independently 11 or O, X 2 If is O, then X 3 is CR 11 and R 1 , R 3 and R 4 are each independently selected from H and fluoro; R 2 is H, fluoro or chloro, R 5 , R 6 , R 7 , R 8 , R 9 and R 11 are each independently H, halo, hydroxyl, amino, cyano, (C 1 ~C 4 ) alkyl, (C 3 ~C 6 ) cycloalkyl, (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) fluoroalkyl, (C 3 ~C 6 ) fluorocycloalkyl, (C 1 ~C 4 ) fluoroalkoxy, or (C 1 ~C 4 ) alkyl-(C 1 ~C 4 ) alkoxy; R 10 is H, fluoro, chloro, cyano, or (C 1 ~C 4 ) alkyl; A, 【Chemistry 3】 And X 1 is CR 11 If R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 At least one of R is halo; 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 and at least one of the others is other than H. Or a pharma- ceutically acceptable salt of said compound.
2. Compounds of Formula I 【Chemistry 4】 [In the formula, Z is O or S; A is, 【Chemistry 5】 and X 1 is CR 11 or N, X 2 and X 3 are each independently 11 or O, X 2 If is O, then X 3 is CR 11 and X 4 and X 5 are both C or X 4 and X 5 One of the groups is C and the other is O, and X 4 If is O, then R 6 does not exist, and X 5 If is O, then R 8 does not exist, R 1 , R 3 and R 4 are each independently selected from H and fluoro; R 2 is H, fluoro or chloro, R 5 , R 6 , R 7 , R 8 , R 9 and R 11 are each independently H, halo, hydroxyl, amino, cyano, (C 1 ~C 4 ) alkyl, (C 3 ~C 6 ) cycloalkyl, (C 1 ~C 4 ) alkoxy, (C 1 ~C 4 ) fluoroalkyl, (C 3 ~C 6 ) fluorocycloalkyl, (C 1 ~C 4 ) fluoroalkoxy, or (C 1 ~C 4 ) alkyl-(C 1 ~C 4 ) alkoxy; R 10 is H, hydroxy, fluoro, chloro, cyano, or (C 1 ~C 4 ) alkyl; A 【Chemistry 6】 And X 1 But, CR 11 If i) R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 At least one of R is halo; 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 is other than H, or ii) Z is S and R 2 is a halo. Or a pharma- ceutically acceptable salt of said compound.
3. Z is S and A is 【Chemistry 7】 and R 2 is fluoro or chloro, and X 1 But, CR 11 3. The compound of claim 1, wherein:
4. R 1 , R 3 and R 4 are H and R 2 The compound of claim 3, or a pharma- ceutically acceptable salt thereof, wherein is fluoro.
5. R 5 is fluoro, chloro, cyano or (C 1 ~C 4 ) alkyl, R 10 5. The compound of claim 4, wherein is H, fluoro or chloro; or a pharma- ceutically acceptable salt thereof.
6. R 6 and R 7 are H, fluoro, chloro, cyano, (C 1 ~C 4 ) alkyl, and (C 1 ~C 4 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein each of the following is independently selected from: 1) alkoxy;
7. R 11 is H, fluoro, chloro, cyano, (C 1 ~C 4 ) alkyl, or (C 1 ~C 4 7. The compound of claim 6, wherein: R is 1 or 2; or a pharma- ceutically acceptable salt thereof.
8. 6-fluoro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid; 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid; 6-chloro-3-(2,4,5-trifluoro-3-methylphenyl)-1-benzothiophene-2-carboxylic acid; 6-chloro-3-(2,4-difluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid; 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid; 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-2; 3-(3-chloro-2,4,5-trifluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid; 3-(4-chloro-2,6-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid; 6-chloro-3-(2,4,6-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid; 6-chloro-3-(3-ethyl-2,4,5-trifluorophenyl)-1-benzothiophene-2-carboxylic acid; or Ammonium 3-(3-ethyl-2,4,5-trifluorophenyl)-6-fluoro-1-benzothiophene-2-carboxylate; or a pharma- ceutically acceptable salt thereof.
9. 6-Fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid ; or 3-(6-chloro-2,4-difluoro-3-methoxyphenyl)-6-fluoro-1-benzothiophene-2-carboxylic acid, ATROP-2; or a pharma- ceutically acceptable salt thereof.
10. 【Fig. 8】 or a pharma- ceutically acceptable salt thereof.
11. 【Chemical Formula 9】 A compound which is
12. 【Fig. 10】 or mixtures thereof; or a pharma- ceutically acceptable salt of said compound or mixture of compounds.
13. 【Fig. 11】 or a mixture thereof.
14. 19. A method of treating fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic steatohepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma, comprising administering to a human in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt of said compound.
15. 15. The method of claim 14, wherein non-alcoholic steatohepatitis is treated.
16. 17. A method of treating or reducing the risk of hospitalization due to heart failure, cardiovascular death, congestive heart failure, heart failure with New York Heart Association Class I-IV symptoms, heart failure with reduced left ventricular function (HF-rEF), heart failure with preserved left ventricular function (HF-pEF), heart failure with mid-range ejection fraction (HF-mrEF), cardiovascular death, heart failure in patients with diabetes mellitus type II, coronary heart disease, unstable angina, peripheral arterial disease, peripheral vascular disease, renal vascular disease, pulmonary hypertension, vasculitis, acute coronary syndromes, and modifying cardiovascular risk, comprising administering to a human in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt of said compound.
17. 17. The method of claim 16 for treating heart failure.
18. Type I diabetes, Type II diabetes mellitus, idiopathic type I diabetes (Type Ib), latent autoimmune diabetes in adults (LADA), early onset type 2 diabetes (EOD), atypical diabetes of the young (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, postprandial lipemia, impaired glucose tolerance (IGT) conditions, impaired fasting plasma glucose conditions, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, 19. A method of treating chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, insulin resistance, glucose metabolism disorders, skin and connective tissue disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and vascular compliance disorders, hyperapo B lipoproteinemia, renal disease, end stage renal disease, chronic renal disease at risk of progression, and maple syrup urine disease, comprising administering to a human in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 13 or a pharma- ceutical acceptable salt of said compound.
19. 20. The method of claim 18 for treating renal disease.
20. A method for treating hepatocellular carcinoma, kidney clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, gastric adenocarcinoma, adrenocortical carcinoma, papillary renal cell carcinoma, cervical and endocervical carcinoma, bladder urothelial carcinoma, lung adenocarcinoma, comprising administering to a human in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 13 or a pharma- ceutical acceptable salt thereof.
21. 21. The method of claim 20 for treating hepatocellular carcinoma.
22. 14. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt of said compound, and a pharma- ceutically acceptable carrier, vehicle or excipient.
23. A first compound which is a compound according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt of said compound; an antidiabetic agent; a second compound which is a non-alcoholic steatohepatitis treatment, a non-alcoholic fatty liver disease treatment, a kidney disease treatment, or an anti-heart failure treatment, and Pharmaceutical Carriers, Vehicles or Excipients A pharmaceutical combination composition comprising a therapeutically effective amount of a composition comprising:
24. The second compound is selected from the group consisting of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid; [(1R,5S,6R)-3-{2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid; 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.1.0]hex-6-yl]acetic acid; 24. The pharmaceutical combination composition of claim 23 which is bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide; or 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharma- ceutically acceptable salt thereof.
25. 24. The pharmaceutical combination composition of claim 23, wherein the agent for treating non-alcoholic steatohepatitis or non-alcoholic fatty liver disease is an ACC inhibitor, a GLP1 receptor agonist, a DGAT-2 inhibitor, an FXR agonist, metformin, an incretin analog, or an incretin receptor modulator.
26. 24. The pharmaceutical combination composition of claim 23, wherein the antidiabetic agent is an SGLT-2 inhibitor, metformin, an incretin analog, an incretin receptor modulator, a DPP-4 inhibitor, or a PPAR agonist.
27. 24. The pharmaceutical combination composition of claim 23, wherein the antidiabetic agent is metformin, sitagliptin or ertugliflozin.
28. 24. The pharmaceutical combination composition of claim 23, wherein said anti-heart failure agent is an ACE inhibitor, an SGLT-2 inhibitor, an angiotensin receptor blocker, an angiotensin receptor-neprilysin inhibitor, a beta adrenergic receptor blocker, a calcium channel blocker or a vasodilator.
29. 24. The pharmaceutical combination composition of claim 23, wherein the anti-heart failure agent is valsartan, sacubitril, dapagliflozin, empagliflozin, canagliflozin or ertugliflozin.
30. structure: 【Chemistry 12】 or a pharma- ceutically acceptable salt thereof.
31. 31. The crystal of claim 30, having a powder X-ray diffraction pattern comprising 2-theta values of 7.6±0.2, 14.6±0.2, and 27.9±0.2 (CuKα radiation, wavelength 1.54056 Å).
32. structure: 【Chemistry 13】 or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
Shinkitetorahidoropirijinjudotai oyobi piperijinjudotainoseiho
JP1976048673A
Antifungal agent based on phenyl group-containing amide
JP1990124859A
Urea derivative and its production
JP1993140102A
N-heteroaryl-n'-phenylurea derivative, its production and use thereof
JP1994340647A
Pharmaceutical composition having improved water dispersibility
JP2002241267A
